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ABSTRACT 
 
 Polyphosphate (polyP) is a linear polymer of inorganic phosphates that is secreted by 
activated platelets and is abundant in many pathogenic microorganisms. Our lab has recently 
shown that polyP from bacteria and human platelets play important roles in inflammation and 
coagulation in vitro and in vivo, supporting the paradigm of polyP as the long-sought 
(patho)physiologic activator of the contact pathway of blood clotting. These studies also 
implicate polyP in contributing to thrombosis and consumptive coagulopathies accompanying 
bacterial sepsis.  PolyP polymer lengths are known to vary substantially among different 
organisms and cell types, with shorter polymers secreted by human platelets and much longer 
polymers accumulating in microorganisms, raising intriguing questions about the mechanisms by 
which various polyP sizes differentially modulate the blood clotting system.  To accomplish this 
goal, I used bacterial and platelet-derived polyP, in addition to carefully size-fractionated 
synthetic polyP preparations, to investigate how polyP (dependent on polymer size) promotes 
each of the individual enzyme reactions that result in triggering and propagating blood clotting 
reactions.  This data advances our understanding of the mechanisms by which polyP modulates 
blood clotting and inflammation, with a particular emphasis on the contact pathway and factor V 
activation.  A serious impediment to progress in studying polyP in biological systems is the 
dearth of techniques for manipulating polyP to investigate polyP-protein interactions.  To this 
end, I developed a novel method for covalently crosslinking polyP to solid supports or labeling 
polyP with primary amine-containing solid supports.  This technique of crosslinking polyP has 
already facilitated studies on the ever-expanding role of polyP in blood clotting and other 
important biological processes.    
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Portions of this chapter have been published as Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient 
molecule that links platelets, coagulation, and inflammation. Blood. 2012;119(25):5972-5979. 
CHAPTER 1:  INTRODUCTION
1
 
 
Polyphosphate 
Inorganic polyphosphate (polyP) is structurally very simple, consisting of linear polymers 
of orthophosphate linked by high-energy phosphoanhydride bonds (Figure 1.1).  At 
physiological pH, each internal phosphate unit of polyP carries a monovalent negative charge, 
making polyP an intensely anionic polymer.  PolyP is ubiquitous in biology and can vary in 
polymer length from just a few phosphates to several thousand phosphate units long, depending 
on the organism and the tissue in which it is synthesized.
1,2
  PolyP is synthesized enzymatically 
from ATP; this reaction is fully reversible and may allow bacteria to synthesize ATP from stored 
polyP in times of starvation and environmental stress.
3
  PolyP can be degraded by 
endopolyphosphatases (which cleave within the polyP chain core) and exopolyphosphatases 
(which sequentially remove terminal phosphates from polyP).  Mammalian alkaline phosphatase 
is a potent exopolyphosphatase.
4
  PolyP has a half-life of about 1.5 to 2 hours in human blood or 
plasma, presumably due to exo- and/or endopolyphosphatase digestion.
5,6
  
PolyP has been most extensively studied in prokaryotes and unicellular eukaryotes, but 
roles for polyP in mammalian systems are rapidly emerging. In mammalian cells, polyP has been 
identified in lysosomes,
7
 dense granules,
8
 mitochondria and nuclei.
9
  PolyP associated with poly-
3-hydroxybutyrate has been reported to be a component of the Ca
2+
-ATPase pump in human 
erythrocytes.
10,11
 PolyP has also been shown to induce proliferation and differentiation of 
mesenchymal stem cells via activation of the fibroblast growth factors.
12
  More recently, nucleoli 
of myeloma cells were shown to contain high levels of polyP compared to normal primary 
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plasma cells.
13
  Other functions identified for polyP in mammalian cells include cell 
proliferation,
14
 angiogenesis,
15
 apoptosis,
16
 osteoblast function,
17
 bone mineralization,
18,19
 energy 
metabolism
20
 and tumor metastasis.
21,22
 
 
PolyP in microorganisms 
Prokaryotic and eukaryotic microorganisms store high concentrations of polyP along with 
divalent metal ions such as Ca
2+
, Mg
2+
 and Zn
2+
 in subcellular organelles termed 
acidocalcisomes (also known as volutin or metachromatic granules in some organisms).
23
 
Microorganisms typically contain very long-chain polyP, ranging in length from hundreds to 
thousands of phosphate units,
3
 and furthermore, Neisseria species (including Neisseria 
meningitidis) express long-chain polyP on their capsule.
24,25
 In the bacteria in which it has been 
studied, polyP kinase 1 (PPK1), a membrane-associated enzyme, synthesizes polyP from ATP;
26
 
this reaction is fully reversible and may allow bacteria to resynthesize ATP from stored polyP in 
times of starvation.
3
 PolyP kinase is critical for cell viability in bacteria, as knocking out this 
enzyme results in defective motility and compromised survival during periods of environmental 
stress.
27-31
 PolyP activates the expression of E. coli RpoS, the sigma factor responsible for 
activation of more than 50 genes required for survival during starvation and exposure to UV 
radiation, oxidative damage, and osmotic stress.
32
 
Pseudomonas aeruginosa mutants lacking PPK1 are deficient in motility, quorum sensing, 
biofilm formation and virulence; however, the mutants still possess as much as 20% of the wild-
type levels of polyP, which points to an additional polyphosphate kinase, PPK2.
33-35
  An 
interesting feature of PPK2 is that it kinetically favors GTP synthesis from polyP over polyP 
synthesis in contrast to PPK1, which strongly favors synthesis of polyP from ATP.
36,37
  PPK2 
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may contribute to the GTP-dependent synthesis of alginate in bacterium and its homologs have 
been identified in major bacterial pathogens.
37
  The importance of PPK1 and PPK2 in bacterial 
virulence and mucoid maintenance, respectively, suggest that the two polyP kinases may serve as 
possible targets for the discovery and design of novel antibiotics.    
Dictyostelium discoideum, a heavily-studied social slime mold, is one of a few eukaryotes 
known to possess a homolog of E. coli PPK1.
38
  Similar to bacteria, D. discoideum contains an 
additional PPK (termed DdPPK2), a tetramer that polymerizes into an actin-like filament 
concurrently with the synthesis of long-chain polyP.
39,40
  Interestingly, actin and polyP form a 
complex that masks the ends of the polyP chain, as the complex is susceptible to 
endopolyphosphatase, but not exopolyphosphatase.
39
   
 
PolyP in platelets  
In 1958, Hermansky and Pudlak described two albino patients who presented with increased 
bruising and prolonged bleeding.
41
  Subsequent studies demonstrated bleeding tendencies in 
patients with congenital deficiencies in platelet dense granules (also called delta granules).
42,43
 
Ruiz et al.
8
 noted that the dense granules of human platelets were strikingly similar in appearance 
to acidocalcisomes of unicellular organisms, as both are spherical, acidic,
44
 electron-dense,
45
 and 
contain divalent metal ions including Ca
2+
, Mg
2+
 and Zn
2+
.
46
  Platelet dense granules were 
known to contain inorganic phosphate and pyrophosphate,
46
 but whether they contained polyP 
was unknown.  In 2004, Ruiz et al.
8
 reported for the first time that platelet dense granules have 
abundant polyP, at a concentration inside dense granules of about 130 mM (expressed in terms of 
phosphate monomer, as polyP concentrations are typically reported in the literature).  Consistent 
with this finding, Ruiz et al.
47
 subsequently reported that patients diagnosed with platelet dense 
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granule defects (and experiencing bleeding symptoms) have platelet polyP levels about ten times 
lower than normal. PolyP is efficiently secreted following platelet activation.
8,48
  Since human 
platelets contain 0.74 ± 0.08 μmol polyP/1011 platelets (expressed in terms of phosphate 
monomer),
8
 and given the normal range of platelets in human blood (1.5 to 4.5 × 10
11
 
platelets/L), one can calculate that human blood will contain 1 to 3 µM polyP after full platelet 
activation.  In platelet-rich thrombi, local polyP concentrations are likely to be orders of 
magnitude higher than this. Unlike microbial polyP, platelet polyP is smaller and much less 
heterodisperse, having polymer lengths about 60 to 100 phosphate units long.
8,48
  
 
Initiation of blood clotting via the contact pathway: a critical role for polyP 
The classic blood clotting cascade can be triggered via either the tissue factor pathway or the 
contact pathway (Figure 1.2).  While the tissue factor pathway is essential for hemostasis,
49
 the 
contact pathway is not required since humans and animals lacking factor XII have no bleeding 
tendencies.
50
  As outlined below, however, the contact pathway plays other important roles and 
is triggered when factor XII, prekallikrein and high molecular weight kininogen assemble on 
anionic polymers or surfaces.  Factor XIIa then activates factor XI to XIa, which in turn activates 
factor IX, leading to propagation of the clotting cascade through the final common pathway. 
Although the contact pathway is dispensable for hemostasis, it clearly participates in 
thrombosis.  Clinical studies have associated elevated plasma factor XII with coronary heart 
disease, atherosclerosis
51
 and recurrent coronary events after acute myocardial infarction.
52
 The 
Study of Myocardial Infarction – Leiden (SMILE)53 reported that men in the highest quintile for 
factor XI had an approximately two-fold increased risk of myocardial infarction compared with 
the lowest quintile. Similarly, a Swiss case-control study showed a strong association between 
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plasma kallikrein and factor XI activity with a history of myocardial infarction.
54
 Another recent 
study found a significant reduction in the incidence of ischemic stroke in patients with severe 
factor XI deficiency compared with the general Israeli population.
55
 Activation of the contact 
pathway of blood clotting thus has clinical implications in pathologic thrombus formation in 
humans. 
Animal models also support a role for the contact pathway in thrombosis.  Mice deficient in 
factor XII are protected against thrombus formation in a variety of models of arterial and venous 
thrombosis.
56,57
  Factor XII gene knockout in mice also results in defective immune responses to 
infection,
58
 suggesting that the contact pathway participates in host responses to pathogens. 
Consistent with this concept, several microbial activators of the contact pathway have been 
identified, including bacterial surface proteins,
59,60
 lipopolysaccharide,
61
 teichoic/lipoteichoic 
acid,
61
 and, as discussed here, long-chain polyP.
5,62
 
The first reported role for polyP in blood clotting was a 2006 study from our lab that showed 
that polyP is strongly procoagulant, triggering clotting of plasma via the contact pathway as well 
as modulating downstream clotting reactions (Figure 1.2).
5
  For many years, the identity of the 
true (patho)physiologic activator(s) of the contact pathway has remained elusive, and in fact 
most published studies of this pathway have employed artificial activators such as glass, 
powdered clay (kaolin), diatomaceous earth, dextran sulfate, ellagic acid, or high concentrations 
of sulfatides.  Most artificial contact activators are anionic surfaces or polymers. PolyP is also a 
highly anionic polymer, and we have shown that it binds tightly to the proteins responsible for 
initiating the contact pathway.
 5, 50
   Furthermore, activation of clotting via polyP has a bell-
shaped concentration-dependence, consistent with the idea that polyP serves as a template for 
assembling multiple contact factors.
5
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PolyP accelerates thrombin generation 
As the essential cofactor for activation of prothrombin by factor Xa, factor Va occupies a central 
place in the clotting cascade (Figure 1.2).  In 2006, our laboratory identified that polyP 
accelerates the proteolytic conversion of factor V to Va by both factor Xa and thrombin, 
resulting in an accelerated thrombin burst during plasma clotting reactions.
5
  Accelerating factor 
V activation has interesting consequences for blood clotting.
5
  When roughly platelet-sized polyP 
was added to plasma and triggered clotting with either tissue factor-liposomes or factor Xa plus 
phospholipids, the anticoagulant function of tissue factor pathway inhibitor (TFPI) was totally 
abrogated.
5,62
  TFPI is a multifunctional serine protease inhibitor in plasma and platelets, and one 
of its most important targets is thought to be newly generated factor Xa.
63
  Mast and Broze 
showed that TFPI is a poor factor Xa inhibitor once factor Xa is bound to factor Va, especially in 
the presence of plasma concentrations of prothrombin.
64
  Consistent with this observation, 
spiking plasma with factor Va also abrogates TFPI’s anticoagulant activity.5  Interestingly, 
however, shorter polyP polymers are required to abrogate TFPI function than to enhance factor 
V activation, suggesting that polyP may be directly interacting with TFPI.  Furthermore, platelet 
releasates strongly inhibit TFPI function and that almost all of this TFPI-abrogating activity is 
directly attributable to polyP.
5,48
  And finally, platelets from Hermansky-Pudlak syndrome 
patients exhibit reduced plasma clotting activity, which could be restored by adding polyP.
48
  
Taken together, these studies show that polyP secreted by human platelets profoundly enhances 
blood clotting reactions. 
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PolyP enhances fibrin clot structure and stability 
Thrombin converts fibrinogen into fibrin by limited proteolysis, and the resulting fibrin 
monomers spontaneously associate to form a three-dimensional clot.  When fibrinogen was 
mixed with polyP plus plasma concentrations of Ca
2+
, then added thrombin, the resulting fibrin 
clots were more turbid, had fibrils with higher mass/length ratios, were more resistant to elastic 
stretching, and were more resistant to fibrinolysis than were clots formed under identical 
conditions but without polyP.
65
  After such clots were washed extensively with buffer, they 
exhibited strong, metachromatic staining with toluidine blue, characteristic for the presence of 
polyP.
65
  Thus, polyP appears to become incorporated into fibrin clots, although how polyP alters 
fibrin clot structure is not known.  Heparin, another highly anionic linear polymer, also increases 
fibrin clot turbidity
66
 but unlike the case with polyP, clots formed in the presence of heparin have 
increased susceptibility to fibrinolysis.
67,68
  PolyP therefore alters fibrin clot structure in a 
manner different from that of heparin or other anionic polymers.
69
  PolyP of the size secreted by 
activated platelets is just within the range necessary to enhance fibrin clot structure, although 
optimal fibrin enhancement requires longer polyP polymers.
62
 
Studies from our laboratory have also revealed that pyrophosphate abrogates the ability of 
polyP to enhance fibrin clot structure, while having no discernible effect on fibrin clots formed in 
the absence of polyP.
62
  It has been known for many years that activated platelets secrete 
pyrophosphate in relatively large amounts (comparable to the amount of polyP that they secrete
8
) 
but to our knowledge, no convincing roles for platelet pyrophosphate have been proposed.  These 
results suggest that pyrophosphate may be an overlooked regulator of fibrin clot structure.
62
 
Mutch et al.
70
 reported that polyP attenuates fibrinolysis by inhibiting the binding of fibrin to 
tissue-type plasminogen activator or plasminogen.  PolyP also slows fibrinolysis in plasma clots 
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in a manner that is dependent on the presence of thrombin-activatable fibrinolysis inhibitor 
(TAFI), a carboxypeptidase that removes C-terminal lysine residues from fibrin.
5
  This latter 
function may be a consequence of the earlier thrombin burst when plasma is clotted in the 
presence of polyP. 
 
PolyP drives inflammation and thrombosis 
The contact pathway plays important roles in inflammation.  Activation of the contact pathway 
results in proteolytic liberation of bradykinin (a potent vasoactive peptide) from high MW 
kininogen. Furthermore, a body of work has shown that components of the contact pathway can 
be selectively activated on cell surfaces, with or without triggering of clotting via activation of 
factor XI by factor XIIa.
71
  Accordingly, the contact pathway is perhaps more accurately termed 
the kallikrein-kinin system, which is implicated in acute and chronic inflammation in a number 
of human diseases.
72,73
  The kallikrein-kinin system also represents a point of cross-talk between 
the clotting and complement systems. In addition to bradykinin generation, kallikrein has been 
shown to directly activate complement components C3 and C5,
74,75
 while factor XIIa also 
initiates the classical complement cascade.
76
  A tragic example of pathologic activation of the 
contact pathway in vivo occurred in 2008, when therapeutic heparin contaminated with 
oversulfated chondroitin sulfate entered the drug supply, resulting in 81 deaths.
77
  Follow-up 
studies confirmed that oversulfated chondroitin sulfate (a highly anionic glycosaminoglycan) 
triggers the contact system, resulting in bradykinin generation and activation of complement 
components C3 and C5 in a factor XII- and kallikrein-dependent manner.
78
 
Our studies have shown that long-chain polyP is an extremely potent trigger of the contact 
pathway,
5,48
 raising the possibility that polyP could drive inflammatory reactions.  A recent study 
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from Renné and colleagues investigated in vivo roles for polyP using mouse models of 
inflammation and thrombosis.
48
   PolyP administered intravenously at high doses to wild-type 
mice led to lethal pulmonary embolism while factor XII-deficient mice survived, as did wild-
type mice administered an inhibitor of factor XIIa (CSL829).  In other experiments, platelets 
were activated in vivo in wild-type mice by intravenous injection of an agonist peptide that 
stimulates protease-activated receptors (PARs), resulting in death by pulmonary embolism.
48
 
Factor XII-deficient mice were protected from this otherwise lethal challenge, as were wild-type 
mice given high doses of alkaline phosphatase intravenously prior to administration of agonist 
peptide (to digest polyP).  These experiments demonstrate that polyP can be thrombogenic in 
vivo, in a factor XII-dependent manner.
48
 
As with other activators of the contact system, polyP promotes proteolysis of high MW 
kininogen with concomitant bradykinin release.
48
   In a mouse model of edema, mice were 
injected subcutaneously with polyP, which provoked localized capillary leak (quantified by 
extravasation of Evans blue dye).  Mice lacking either factor XII or the bradykinin B2 receptor 
were protected from polyP-induced edema, as were wild-type mice that had been administered 
factor XIIa inhibitors.  In another mouse model, intraperitoneal injection of E. coli-derived polyP 
into wild-type mice led to a rapid drop in systemic arterial blood pressure and death of 90% of 
the mice in 15 minutes, while mice lacking either factor XII or bradykinin B2 receptors survived 
this challenge.
48
  These experiments show that polyP can be strongly proinflammatory in vivo, in 
a manner that depends on factor XII activation and bradykinin generation. 
The role of polyP in inflammation independent of the contact pathway has also received 
increasing attention in recent years.  Extracellular histones have been shown to exhibit potent 
proinflammatory and procoagulant activities.
79
  Esmon and colleagues have shown that polyP 
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substantially augments the procoagulant activity of histones, resulting in enhanced platelet 
activation and thrombin generation independent of factor XII or tissue factor.
80
  The mechanism 
by which polyP enhances histones’ procoagulant activity is not known.  Another recent study 
from Rezaie and coworkers reported that polyP exerts a proinflammatory effect via NF-κB 
activation.
81
  It is conceivable that polyP may also interact with pathogen-associated molecular 
pattern receptors on the cell surface or with chemokines to modulate inflammatory reactions.  
Future studies with pathogen-derived polyP are required to assess the multiple roles of polyP in 
host-pathogen responses.   
 
Methods for preparing and analyzing polyP 
An expanding body of research is investigating the roles of polyP in biological systems, but 
difficulties facing researchers in this field include the relative scarcity of commercial sources of 
size-fractionated polyP, as well as a dearth of techniques for manipulating and detecting polyP at 
µg and ng quantities (other than using radiolabeled polyP, which is not always practical). The 
late Dr. Arthur Kornberg, in his last paper on polyP biology,
37
 stated “for more widespread 
research on polyP, improvements in assay methods are needed. Among the reasons for the 
neglect of polyP research has been the lack of sensitive and facile analytical methods to assess its 
concentration in biological sources. . .” Recent studies from several groups, including our own, 
are starting to fill this gap. 
PolyP is an industrial chemical with applications in water treatment, fertilizer production, 
food processing and the production of flame retardants.
82
  It can be chemically synthesized in 
very large quantities (metric tons) simply by heating sodium orthophosphate to a few hundred 
degrees Celsius, and then rapidly cooling.
83
  Commercial sources for heterodisperse polyP 
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preparations of various sizes include Sigma-Aldrich (St. Louis, MO) and BK Giulini (Ladenberg, 
Germany).   A preparation of water-soluble, high MW polyP can be isolated from very high MW 
“insoluble” polyP by differential solubilization using LiCl solutions.83  Other size ranges of 
polyP can be prepared via partial alkaline or acidic hydrolysis of long-chain polyP, enzymatic 
degradation with endopolyphosphatases, or differential acetone precipitation under various salt 
conditions.
83
  Narrow size fractions of polyP are best prepared using preparative gel 
electrophoresis.
62,84
  Polymer lengths of short- to medium-chain polyP can be characterized using 
paper chromatography, ion-exchange chromatography (2-12mers),
85
  gel-filtration, or 
31
P-NMR 
spectroscopy.
8,48,62
   Larger and more heterodisperse polymers are best sized using analytical gel 
electrophoresis.
62,84
   PolyP may be detected in polyacrylamide gels using either toluidine blue or 
DAPI staining.
83,86
  PolyP can be quantified as monophosphate following complete hydrolysis by 
acid or by enzymatic digestion (with, for example, exopolyphosphatase from Saccharomyces 
cerevisiae or calf intestinal alkaline phosphatase).
83,87
    In solution and in cells and tissues, polyP 
can also be detected (and, to some extent, quantified) using the same dyes that are used to stain 
polyP in gels, including toluidine blue
83,88,89
 or DAPI,
87,90-92
 which exhibit metachromatic 
staining of polyP.  Low levels of polyP can be accurately quantified using enzymatic methods, 
although these approaches are laborious and some of them require using radioisotopes (
32
P) for 
high sensitivity.
83,93
 
The ubiquitous nature of polyP throughout biology, together with its simple structure, make 
it unlikely that specific blocking antibodies could be raised against polyP.   Alternative methods 
for targeting polyP are being developed, however.   For example, in the fifth and sixth chapters 
of this thesis, we successfully used the isolated polyP-binding domain of E. coli 
exopolyphosphatase (i.e., lacking the phosphatase catalytic domain) to block the procoagulant 
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function of polyP in platelet releasates,
94
 in a manner akin to using a blocking antibody.   
Alternatively, recombinant yeast exopolyphosphatase has been employed to digest polyP.
13
  
Alkaline phosphatase (a highly active exopolyphosphatase), which also enzymatically degrades 
polyP, has been successfully used to destroy polyP procoagulant activity in vitro.
5,48
  In vivo, 
treatment of polyP with alkaline phosphatase abrogated activation of the contact system and 
bradykinin generation, abolished procoagulant platelet activity, and blocked platelet-induced 
thrombosis in mice.
48
  A potential drawback to using a relative nonspecific enzyme such as 
alkaline phosphatase is that it can also enzymatically degrade other phosphate-containing 
compounds such as ADP, an important platelet agonist.  And finally, the isolated polyP binding 
domain of E. coli exopolyphosphatase has been used successfully as a probe to localize polyP in 
yeast cells
95
 and in acidocalcisomes in eggs of sea urchins
96
 and insects.
97
 
 
Scope of this thesis 
This first chapter serves as a brief introduction to polyP biology and the recently reported 
roles of polyP in individual blood clotting reactions.  The second chapter of this thesis illustrates 
that polyP exerts differential effects on the contact pathway of blood clotting depending on 
polymer size.  The third chapter identifies reaction conditions under which the terminal phos-
phates of polyP can be made to enter into stable phosphoramidate linkages with almost any 
primary amine-containing compound, using the zero-length coupling reagent, EDAC (1-ethyl-3-
[3-dimethylaminopropyl] carbodiimide).  Using EDAC-mediated coupling chemistry, the 
terminal phosphates of polyP can be covalently attached to almost any primary amine-containing 
solid supports or probes such as biotin, fluorophores, and polyamines.  The fourth chapter 
identifies a panel of polyphosphate inhibitors, including cationic proteins, polymers and small 
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molecules and compares their effectiveness in abrogating polyP-mediated procoagulant and 
proinflammatory reactions in vivo and in vitro.  The fifth chapter shows that polyP of the size 
secreted by platelets strongly supports factor XI activation by thrombin and factor XIa 
(autoactivation).   The sixth chapter demonstrates how polyP accelerates factor V procofactor 
activation by factor XIa.  Finally, the seventh chapter will summarize the prohemostatic, 
prothrombotic and proinflammatory effects of polyP.  This final section will also propose 
microbial polyP as a (patho)physiologic activator of the contact pathway and a key player in the 
web of host-pathogen interactions.   
 
FIGURES 
 
 
 
 
Figure 1.1. Structure of inorganic polyP.  PolyP is a linear, highly anionic polymer of 
phosphates held together by high-energy phosphoanhydride bonds.  Platelet polyP is 
approximately 60 to 100 phosphate units long,
8,48
 while microbial polyP can range up to 
thousands of phosphate units long.
3,98
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Figure 1.2. The various effects of polyP in blood clotting.  Before the beginning of this thesis 
project, polyP was identified to potently act at three points in the clotting cascade, indicated in 
red: 1, initiates the contact pathway of blood clotting;
5,48
  2, accelerates factor V activation and 
abrogates TFPI function (the latter not shown explicitly);
5
  and 3, enhances fibrin 
polymerization.
65,70
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2
This chapter in its entirety has been published as Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate 
exerts differential effects on blood clotting, depending on polymer size. Blood. 2010;116(20):4353-4359. 
 
CHAPTER 2:  POLYPHOSPHATE EXERTS DIFFERENTIAL EFFECTS ON THE 
CONTACT PATHWAY DEPENDENT ON POLYMER SIZE
2
 
 
 
ABSTRACT 
Polyphosphate, a linear polymer of inorganic phosphate, is secreted by activated platelets 
and accumulates in many infectious microorganisms. We recently showed that polyphosphate 
modulates the blood coagulation cascade at three steps:  it triggers the contact pathway, it 
accelerates factor V activation, and it enhances fibrin polymerization. We now report that 
polyphosphate exerts differential effects on blood clotting depending on polymer length. Very 
long polymers (>500mers, such as those present in microorganisms) were required for optimal 
activation of the contact pathway, while shorter polymers (~100mers, similar to the polymer 
lengths released by platelets) were sufficient to accelerate factor V activation and abrogate the 
anticoagulant function of tissue factor pathway inhibitor.  Optimal enhancement of fibrin clot 
turbidity by polyphosphate required >250mers.  Pyrophosphate, which is also secreted by 
activated platelets, potently blocked polyphosphate-mediated enhancement of fibrin clot 
structure, suggesting that pyrophosphate is a novel regulator of fibrin function. In conclusion, 
polyphosphate of the size secreted by platelets is very efficient at accelerating blood clotting 
reactions but is less efficient at initiating them or at modulating clot structure. Microbial 
polyphosphate, which is highly procoagulant, may function in host responses to pathogens. 
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INTRODUCTION 
 Polyphosphate (polyP) — a linear polymer of inorganic phosphate — accumulates in a 
variety of microorganisms
1
 and is secreted by activated human platelets.
2,3
  We recently showed 
that polyP is a potent modulator of the human blood clotting system.
3-6
  The polymer lengths of 
polyP are known to vary substantially among different organisms and cell types, with relatively 
short polymers being secreted by human platelets (approximately 60-100 phosphate units long)
2,3
 
and very long polymers accumulating in microorganisms (many hundreds to over 1000 
phosphate units long).
1
 In this study, we demonstrate that shorter versus longer polymers of 
polyP have differential effects on the blood clotting system, with important 
physiologic/pathophysiologic implications. 
PolyP has been widely described in unicellular organisms such as bacteria, fungi, algae 
and protozoa, where it plays diverse physiologic roles, including regulating growth, stress 
responses, and virulence.
1,7
 Comparatively less is known about the metabolism or physiologic 
roles of polyP in mammalian cells,
8
 although polyP is reported to induce apoptosis in plasma 
cells,
9
 promote calcification in osteoblasts,
10
 block metastasis of melanoma cells in a mouse 
model,
11
 and possibly serve as a regulatory factor in proliferative signaling pathways.
12
 
PolyP is present at high concentrations in dense granules of human platelets and is 
secreted upon platelet activation.
2,3
 PolyP has a half-life in plasma of about ninety minutes, 
owing to degradation by phosphatases.
4,13
 We recently showed that polyP is a potent hemostatic 
regulator, acting at three points in the blood clotting cascade: it initiates the contact pathway of 
blood clotting;
3,4
 it accelerates the activation of factor V (FV) by thrombin and factor Xa (FXa);
4
 
and it enhances the thickness of fibrin fibers.
5
 Our previous studies were conducted with 
heterodisperse polyP preparations, so the precise size-dependence of the actions of polyP on 
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blood clotting was unknown.  In the present study, we isolated polyP preparations of carefully 
defined polymer lengths and used them to investigate the effects of polyP on the blood clotting 
system.  We now report that initiation of the contact phase of blood clotting, accelerating FV 
activation, and enhancing fibrin clot structure exhibited markedly different polyP size 
requirements.  We further report that inorganic pyrophosphate (PPi) — which is also secreted by 
activated human platelets — abrogated the polyP-mediated enhancement of fibrin clot structure. 
These findings have implications for the role of microbial versus endogenous (platelet-derived) 
polyP in modulating the blood clotting system in health and disease. 
 
EXPERIMENTAL PROCEDURES 
Materials 
Sodium phosphate, sodium PPi, sodium triphosphate, kaolin, ADP, ATP, soluble polyP 
preparations of varying polymer size ranges (marketed as “sodium phosphate glass”), and high 
MW polyP (marketed as “phosphate glass, water insoluble”) were from Sigma-Aldrich (St. 
Louis, MO). In this paper, we use the naming convention of the supplier (Sigma) for the 
purchased polydisperse polyP preparations: type 25, type 45, type 65 (catalog number S6253), 
and type 75+ (catalog number S8262), with nominal mean polymer lengths of 25, 45, 65 and >75 
phosphates, respectively. (In previous studies,
4-6
 we referred to polyP type 75+ as “polyP75”.) In 
this paper, we refer to size-fractionated polyP preparations of very narrow size distributions 
(described below) by their measured polymer length followed by “mer” (for example, 105mer).  
Citrated, pooled normal human plasma was from George King Biomedical (Overland 
Park, KS) and FXII-deficient plasma was from Hematologic Technologies (Burlington, VT). 
Purified human fibrinogen, FXa, and α thrombin were from Enzyme Research Laboratories 
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(South Bend, IN). Phospholipid vesicles consisting of 20% phosphatidylserine and 80% 
phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) were made by sonication. 
Recombinant tissue factor pathway inhibitor (TFPI) was a kind gift from Dr. George Broze. 
 
Isolation of polyP from bacteria 
PolyP was extracted from an exopolyphosphatase-deficient strain of Salmonella enterica serovar 
Typhimurium provided by Dr. James Slauch.  Extraction and purification of polyP from bacteria 
was adapted from Ault-Riche et al.
14
 as follows: Bacteria were grown at 37°C in LB in shaking 
cultures to mid-log phase (A600 = 0.9), collected by centrifugation, resuspended in MOPS 
medium
15
 containing 0.1 mM NaH2PO4 and 4 mg/mL glucose, and incubated with shaking at 
37°C for an additional 1-2 hours to induce polyP accumulation.  Bacteria were collected by 
centrifugation, resuspended in 10 mM Tris (pH 8.0), 2.7 kU/mL Ready-Lyse lysozyme 
(Epicentre, Madison, WI), 1.4 mM EDTA, and sonicated for 5 minutes.  The lysate was 
supplemented with 3.5 mM MgCl2 and 30 U/mL Benzonase nuclease (Novagen, San Diego, CA) 
and incubated for 30 minutes at 37°C, after which solid guanidinium isothiocyanate (4 M final) 
was dissolved in the lysate and the mixture heated for 5 minutes at 100°C.  The mixture was 
cooled and the pH adjusted to 5.5 with sodium acetate, followed by addition of cold ethanol 
(30% final).   Glass milk
16
 was added (2 μL of 50% glass milk slurry per mL of original culture) 
and polyP was allowed to bind for 10 minutes at 25°C with mixing.  Glass milk was collected by 
centrifugation, then washed thrice with 5 mM Tris HCl pH 7.4, 50 mM NaCl, 50% ethanol.  
PolyP was eluted by resuspending the glass milk in 50 mM Tris pH 8.74 at 95°C for 5 minutes.  
Any contaminating nucleic acids were digested by incubating with 100 U/mL Benzonase, 0.2 
mM ammonium molybdate for 30 minutes at 37°C, after which polyP was precipitated by adding 
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NaCl (50 mM final) followed by 2 volumes of ice-cold acetone.  After incubating at -80°C for 30 
min, the precipitate was collected by centrifugation at 10,000 x g, air dried for 10 min, and 
dissolved in purified water. Yield was 61 g polyP per L of bacterial culture. 
 
Isolation of PolyP from Platelets 
PolyP was purified from human pheresis platelets (~3-4 x 10
11
 platelets/pheresis unit) obtained 
from the Regional Blood Center of Central Illinois. PolyP isolation was as described
3
 with these 
minor modifications: the lysis buffer contained 0.5% SDS; proteinase K digestion was conducted 
at 50ºC; the pH of the solution following Dowex resolubilization was neutralized with 40 mM 
Tris base; and the final polyP preparation was dialyzed overnight, using 1000 MW cutoff 
dialysis tubing, against 20 mM Tris pH 7.4 plus Chelex 100 resin (Bio-Rad, Hercules, CA) to 
ensure removal of any bound metal ions. 
 
Size-fractionation of polyP 
PolyP was size-fractionated by preparative PAGE based on the method of Clark and Wood.
17
  
For shorter polymers (<150mers), a mixture of 5 mg polyP type 25 plus 5 mg polyP type 75+ 
was resolved on 18 x 16 cm 15% polyacrylamide or 40 x 16 cm 20% polyacrylamide gels in 
TBE (90 mM Tris, 90 mM borate, 2.7 mM EDTA, pH 8.3) until xylene cyanol FF migrated 7 cm 
and bromophenol blue, 14 cm.  For longer polymers (>150mers), “insoluble” high MW polyP 
was washed twice with purified water on a fritted glass funnel to deplete very short polymers, 
then resuspended in 250 mM LiCl and stirred for 2 hours at room temperature, after which 
residual insolubles were removed by centrifugation (5000 x g for 10 minutes).  Dissolved polyP 
was precipitated from the supernatant by slowly adding 2.5 volumes of acetone, collected by 
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centrifugation (10,000 x g for 20 minutes), dried overnight, and dissolved in purified water, 
resulting in a highly disperse population of polyP polymer lengths.  Approximately 20 mg of this 
preparation was resolved on 18 x 16 cm 4% or 6% polyacrylamide gels (in TBE) until xylene 
cyanol FF migrated 7 cm and bromophenol blue, 14 cm.  Narrowly size-fractionated polyP 
preparations were eluted from individual 1 cm-wide slices of the 4%, 6%, 15% or 20% gels, 
while heterogeneous preparations containing very long polymers greater than either 400mer or 
1000mer (termed polyP400+ and polyP1000+ respectively) were obtained by pooling several 1 cm-
wide gel slices from 4% gels. 
PolyP was eluted from gel slices by crushing and agitating overnight in 2.5 mL purified 
water. Fragments of polyacrylamide were removed by centrifugation using Handee centrifuge 
columns (Pierce, Rockford, IL), and the eluted polyP was dialyzed against purified water 
overnight using Snakeskin
®
 dialysis tubing (MW-cutoff, 3500) for polymers >100mers, or Slide-
A-Lyzer mini dialysis units (MW-cutoff, 1000; both from Pierce, Rockford, IL) for polymers 
<100mers.  
31
P NMR spectra of polyP preparations were acquired at 20°C with a Varian Unity INOVA 
600 spectrometer using a 5mm Varian AutoTuneX 
1
H/X PFG Z probe, 13.5 µs (90°) pulse 
excitation, 16 kHz spectral width, and 5 second recycle time.  Chemical shifts were referenced to 
0 ppm using an external phosphoric acid standard.  Spectra were signal averaged until the 
phosphate α peak (approximately -6 ppm) achieved a signal-to-noise ratio of at least 5:1 
(typically 20,000 to 45,000 scans, depending on sample size and concentration) and processed 
with baseline correction and 25-Hz line broadening prior to Fourier transformation.   Each 
spectrum showed a peak corresponding to external phosphates (α peak at about -6 ppm) and a 
second peak corresponding to internal phosphates (-22 to -24 ppm); for some samples, a third 
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peak was also observed, corresponding to phosphates neighboring the external residues (β peak 
at -21 to -22 ppm; see Figure 2.1 for a typical spectrum). Quantitation was performed by 
integrating the area under the curves for the each peak.  Because each polyP polymer has two α 
residues, the number of internal phosphorus atoms, N, was determined using the equation, N/2 = 
t/α, where α is the integration of the α peak and t the integration of the internal phosphate peak 
(plus the β peak, when present). PolyP polymer lengths equaled N+2. 
PolyP preparations whose mean polymer lengths had been determined by NMR (and 
found to be 10, 34, 51, 60, 98, 110, 257 and 1350 phosphates long) were employed as size 
standards for estimating polymer lengths of the rest of the polyP preparations by analytical 
PAGE,
17
 using 5% or 15% polyacrylamide gels with 7 M urea in TBE (Ready Gels from Bio-
Rad), and detecting polyP by toluidine blue staining or DAPI negative staining.
18
 
 
PolyP concentrations 
PolyP concentrations were measured by quantifying inorganic phosphate
19
 after complete 
hydrolysis in 1 M HCl at 100°C for 30 minutes.  Briefly, 50 µL hydrolyzed phosphate sample 
was mixed with 100 µL malachite green reagent (0.075% malachite green, 0.045% Tween-20, 
4.2% ammonium molybdate, 5 M HCl) in polypropylene multiwell plates (Corning, Corning 
NY) and incubated for 20 minutes at room temperature, after which A660 was measured in a 
Spectramax microplate reader (Molecular Devices Corp, Sunnyvale, CA) and phosphate 
concentrations determined by reference to a standard curve. Note that all polyP concentrations 
reported in this study are given in terms of phosphate monomer concentration (monomer 
formula: NaPO3). 
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Clotting assays 
Clotting times of citrated human plasma were quantified at 37°C using a STart4 coagulometer 
(Diagnostica Stago, France). Tests of the contact pathway of blood clotting were conducted 
using final concentrations of 33% plasma, 25 µM phospholipid, 0-40 µM polyP, 41.7 mM 
imidazole pH 7.0, and 8.33 mM CaCl2. Prewarmed polyP in imidazole buffer was incubated in 
coagulometer cuvettes with prewarmed plasma and phospholipid for 3 minutes, after which 
clotting was initiated by addition of CaCl2.  For comparison, a standard curve was prepared using 
various concentrations of kaolin (0.04 to 3333 g/mL), and no polyP, in the same clotting assay 
(data not shown). The specific activities of polyP preparations were then calculated, by reference 
to this standard curve, to yield kaolin equivalents
20
 (i.e., the kaolin concentration that yields the 
same clotting time as polyP, when both are plotted in terms of g/mL).  
Clotting reactions initiated by FXa contained 33% plasma, 33 µM phospholipid, 0-40 µM 
polyP, 16.7 mM Tris pH 7.4, 33.3 mM NaCl, 0.03% bovine serum albumin, 333 pM FXa, and 
8.33 mM CaCl2. Plasma was prewarmed separately from polyP and FXa components to 
minimize inhibition of FXa by plasma inhibitors and to prevent contact activation of plasma by 
polyP.  Components were then mixed simultaneously in prewarmed coagulometer cuvettes to 
initiate clotting. As the ability of polyP to shorten FXa clotting times has been attributed to 
acceleration of FV activation, we converted these shortened FXa clotting times into polyP 
specific activities by comparison to a standard curve in which the FXa-initiated clotting reaction 
was conducted in the absence of polyP but with varying concentrations (0 to 6.7 nM) of FVa 
added to the plasma. The specific activities of polyP preparations were calculated, by reference 
to this standard curve, to yield FVa equivalents (i.e., comparing the FVa concentration that 
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would yield the same clotting time as polyP, when both are plotted in terms of molar 
concentrations). 
In some experiments, the ability of polyP to antagonize the anticoagulant activity of TFPI 
was quantified by adding TFPI to plasma (400 ng/mL final), and initiating clotting with 2 nM 
FXa. For comparison, a standard curve was prepared in the absence of polyP but with varying 
TFPI concentrations (0-400 ng/mL) added to the plasma. This standard curve was then used to 
calculate the percent inhibition of TFPI activity.  
 
Fibrin clot turbidity 
Fibrin clots were formed in medium-binding, polystyrene 96-well plates as previously 
described.
5
 Briefly, mixtures of fibrinogen, polyP and calcium ions were preincubated for 15 
minutes at room temperature, after which thrombin was added to trigger clot formation.  Final 
(160 μL) reactions contained 2.6 mg/mL fibrinogen, 10 nM thrombin, 0-400 µM polyP, 50 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 0.02% NaN3, and 2.5 mM CaCl2.  Turbidities (A405) of fibrin 
clots were quantified using a Spectramax microplate reader 60 minutes after thrombin addition. 
 
RESULTS 
We previously reported that heterodisperse polyP preparations are potent modulators of blood 
clotting.
3-5
 In particular, we showed that heterodisperse, commercially available polyP type 75+, 
whose polymer lengths encompass the polyP sizes secreted by human platelets, was more potent 
in triggering the contact pathway than was polyP type 25.  However, both polyP type 25 and 75+ 
contain some polymers that are considerably longer (and shorter) than their nominal mean 
polymer lengths, so the minimum polyP polymer lengths required to modulate blood clotting 
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were not known.  This is important because polyP secreted by platelets (60mers to 100mers)
2
 are 
considerably shorter than the polyP found in infectious microorganisms (frequently in excess of 
1000 phosphate units long).
1
 We therefore tested the hypothesis that very long polyP polymers 
(500mers to 1500mers) exert differential effects on blood clotting compared to the much shorter 
polyP polymers that are secreted by platelets.  In order to test this hypothesis we isolated polyP 
preparations with narrow size distributions. 
 
Size-fractionation of polyP and determination of polymer length 
PolyP was size-fractionated by preparative PAGE, and the polymer sizes of selected fractions 
were determined by NMR (an example is in Figure 2.1). We also used NMR analyses to 
determine the mean polymer lengths for polyP type 65 (67 phosphates) and type 75+ (158 
phosphates). Figure 2.2 shows the size distributions of several commercial, heterodisperse polyP 
preparations, compared to narrowly size-fractionated polyP preparations used in this study.  We 
also prepared heterodisperse polyP with polymer sizes >400mer (polyP400+; Fig. 2.2A), and 
>1000mer (polyP1000+; Fig. 2.2B). PolyP purified from S. Typhimurium was very heterodisperse, 
with polymers ranging in size from about 100mers to about 1300mers (Fig. 2.2B) while platelet-
derived polyP was fairly homogeneous in size (Fig 2.2C) and comparable to the size range 
reported previously.
2,3
  
 
Very long polyP polymers are most efficient at initiating clotting via the contact pathway 
Using polyP preparations of narrowly defined polymer size, we found that polyP from 
monophosphate to 30mers did not shorten the clotting time of recalcified plasma, when tested at 
20 μM polyP (data not shown).  53mers detectably accelerated plasma clotting, with clotting 
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times decreasing as polyP polymer length increased.  In order to understand the relative 
potencies of these different polyP preparations, we converted their clotting times into specific 
activities based on “kaolin equivalents.”20 This was accomplished by determining the 
concentration, on a mass basis, of kaolin that would yield the same clotting time observed with a 
given concentration of polyP (data not shown). The results (Figure 2.3A) show that polyP 
specific activities increased as polymer length increased. Thus, polyP purified from human 
platelets (size range, approximately 60-100mer) had a specific activity in this clotting assay that 
was, on a mass basis, 4.9 + 0.9 fold higher than kaolin. Note that polyP purified from human 
platelets had essentially the same specific activity as synthetic polyP of the same size (Figure 
2.3A). Bacterial polyP had a very high specific activity, while the strongest procoagulant activity 
in this assay was exhibited by polyP1000+, which had a specific activity >3000-fold higher than 
that of kaolin. 
The procoagulant activity of polyP in this clotting assay was dependent on the contact 
pathway, since FXII-deficient plasma did not clot (all clotting times were >1000 seconds with 20 
M polyP; not shown). 
Adding an excess of short-chain polyP of a variety of sizes inhibited plasma clotting 
initiated by long-chain polyP (Figure 2.3B).  On the other hand, a similarly large excess of very 
short phosphates (monophosphate, PPi and triphosphate) had no effect on polyP-initiated clotting 
via the contact pathway (Figure 2.3B). 
 
Shorter polyP polymers accelerate FXa-initiated clotting 
We previously reported that polyP type 75+ shortened plasma clotting times initiated by either 
tissue factor or FXa, an effect that we demonstrated was due to accelerating FV activation.
4
 In 
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the present study, we evaluated this aspect of polyP’s procoagulant effect using polyP polymers 
of defined lengths in clotting assays initiated by FXa.  Short polymers did not appreciably 
shorten FXa-initiated plasma clotting times, but longer polyP polymers (>60mers) detectably 
accelerated plasma clotting (data not shown). We converted these clotting times into specific 
activity (FVa equivalents, on a molar basis) by reference to a standard curve in which plasma 
was spiked with varying FVa concentrations (standard curve not shown). The results (Figure 2.4) 
show that maximal specific activities in this clotting assay were achieved with polyP polymers 
that were about 125 to 200 phosphates long, while progressively longer polymers (especially 
>400mers, including bacterial polyP) had somewhat reduced specific activities compared to 
125mers. A large excess of monophosphate, PPi, or triphosphate did not antagonize the 
procoagulant activity of longer-chain polyP (not shown). PolyP shortened FXa-initiated clotting 
times equally well in normal and FXII-deficient plasma (Figure 2.4B), indicating that this effect 
of polyP is independent of the contact pathway of blood clotting. 
 
Shorter polyP polymers abrogate TFPI anticoagulant activity 
We previously reported that polyP abrogated the anticoagulant function of TFPI, which was 
largely attributed to the ability of polyP to accelerate FV activation;
4
 FVa is known to protect 
FXa from TFPI inhibition,
21
 which we previously confirmed.
4
 When we tested the ability of 
polyP preparations of defined polymer lengths to abrogate TFPI anticoagulant activity, we found 
that polymers as short as 11mers detectably accelerated clotting in the presence of TFPI, while 
longer polymers were more potent in antagonizing TFPI anticoagulant function (data not shown). 
Maximal abrogation of TFPI anticoagulant activity was observed with polyP preparations in the 
size range of ~70mers to ~250mers (Figure 2.5). Platelet-derived polyP exhibited an intermediate 
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potency in antagonizing TFPI function, while bacterial polyP and polyP type 65 were very potent 
in this assay. Adding a large excess of monophosphate, PPi, or triphosphate did not reverse the 
inhibition of TFPI anticoagulant activity by longer-chain polyP (data not shown). 
 
Longer polyP polymers enhance fibrin clot turbidity 
We recently described an additional procoagulant effect of polyP downstream of thrombin 
generation: when polyP was added to clotting reactions consisting of purified fibrinogen, 
thrombin and calcium ions, the resulting fibrin fibrils had markedly increased diameters.
5
 Our 
previous study was performed with a heterodisperse polyP preparation (type 75+), so here we 
tested the ability of polyP preparations of defined polymer lengths to enhance fibrin clot 
structure, assessed by increased clot turbidity (Figure 2.6A).  Shorter polymers (<100mers) did 
not influence fibrin clot turbidity, while progressively longer polymers increased clot turbidity, 
with >250mers supporting maximal turbidity increases. Bacterial polyP promoted similarly large 
increases in fibrin turbidity (Figure 2.6A).  Notably, the magnitude of the increase in fibrin clot 
turbidity elicited by long-chain polyP (700mers and polyP400+) was roughly double that elicited 
by polyP type 65 or 75+ (Figures 2.6A and 2.6B). 
We investigated the ability of small phosphate-containing molecules to abrogate the 
enhancement of fibrin clot turbidity by long-chain polyP.  Neither ADP nor ATP diminished the 
turbidity of fibrin clots formed in the presence of polyP400+, but monophosphate, PPi and 
triphosphate — to varying extents — inhibited the ability of polyP400+ to enhance fibrin clot 
turbidity (Figure 2.6C).  In particular, PPi potently blocked the polyP-mediated enhancement of 
fibrin clot turbidity, with half-maximal inhibition at 58 µM and complete abrogation at 250 µM 
PPi.  Monophosphate and triphosphate were far less potent than PPi; even at 1 mM they 
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decreased the polyP-mediated enhancement of fibrin clot turbidity by only 65% (Figure 2.6C).  
PPi had no measurable effect on fibrin clot turbidity in the absence of polyP (not shown).  PolyP 
polymers from 23mers to 73mers (tested at 150 µM) did not detectably diminish the 
enhancement of fibrin clot turbidity induced by 100 µM polyP400+ (Figure 2.6D).  
 
DISCUSSION 
We previously reported that heterodisperse polyP preparations modulate the human blood 
clotting system by initiating the contact pathway of blood clotting,
3,4
 accelerating the activation 
of FV by thrombin and FXa,
4
 and enhancing the thickness of fibrin fibers.
5
 Here we demonstrate 
that polyP polymers of different lengths exert differential effects on blood coagulation.  In a 
separate study, we recently showed that polyP purified from human platelets triggered plasma 
clotting via the contact pathway, promoted activation of FXII and prekallikrein in plasma, 
promoted bradykinin formation in plasma, caused bradykinin-mediated edema when injected 
subcutaneously in mice, and triggered thrombosis when injected intravenously in mice.
3
 That 
study showed that FXII-deficient mice were protected from the lethal effects of injected polyP, 
and also that phosphatase treatment of activated platelets (to hydrolyze released polyP) abrogated 
their ability to trigger clotting via the contact pathway.
3
 In the present study, we found that polyP 
polymers of the sizes secreted by platelets (60mers to 100mers) initiated clotting via the contact 
pathway with a potency, on a mass basis, that was about fivefold greater than that of kaolin, a 
potent trigger of the contact pathway of blood clotting. Thus, the results in the present study are 
fully consistent with our previous demonstration that polyP secreted from platelets exerts 
procoagulant and proinflammatory activity in vivo.
3
 On the other hand, longer polyP polymers, 
including those isolated from bacteria, are even more potent at activating the contact pathway of 
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blood clotting — and in fact, these long polyP polymers are, on a mass basis, thousands of times 
more potent than kaolin in triggering blood clotting. 
We now report that short polyP polymers antagonized the ability of very long polyP 
polymers to trigger blood clotting via the contact pathway.  Long polyP polymers likely act as 
templates to assemble the multiple proteins necessary to fully activate the contact pathway, and 
in fact we recently showed that polyP binds to FXII, high MW kininogen, FXI and prekallikrein 
(with the tightest binding to FXII and high MW kininogen).
3
 We speculate that shorter polyP 
polymers also bind to these individual clotting proteins but are not long enough to bind multiple 
proteins simultaneously, thereby acting as competitors that keep these proteins from assembling 
effectively together on polymers long enough to promote the mutual activation of FXII and 
prekallikrein.  Notably, polyP isolated from human platelets spans a narrow size range, and in 
particular, platelet polyP lacks polymers shorter than 60mers which could inhibit the activation 
of the contact pathway.
2,3
 On the other hand, commercial polyP preparations are typically very 
heterodisperse, with polyP type 65 and type 75+ containing significant quantities of very short 
polyP polymers.  This may explain a recent report that polyP type 65 (from the same commercial 
source as in this study) was very effective at promoting FXII autoactivation in plasma, but much 
less effective at promoting FXI or prekallikrein activation.
22
 Enzymes of the contact pathway 
participate in a variety of (patho)physiologic processes other than triggering blood clotting, 
including blood pressure regulation as well as modulating fibrinolysis, angiogenesis and 
apoptosis; in fact, this system has been described as the plasma kallikrein-kinin system, since 
prekallikrein can be activated on cell surfaces independent of FXII.
23
 It is possible that shorter 
polyP polymers may promote activation of some of the enzymes of the contact pathway even 
when this does not lead to actual clot formation, an idea that we are investigating further. 
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In this study we showed that bacterial polyP was very potent at triggering the contact 
pathway of blood clotting. Damaged microorganisms might release intracellular polyP, and 
organisms such as Neisseria meningitidis and Neisseria gonorrhoeae express large amounts of 
long-chain polyP on the exterior of their cells.
24,25
 We previously showed that exposure of long-
chain bacterial polyP to plasma also leads to elaboration of inflammatory mediators like 
bradykinin.
3
  We therefore propose that the response of the clotting system to very long chain 
polyP may be a part of the host response to pathogens. 
Long-chain polyP may also come from endogenous sources in mammals; many tissues 
contain polyP with a size range of 50mers to 800mers, while brain contains primarily long chain 
polyP (approximately 800mers).
8
 Release of long-chain polyP molecules from intracellular 
compartments in association with ischemia-triggered cell injury might play a role in contact 
activation and subsequent thrombus formation, as well as contact pathway-mediated 
inflammatory responses. In mouse models of cerebral artery ischemia-reperfusion, deficiency of 
contact pathway clotting factors was neuroprotective.
26
 
PolyP enhances the turbidity of fibrin clots by causing the formation of thicker fibrin 
fibrils that appear to incorporate polyP into the clot.
5
 In the present study, we found that polyP 
polymers shorter than 100mers had no measurable effect on fibrin clot turbidity, suggesting that 
polyP of the size secreted by platelets will not modulate fibrin clot structure.  On the other hand, 
polyP polymers longer than 250mers maximally enhanced fibrin clot turbidity, as did bacterial 
polyP.  Interestingly, we found that PPi potently inhibited the enhancement of fibrin clot 
turbidity by long-chain polyP.  Platelet dense granules contain abundant PPi (approximately 1.5 
mol PPi per 10
11
 platelets), which is secreted in response to platelet agonists.
27
 PPi released 
from platelets could readily attain a concentration of 2-7 M in whole blood, with orders of 
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magnitude higher concentrations possible within platelet-rich thrombi.  A clear role for platelet-
released PPi has not been previously defined, but we propose that PPi is a novel modulator of 
fibrin clot structure.  Further studies of the interactions between PPi and fibrin(ogen), and the 
ability of PPi to block the effects of polyP on fibrin structure, are clearly warranted. 
PolyP may have potential as a procoagulant agent to control bleeding. We previously 
reported that heterodisperse polyP type 75+ could reverse the anticoagulant effect of a number of 
anticoagulant drugs, as well as shorten the clotting times of hemophilic plasmas and plasmas 
from patients on coumadin therapy.
6
 On the other hand, injection of heterodisperse polyP 
preparations intravenously in mice can elicit generalized activation of the contact pathway, 
resulting in release of vasoactive substances and inflammatory mediators leading to hypotension 
and edema.
3
 The present study showed that short polyP polymers had limited ability to activate 
the contact pathway, but retained ability to accelerate FV activation and abrogate the 
anticoagulant activity of TFPI.  It would therefore be interesting to investigate if suitably size-
fractionated polyP preparations could be used pharmacologically to control bleeding while 
limiting the unwanted side effect of systemic activation of the contact pathway. 
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FIGURES 
 
 
 
 
 
 
 
Figure 2.1. One-dimensional 
31
P NMR spectrum of 34mer polyP.  Peaks corresponding to the 
two external phosphates (α), phosphates adjacent to the external phosphates (β), and internal 
phosphates, as indicated. 
 
 
Figure 2.2.  Size distributions of polyP preparations used in this study.  PolyP was resolved 
by electrophoresis on 5% polyacrylamide gels with 7 M urea (A, B) or on 15% polyacrylamide 
gels with 7 M urea (C) and detected by DAPI negative staining; or resolved on 15% 
polyacrylamide gels with 7 M urea and detected by toluidine blue staining (D).  Lanes containing 
size-fractionated polyP preparations are labeled by estimated polymer length, while the 
heterodisperse polyP preparations are labeled polyP type 25, type 45, type 65, type 75+, 
polyP400+, polyP1000+, “Platelet” (human platelet-derived polyP), “Bact” (S. Typhimurium polyP), 
  
44 
 
and “Start” (the solubilized “insoluble” polyP preparation that was used as the starting material 
for obtaining very long-chain polyP).  Note that polyP types 25, 45, 65, and 75+ refer to the 
nominal mean polymer lengths (given by the supplier), while the rest of the polyP sizes indicated 
in this figure were determined either by NMR analyses, or were estimated from the sample’s 
migration on analytical PAGE using polyP standards whose mean polymer lengths were 
determined by NMR (analyses not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3.  Initiation of clotting via the contact pathway is most efficient with very long 
polyP polymers.   (A) Clotting was initiated by preincubating 5 M polyP with citrated plasma 
for 3 minutes at 37ºC, after which calcium chloride was added and the time to clot formation 
recorded. PolyP specific activities were calculated by comparing polyP-initiated clotting times to 
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a standard curve in which clotting was initiated by varying kaolin concentrations (not shown), 
yielding “kaolin equivalents” on a mass basis. Activities of sized-fractionated polyP preparations 
() are compared to platelet-derived polyP (; also indicated with arrows), bacterial-derived 
polyP (“Bact”), polyP type 65, and PolyP1000+. The inset focuses on polymers shorter than 
200mer. The point for platelet polyP was plotted at its mean polymer length (80mer). (B) 
Inhibition of contact pathway-initiated clotting by an excess of small polyP polymers. Plasmas 
were preincubated for 3 minutes 37ºC with a combination of 10 M polyP1000+ and the indicated 
concentrations of shorter phosphate/polyP preparations (identified as “inhibitor” on the x axis), 
after which calcium chloride was added to allow clotting.  The short phosphates were: 
monophosphate (), PPi (), and triphosphate () (none of which had any effect); and 11mer 
polyP (), 16mer polyP (), 35mer polyP (), and 53mer polyP (), and 83mer () (which 
prolonged the clotting times in a concentration-dependent manner). The dotted line represents 
the clotting time in the absence of polyP.  Data in all panels are mean  standard error (n = 3). 
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Figure 2.4.  FXa-initiated clotting is accelerated by shorter polyP polymers than are 
required for initiating clotting via the contact pathway.  PolyP (5 M) was added 
simultaneously to normal plasma together with 333 pM FXa and calcium chloride, and time to 
clot formation was measured.  (A) PolyP specific activities were calculated by comparing polyP 
clot times to a standard curve in the absence of polyP, but in which varying FVa concentrations 
were added to plasma (not shown). The FVa concentration (in nM FVa) that yielded the same 
clotting time as a given polyP preparation was then divided by the polyP concentration (5000 
nM). Sized-fractionated polyP preparations () are compared to bacterial-derived polyP 
(“Bact”) and polyP type 65. The inset focuses on polymers shorter than 200mer. (B) Shortening 
of the FXa clotting time by polyP is independent of FXII.  PolyP preparations of the indicated 
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polymer sizes (all at 20 M phosphate) were added to FXa-initiated clotting reactions conducted 
with either pooled normal plasma (white bars) or FXII-deficient plasma (black bars). Clotting 
times with polyP were normalized to the clotting time of the respective plasma without polyP.  
Data in all panels are mean  standard error (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Accelerating FXa-initiated clotting requires even shorter polyP polymers in the 
presence of added TFPI.  Clotting reactions were conducted as in Figure 2.4A except that 
plasma contained 400 ng/mL TFPI, clotting was initiated with 2 nM FXa and polyP, when 
included, was at 20 M.  Percent TFPI inhibition was calculated by comparing polyP clot times 
to a standard curve in the absence of polyP, but in which 0 to 400 ng/mL TFPI had been added to 
plasma (not shown). Sized-fractionated polyP preparations () are compared to platelet-derived 
polyP (“Platelet”, at 150 M), bacterial-derived polyP (“Bact”), and polyP type 65. The inset 
focuses on polymers shorter than 200mer.  Data are mean  standard error (n = 3). 
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Figure 2.6.  Optimal enhancement of fibrin clot turbidity requires relatively long polyP 
polymers. Fibrin clots were prepared by adding thrombin to fibrinogen that had been 
preincubated with Ca
2+
 and polyP, and clot turbidity (A405) was quantified 60 minutes after 
thrombin addition.  (A) Clot turbidity as a function of polyP polymer size (all at 150 M 
phosphate).  The value for x = 0 is in the absence of added polyP, while “Bact” indicates S. 
Typhimurium-derived polyP. The inset focuses on polyP preparations shorter than 180mer.  (B) 
Clot turbidity as a function of polyP concentration, using the following polyP polymer lengths: 
65mer (), 158mer (), 700mer (), polyP type 65 (), polyP type 75+ (), and polyP400+ 
().  (C) PPi abrogates the ability of polyP to enhance clot turbidity. Fibrinogen was 
preincubated with calcium ions, 150 M polyP400+ and the indicated concentrations of 
phosphate-containing substances, after which thrombin was added.  The substances tested were:  
monophosphate (), PPi (), triphosphate (), ADP (), and ATP ().  The dotted line 
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represents clot turbidity in the absence of polyP.  (D) PPi, but not other polyP polymers, 
abrogates the ability of polyP400+ to enhance clot turbidity.  Phosphate polymers of the indicated 
lengths (all at 150 M phosphate) were included in fibrin clotting reactions as performed in 
panel C.  The open bar with the asterisk represents clot turbidity in the absence of polyP, while 
the open bar with “0” represents clot turbidity with polyP400+ but no added small phosphate 
polymer. 
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CHAPTER 3:  PHOSPHORAMIDATE END LABELING OF POLYPHOSPHATES
3
 
 
ABSTRACT 
 Polyphosphates, linear polymers of inorganic phosphates linked by phosphoanhydride 
bonds, are widely present among organisms and play diverse roles in biology, including 
functioning as potent natural modulators of the human blood clotting system.  However, studies 
of protein-polyphosphate interactions are hampered by a dearth of methods for derivatizing 
polyphosphate or immobilizing it onto solid supports.  We now report that EDAC (1-ethyl-3-[3-
dimetyhlamino-propyl]carbodiimide) efficiently promotes the covalent attachment of a variety of 
primary amine-containing labels and probes to the terminal phosphates of polyphosphates via 
stable phosphoramidate linkages.  Using 
31
P NMR, we confirmed that EDAC-mediated reactions 
between primary amines and polyphosphate results in phosphoramidate linkages with the 
terminal phosphate groups.  We show that polyphosphate can be biotinylated, labeled with 
fluorophores and immobilized onto solid supports; that immobilized polyphosphate can be 
readily used to quantify protein binding affinities; that covalently derivatized or immobilized 
polyphosphate retains its ability to trigger blood clotting; and that derivatizing the ends of 
polyphosphate with spermidine protects it from exopolyphosphatase degradation.  Our findings 
open up essentially the entire armamentarium of protein chemistry to modifying polyphosphate, 
which should greatly facilitate studies of its biological roles. 
 
 
  
53 
 
INTRODUCTION 
Inorganic polyphosphate (polyP), a linear polymer of orthophosphate residues linked via 
phosphoanhydride bonds, is widely distributed in biology and plays important and diverse roles 
in nature.
1,2
  We recently showed that polyP is a potent modulator of the blood clotting cascade,
3-
5
 and an expanding body of research is investigating its roles in other biological systems.
6-11
  
Many technical obstacles remain, for investigating the biological roles of polyP and there is a 
real need for improved microscale methods for analyzing polyP.  In particular, there is a dearth 
of approaches for covalently modifying polyP or attaching it to solid supports.  One of the few 
published methods for immobilizing polyP onto surfaces is via Lewis acid/base interactions 
between polyP and zirconia beads.
12
  Although we have successfully used this method,
13
 it 
suffers from relatively high nonspecific binding of proteins to zirconia.  Furthermore, this 
chemistry is not readily adaptable for attaching labels to polyP, or to immobilizing polyP onto 
the sorts of solid supports routinely used in analyses of protein interactions.  The goal of the 
present study was therefore to develop conditions for routine covalent attachment of labels to the 
terminal phosphates of polyP. 
The zero-length cross-linking reagent, EDAC (1-ethyl-3-[3-dimetyhlamino-
propyl]carbodiimide), is widely used to couple primary amines to carboxylic acids via amide 
linkages.  However, EDAC can also be used to couple primary amines to organic phosphates—
including the 5’ phosphates of oligonucleotides—via stable phosphoramidate linkages.14  We 
now report that the terminal phosphates of polyP can be made to enter into covalent phosphor-
amidate linkages with primary amine-containing compounds via EDAC (Scheme 3.1).  This 
finding essentially opens up the entire armamentarium of protein chemistry to modifying polyP, 
greatly facilitating investigations into polyP’s biological activities.  In the present study, we 
  
54 
 
demonstrate conditions under which polyP can be biotinylated, labeled with fluorophores, and 
immobilized onto solid supports.  We use the latter to quantify the binding affinities of three 
blood clotting proteins for polyP, and to demonstrate that covalently immobilized polyP retains 
its ability to trigger blood clotting.  Furthermore, we also show that derivatizing the ends of 
polyP via phosphoramidate linkages protects it from exopolyphosphatase degradation. 
 
EXPERIMENTAL PROCEDURES 
Materials 
Amine Surface and Carbo-BIND (hydrazide) multiwell strips were from Corning (Corning, NY); 
Nunc Immobilizer Streptavidin multiwell strips and Covalink-NH plates were from Thermo-
Fisher (Waltham, MA); polystyrene coagulometer cuvettes were from Diagnostica Stago 
(Parsippany, NJ); amine-PEG2-biotin was from Pierce (Rockford, IL, USA); polyethylenimine, 
spermidine, streptavidin, benzamidine and EDAC were from Sigma-Aldrich (St. Louis, MO); 
Cascade Blue-ethylenediamine was from Invitrogen (Carlsbad, CA); factor XIa, kallikrein, and 
thrombin were from Enzyme Research Laboratories (South Bend, IN); calf intestinal alkaline 
phosphatase was from Promega (Madison, WI); phospholipids were from Avanti Polar Lipids 
(Alabaster, AL); Biacore CM5 sensorchips were from GE Healthcare (Piscataway, NJ); 
chromogenic substrates S-2366 and S-2322 were from diaPharma (West Chester, OH); 
recombinant factor VIIa, and substrates Spectrozyme TH and Spectrozyme fVIIa were from 
American Diagnostica (Stamford, CT); and Sepabeads EC-HA were kindly provided by 
Resindion SRL (Milan, Italy).  PolyP5, polyP25 and polyP45 (nominal mean polymer lengths, 5, 
25 and 45, respectively, marketed as “sodium phosphate glass, types 5, 25 and 45”), and a 
heterodisperse preparation of very high MW polyP (marketed as “phosphate glass, water 
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insoluble”) were from Sigma-Aldrich, as were sodium monophosphate, pyrophosphate, and 
triphosphate.  A water-soluble fraction of relatively high MW polyP (here termed polyPHMW) 
was obtained from  “water insoluble phosphate glass” by stirring it in 250 mM LiCl and 
processing as described.
5
  PolyP14, polyP60 and polyP130 (polymer lengths, 14, 60 and 130, 
respectively) were kindly provided by Regenetiss, Inc. (Tokyo, Japan).  PolyP concentrations are 
given throughout this paper in terms of phosphate monomer (monomer formula: NaPO3). 
 
Immobilization of polyP onto polystyrene microplate wells and coagulometer cuvettes   
A variety of reaction conditions were tested in order to optimize EDAC-mediated covalent 
coupling of polyPHMW to primary amines displayed on Amine Surface stripwells.  Parameters 
varied included the concentrations of EDAC, polyP, divalent metal ions and 2-(N-
morpholino)ethanesulfonic acid (MES); pH; coupling time; and the presence or absence of 0.1 M 
imidazole.  Optimal coupling conditions for immobilizing polyP on Amine Surface stripwells 
were to treat each well at 37°C for 3 h to overnight with 200 l of a freshly-made solution of 10 
to 100 μM polyPHMW in 25 mM EDAC and 77 mM MES pH 6.5.  Unreacted polyP was then 
removed by two 10 min washes with 2 M LiCl followed by two 5 min water washes.  When 
desired, immobilized polyP was quantified following hydrolysis in 1 M HCl at 100°C by 
malachite green assay.  Briefly, 50 µL hydrolyzed phosphate sample was mixed with 100 µL 
malachite green reagent (0.1% malachite green, 4.2% ammonium molybdate, 4 M HCl) in 
Corning polypropylene multiwell plates and incubated for 20 min at room temperature, after 
which A660 was measured and phosphate concentrations determined by reference to a standard 
curve.
5
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Optimal conditions for immobilizing polyPHMW onto polystyrene coagulometer cuvettes 
were to treat each well overnight at 37°C with 200 µl of 400 ng/mL polyethylenimine in 0.1 M 
carbonate buffer pH 9.2, wash 5 times in purified water, then incubate each well for 4 h with 200 
l of a freshly made solution of 245 µM polyPHMW in 50 mM EDAC, 1 mM CaCl2, and 77 mM 
MES pH 6.5.  Wells were washed twice with 2 M LiCl, then twice with water. 
 
Covalent coupling of biotin or fluorophores to polyP 
For biotinylation of polyP, typical conditions were to incubate 10 mM polyPHMW overnight at 
37°C with 0.5 mM amine-PEG2-biotin, 100 mM EDAC, and 100 mM MES pH 6.5.  For 
fluorescent labeling of polyP, typical reaction conditions were as for biotinylation except that 1 
mM Cascade Blue-ethylenediamine replaced biotin and 1 mM CaCl2 was added.  Biotin-polyP 
and Cascade Blue-polyP adducts were purified by size-exclusion chromatography.  PolyP and 
Cascade Blue-polyP preparations were resolved by polyacrylamide gel electrophoresis using 
10% polyacrylamide gels in TBE (90 mM Tris, 90 mM borate, 2.7 mM EDTA, pH 8.3) and 
detected either by fluorescence (excitation at 365 nm) or by staining with toluidine blue as 
described.
15
 
 
Binding of thrombin, kallikrein, factor XIa or factor VIIa to microplate-immobilized polyP  
PolyPHMW was immobilized on Amine Surface stripwells using EDAC-mediated coupling as 
described above.  Alternatively, biotin-polyPHMW was immobilized by incubating 67 M biotin-
polyPHMW overnight at 4°C in streptavidin stripwells.  Following washing, wells were blocked 
for 3 h with 50 mM Tris-HCl pH 7.4, 0.05% Tween-20 (Tris-Tween) plus 5% bovine serum 
albumin.  Wells were then incubated with various concentrations of factor XIa, kallikrein, 
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thrombin or factor VIIa in Tris-Tween plus 0.6% bovine serum albumin, after which the wells 
were washed thrice with Tris-Tween.  (In the case of factor VIIa, all solutions also contained 2.5 
mM CaCl2.)  Bound factor XIa, kallikrein, thrombin or factor VIIa were detected by quantifying 
initial rates of hydrolysis of S-2366, S-2322, Spectrozyme TH or Spectrozyme fVIIa, 
respectively, and the single-site ligand binding equation was fitted to the data by nonlinear 
regression using Prism (GraphPad Software, La Jolla, CA). 
 
Clotting Assays  
Clotting times were quantified at 37°C on a Diagnostica Stago STart4 coagulometer by mixing, 
in coagulometer cuvettes, 50 l prewarmed citrated human plasma (George King Biomedical, 
Overland Park, KS) with 50 l prewarmed 20% phosphatidylserine/80% phosphatidylcholine 
vesicles (made by sonication) in imidazole buffer; incubating for 3 minutes; then initiating 
clotting by adding 50 l prewarmed CaCl2.  Final concentrations were 33% plasma, 25 µM 
phospholipid, 41.7 mM imidazole pH 7.0, 8.33 mM CaCl2 in 150 l. 
 
NMR Analyses   
31
P NMR spectra of polyP preparations were acquired at 20°C as previously described,
5
 with a 
Varian Unity INOVA 600 spectrometer using a 5 mm Varian AutoTuneX 
1
H/X PFG Z probe, 
13.5 µs (90°) pulse excitation, 16 kHz spectral width, and 5 second recycle time.  Chemical 
shifts were referenced to 0 ppm using an external phosphoric acid standard.  Spectra were 
processed using 10 Hz line broadening. 
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Immobilization of PolyP onto Polymethacrylate Beads  
PolyP was immobilized on primary amine-containing polymethacrylate beads (Sepabeads EC-
HA) by gentle agitation of 100 mg (dry weight) of beads overnight at 37°C with 25 mM 
polyPHMW (or varying concentrations of other polyP polymer sizes) in 100 mM MES pH 6.5, 100 
mM EDAC, and 1 mM CaCl2, then washing with a solution of 2 M LiCl and 10 mM EDTA 
followed by water.  Immobilized polyP was quantified by malachite green assay following 
hydrolysis in 1 M HCl at 100°C.
5
  The typical yield of bound polyPHMW was 11 µg polyP per mg 
dry weight of Sepabeads. 
For binding assays, polyPHMW-Sepabeads were blocked with 10% bovine serum albumin 
overnight at 4°C, washed twice with binding buffer (50 mM Tris-HCl pH 7.4, 50 mM NaCl, 
0.1% bovine serum albumin), and incubated at room temperature for 30 min with thrombin, 
factor XIa, or kallikrein in binding buffer.  The supernatants were collected by centrifugation 
using mini spin columns (Pierce), and beads were washed with binding buffer followed by 
elution buffer (50 mM Tris-HCl pH 7.5, 1 M NaCl, 0.1% bovine serum albumin).  Enzymes 
were quantified by measuring initial rates of chromogenic substrate hydrolysis as described 
above. 
 
Surface Plasmon Resonance (SPR) studies 
SPR analyses were conducted at 25°C using a Biacore 3000 instrument (Biacore, Columbia, 
MD).  Streptavidin was covalently bound to CM5 sensorchips by the standard amine coupling 
method; after blocking and washing, biotin-polyPHMW was flowed over the surface until the 
signal reached 400 resonance units (RUs).  Varying concentrations of thrombin in 50 mM Tris-
HCl pH 7.4, 50 mM NaCl, 5 mM benzamidine, 0.005% surfactant P20 were then flowed over the 
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chip surface at 50 l/min using a 2 min association phase and 3 min dissociation phase, with 
background subtraction using a reference cell without polyP.  Sensorchips were regenerated by 
washing with 1 M NaCl between runs. 
 
Preparation and Digestion of Spermidine-PolyP Adducts 
5 mM polyP130 was incubated for 6 h at 37°C with 70 mM spermidine, 100 mM MES pH 6.5, 
300 mM EDAC, after which polyP was purified by size-exclusion chromatography in the 
presence of 1 M LiCl followed by acetone precipitation as previously described.
5
  To examine 
resistance to exopolyphosphatase digestion, 12 M spermidine-polyP adduct was digested at 
37°C with 5 U/ml calf intestinal alkaline phosphatase in 50 mM Tris-HCl pH 7.4, 1 mM MgCl2, 
0.1 mM ZnCl2.  Timed samples were removed and free monophosphate was quantified by 
malachite green assay.
5
  At the end of the experiment, an aliquot of the reaction was hydrolyzed 
for 1 h at 100°C in 1 M HCl and monophosphate was quantified. 
 
Abbreviations:  EDAC, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide; MES, 2-(N-
morpholino)ethanesulfonic acid; polyP, polyphosphate; polyPHMW, high molecular weight 
polyphosphate, SPR, surface plasmon resonance; RU, resonance units 
 
RESULTS 
Covalent immobilization of polyP onto amine-derivatized polystyrene microplates and 
chromatography beads 
To optimize the reaction conditions for EDAC-mediated formation of phosphoramidate linkages 
between primary amines and the terminal phosphates of polyP, we found it convenient to employ 
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Amine Surface microplates as the source of primary amine.  The degree of immobilization of 
polyP onto this surface was then used as the readout for optimizing conditions.  (We found that 
noncovalently bound polyP was quantitatively removed from these plates by washing the wells 
with 2 M LiCl.)  Figure 3.1A shows the results of a typical optimization study, in this case to 
optimize the polyP concentration.  We obtained substantial covalent attachment of polyP to the 
amine-derivatized polystyrene surface when reactions were carried out in the presence EDAC 
(but not in its absence), with maximal coupling at >2 µg/ml polyP.  At 1 and 2 µg/ml polyP, the 
efficiency of coupling to the surface was 49% and 27%, respectively.  When polyP was reacted 
with EDAC in secondary amine-modified (Covalink NH) or hydrazide-modified (Carbo-Bind) 
microplates under the same conditions, little or no bound polyP was detected over background 
(data not shown), suggesting that this reaction is much more efficient with primary amines. 
Additional studies were undertaken to optimize the reaction conditions for covalently 
linking polyP to primary amines on Amine Surface microplates (data not shown, but the findings 
summarized in this paragraph):  Optimal polyP immobilization was obtained when the EDAC 
concentration was 25 to 300 mM, when the pH was 6 to 7 (using 25 to 100 mM MES buffer), 
and when the reaction was allowed to proceed for 2 h to overnight.  We also found that inclusion 
of 1 mM Ca
2+
, Mg
2+
, or Mn
2+
 increased the immobilization of polyP by about 1.5- to 2-fold 
relative to reactions in the absence of divalent metal ions. 
EDAC-mediated formation of phosphoramidate linkages between primary amines and the 
5’ phosphates of oligonucleotides is reported to be more efficient in the presence of imidazole, 
due to the formation of reactive phosphorimidazolide intermediates.
14
  We found, however, that 
the efficiency of EDAC-mediated immobilization of polyP onto Amine Surface microplates was 
unaffected by the presence of up to 100 mM imidazole (not shown). 
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We also investigated the effect of polyP polymer length on efficiency of EDAC-mediated 
coupling to primary amines, using amine-containing polymethacrylate chromatography beads 
(Sepabeads EC-HA).  To do this, we coupled polyP preparations of varying polymer lengths 
(holding the concentration of ends at a constant 1 mM) to the beads, then quantified the extent of 
covalent attachment of polyP.  The results (Figure 3.1B) show that pentaphosphates and shorter 
coupled poorly to the beads, while 14mers and longer coupled relatively efficiently.  Even at 50 
mM, monophosphate still coupled inefficiently to the beads, demonstrating that the terminal 
phosphates of polyP are much more efficiently coupled to amines by EDAC than are small 
inorganic phosphates. 
 
31
P NMR spectroscopy of a polyP-spermidine adduct 
 NMR was used to obtain evidence for phosphoramidate linkages with the terminal phosphates of 
polyP.  Figure 3.2 shows representative 
31
P NMR spectra of underivatized polyP45 and of 
spermidine-labeled polyP45.  For underivatized polyP, the 
31
P signal for the terminal phosphates 
at approximately -5 ppm (α peak in Figure 3.2A) was well resolved from the much larger peak 
for internal phosphates at about -21 ppm.  (In this particular spectrum, the penultimate phosphate 
residues— peak—were also clearly resolved, although this is not always the case).  For 
spermidine-derivatized polyP (Figure 3.2B), the signal at -5 ppm was greatly reduced and a new 
peak at about -0.5 ppm appeared, which we attribute to the presence of the P-N bond in the 
phosphoramidate-linked spermidine-polyP adduct. 
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Binding affinities of blood clotting proteases for immobilized polyP   
We previously demonstrated that thrombin binds to polyP with relatively high affinity, via its 
anion-binding exosite II.
13
  We also showed that polyP is a potent triggering agent for the contact 
pathway of blood clotting,
3
 and that it binds to prekallikrein and factors XI and XII.
4
  As an 
example of the utility of immobilized polyP, we used it to quantify the binding of thrombin, 
factor XIa, kallikrein and factor VIIa to polyP.  In Figure 3.3A-D, polyP was immobilized by 
EDAC-mediated covalent coupling to amine-derivatized polystyrene microplate wells.  This was 
successfully used to quantify the binding affinities of thrombin, factor XIa and kallikrein for 
polyP, yielding Kd values of 66, 32 and 92 nM, respectively.  Factor VIIa, on the other hand, did 
not bind to immobilized polyP (Figure 3.3D).  Alternatively, biotinylated polyP was immobilized 
via capture on streptavidin-coated microplate wells, and this presentation of polyP was also used 
to quantify thrombin binding.  It yielded a Kd value of 56 nM (Figure 3.3E), very similar to that 
obtained when polyP was covalently linked to amine-derivatized wells (Figure 3.3A). 
In another experiment, thrombin, factor XIa, and kallikrein were incubated with polyP-
derivatized, primary amine-containing chromatography beads, after which recovery of the 
enzyme was quantified in the flow-through and high-salt eluates (Figure 3.3F).  These proteins 
bound quantitatively to polyP-derivatized beads and were eluted quantitatively by high salt 
concentration.  There was negligible background binding to beads that had been treated with 
polyP in the absence of EDAC, or with EDAC in the absence of polyP (not shown).  This 
demonstrates the utility of using polyP-derivatized beads to identify and isolate polyP binding 
proteins by pull-down assays, etc. 
We also performed initial SPR analyses of thrombin binding to polyP by first 
immobilizing biotin-polyPHMW onto streptavidin sensorchips and then flowing varying 
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concentrations of thrombin over the surface.  The results (Figure 3.4) demonstrate the utility of 
immobilizing biotin-polyP onto streptavidin-derivatized sensorchips in order to use SPR to study 
the kinetics of protein-polyP binding interactions. 
 
Fluorescently Labeled PolyP 
End-labeling of polyP with fluorophores would be highly advantageous for detecting polyP 
binding to proteins, cells and tissues, and for following polyP in vivo.  Accordingly, we reacted 
the primary amine-containing fluorescent dye, Cascade Blue-ethylenediamine, with polyP45 in 
the presence or absence of EDAC, purified the polyP and resolved it by polyacrylamide gel 
electrophoresis (Figure 3.5).  PolyP that had been reacted with Cascade Blue-ethylenediamine in 
the presence of EDAC was intensely fluorescent (Figure 3.5B, lanes 1 and 2), whereas polyP 
incubated with the dye but without EDAC had no detectable fluorescence (Figure 3.5B, lane 3). 
 
Derivatizing the terminal phosphates of polyP confers resistance to exopolyphosphatase 
digestion 
Some polyP preparations isolated from biological sources are reported to be naturally resistant to 
exopolyphosphatase degradation, apparently due to an unidentified modification of the terminal 
phosphates.
1
  This prompted us to investigate the possibility that attaching primary amine-
containing compounds to the terminal phosphates of polyP via phosphoramidate linkages might 
protect polyP from exopolyphosphatase degradation.  Accordingly, we reacted polyP130 with 
spermidine in the presence of EDAC, isolated the polyP, and then over-digested it with excess 
calf intestinal alkaline phosphatase (a very active exopolyphosphatase).
16
  As can be seen in 
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Figure 3.6, the polyP-spermidine adduct was highly resistant to phosphatase degradation, while 
underivatized polyP was rapidly digested to completion. 
 
Immobilized and derivatized polyP retains procoagulant activity 
We investigated whether immobilizing or end-labeling polyP would interfere with its 
procoagulant activity.  EDAC was employed to covalently react long-chain polyP with 
polyethylenimine that had been coated onto polystyrene coagulometer cuvettes, after which the 
cuvettes were employed in plasma clotting assays.  Immobilized polyP dramatically shortened 
the plasma clotting time, demonstrating that it retains significant ability to activate the contact 
pathway of blood clotting (Figure 3.7A).  Similarly, in solution, 20 M spermidine-labeled polyP 
was as active in triggering the clotting of human plasma as was 20 M underivatized polyP 
(Figure 3.7B). 
 
DISCUSSION 
Studies of protein-polyP interactions have been hampered by a paucity of methods for 
derivatizing and immobilizing polyP.  Here, we demonstrate that polyP preparations of varying 
chain lengths can be efficiently derivatized using the water-soluble carbodiimide, EDAC, to 
create phosphoramidate linkages between the terminal phosphates of polyP and several primary 
amines.  We optimized the reaction conditions and provided NMR evidence for the presence of 
phosphoramidate linkages with the terminal phosphates of polyP.  As examples of the utility of 
this approach, we quantified Kd values for the binding of polyP to the blood clotting proteases, 
thrombin, factor XIa and kallikrein.  Relatively low nonspecific background was observed using 
primary amine-containing solid supports, making this a very attractive method for immobilizing 
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polyP.  We also demonstrated the utility of using biotinylated polyP in SPR studies to measure 
protein binding to polyP. 
Carbodiimide-mediated crosslinking of polyP to labels, probes and solid supports should 
greatly facilitate studies on the ever-expanding role of polyP in important biological processes, 
including blood clotting.  In addition to the examples provided in this study, the ability to 
covalently couple amine-containing compounds will also allow other types of labeling reactions 
with polyP, opening up essentially the entire armamentarium of protein chemistry.  For example, 
polyP that has been end-labeled with a polyamine such as ethylenediamine, cadaverine or 
spermidine will have free primary amino groups available for further reactions, including 
coupling to succinimidyl ester derivatives of solid supports, biotin, fluorescent dyes or other 
probes, which are often more readily available commercially than are the same compounds with 
primary amines.  Another example would be to couple a disulfide-containing primary amine such 
as cystamine to the ends of polyP; following reduction, this will provide free sulfhydryls tethered 
to the ends of polyP for reaction with maleimide- or iodoacetate-derivatives of biotin, fluorescent 
dyes or other labels. 
We also found that modifying the ends of polyP by covalently attaching spermidine protected 
polyP from exopolyphosphatase degradation, suggesting that such end-labeled polyP derivatives 
may be more stable in biological systems.  These end-labeled polyP adducts may also be useful 
in detecting the presence of endo- versus exopolyphosphatase enzyme activities, since the 
derivatized polyP preparations should be sensitive to digestion by the former but not the latter. 
Previously, we demonstrated that soluble polyP can act as a general hemostatic agent, 
shortening the clotting time of plasma from patients with hemophilia and reversing the effect of 
several anticoagulant drugs.
17
  In this study, we found that covalently attaching amine-containing 
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compounds to the terminal phosphates of polyP did not interfere with polyP’s procoagulant 
activity, and polyP retained potent clotting activity when covalently attached to solid supports.  
This latter finding opens the possibility of covalently immobilizing polyP onto wound dressings, 
collagen sponges, etc., to create improved topical hemostatic agents to control bleeding. 
 
 
FIGURES 
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Figure 3.1.  Attachment of polyP to solid supports.  (A) Dose response for covalently 
immobilizing polyP onto Amine Surface microplates.  Varying polyPHMW concentrations were 
reacted overnight at 37ºC in microplate wells in the absence () or presence () of 100 mM 
EDAC, after which unbound polyP was removed by washing with 2 M LiCl.  Data are mean + 
S.E.M. (n=3).  (B) Influence of polymer length on coupling efficiency.  PolyP preparations of 
varying mean polymer lengths were reacted overnight at 37ºC with Sepabeads EC-HA and 100 
mM EDAC with 1 mM CaCl2, after which unbound polyP was removed by washing with 2 M 
LiCl and 10 mM EDTA.  PolyP concentrations (given in terms of phosphate) were adjusted to 
yield a constant 1 mM ends: 1 mM monophosphate and pyrophosphate; 1.5 mM triphosphate; 
2.5 mM polyP5; 7 mM polyP14; 12.5 mM polyP25; 22.5 mM polyP45; 30 mM polyP60; and 65 
mM polyP130.  Controls plotted on the right include 50 mM monophosphate as well as reactions 
without EDAC. Data are expressed as mean percent recoveries of offered polyP (+ S.E.M.; n=3 
to 5).  In both panels, bound polyP was quantified as monophosphate following acid hydrolysis. 
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Figure 3.2.  One-dimensional 
31
P NMR spectra of (A) underivatized polyP45 and (B) 
spermidine-labeled polyP45.  Peaks corresponding to the external phosphates (), penultimate 
phosphates (β), and internal phosphates (internal) are indicated. 
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Figure 3.3.  Binding of clotting proteases to immobilized polyP.  (A-C) PolyPHMW was 
coupled via EDAC to Amine Surface microplate wells, which were then used to quantify the 
binding of (A) thrombin, (B) factor XIa,  (C) kallikrein, or (D) factor VIIa.  (E) Biotinylated 
polyPHMW was immobilized on streptavidin-coated microplate wells, which were then used to 
quantify thrombin binding.  For panels A-E, solid squares are binding data after background 
subtraction, while open circles are background binding (from wells without polyP); lines 
represent the single-site ligand binding equation fitted to the binding data, yielding the indicated 
Kd values.  (F) PolyPHMW was coupled via EDAC to primary amine-containing Sepabeads.  
Thrombin (27 pmol), factor XIa (10 pmol), or kallikrein (10 pmol) were incubated with polyP-
Sepabeads, after which the beads were collected and washed by centrifugation.  Enzyme 
recovery was quantified in the flow-through (open bars) and high-salt eluates (closed bars), with 
recoveries calculated as percent of the starting material.  Data are mean + S.E.M. (n=3). 
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Figure 3.4.  Representative SPR sensorgrams of thrombin binding to polyP.  Biotin-
polyPHMW was immobilized onto a streptavidin-derivatized sensorchip, after which varying 
concentrations of thrombin were flowed over the chip surface and RU values were measured 
using a Biacore 3000 instrument.  Thrombin concentrations were 20 nM (lower curve), 60 nM 
(middle curve), and 120 nM (upper curve). 
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Figure 3.5.  Fluorescently labeled polyP.  The primary amine-containing fluorophore, Cascade 
Blue ethylenediamine, was reacted with polyP45 in the presence of EDAC.  PolyP was then 
purified, resolved by polyacrylamide gel electrophoresis, and  the gels were either (A) stained 
with toluidine blue, or (B) photographed under illumination by 365 nm UV light.  Reaction 
conditions were: lane 1, 1 mM fluorophore + EDAC; lane 2, 0.5 mM fluorophore + EDAC; lane 
3, 1 mM fluorophore without EDAC. 
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Figure 3.6.  Phosphoramidate derivatization of the terminal phosphates of polyP confers 
resistance to  exopolyphopshatase digestion.  PolyP130 was either untreated () or reacted with 
spermidine in the presence (□) or absence (∆) of EDAC, after which the polyP was purified and 
then digested at 37ºC with 5 U/ml alkaline phosphatase.  Levels of free monophosphate were 
quantified in timed samples, and at the end of the experiment, monophosphate was quantified 
following complete acid hydrolysis.  Data are mean + S.E.M. (n=3), although the error bars are 
smaller than the data points and therefore not visible. 
  
  
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.  Immobilized and derivatized polyP retains procoagulant activity.  (A) 
PolyPHMW was immobilized via EDAC onto polyethylenimine-coated polystyrene coagulometer 
cuvettes.  Clotting was then initiated by incubating human plasma in the wells for 3 min at 37ºC, 
after which CaCl2 was added and the time to clot formation recorded.  Control cuvettes included 
those untreated with polyethylenimine, EDAC and/or polyP, as indicated.  (B) Clotting assays 
were conducted as in panel A except that untreated cuvettes were employed and 20 M 
polyPHMW-spermidine in solution was preincubated with plasma for 3 min at 37ºC, after which 
CaCl2 was added and the time to clot formation recorded.  Controls included polyPHMW that had 
been reacted without EDAC and/or spermidine, and also wells that received plasma but no 
polyP, as indicated.  Data are mean + S.E.M. (n=3). 
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CHAPTER 4:  INHIBITION OF POLYPHOSPHATE AS A NOVEL STRATEGY FOR 
PREVENTING THROMBOSIS AND INFLAMMATION
4 
 
ABSTRACT 
Inorganic polyphosphates are linear polymers of orthophosphate that modulate blood 
clotting and inflammation. Polyphosphate accumulates in infectious microorganisms and is 
secreted by activated platelets; long-chain polyphosphate in particular is an extremely potent 
initiator of the contact pathway, a limb of the clotting cascade important for thrombosis but 
dispensable for hemostasis. Polyphosphate inhibitors therefore might act as novel 
antithrombotic/anti-inflammatory agents with reduced bleeding side effects. Anti-polyphosphate 
antibodies are unlikely owing to polyphosphate’s ubiquity and simple structure, and while 
phosphatases such as alkaline phosphatase can digest polyphosphate, they take time and may 
degrade other biologically active molecules. We now identify a panel of polyphosphate 
inhibitors, including cationic proteins, polymers and small molecules, and report their 
effectiveness in vitro and in vivo. We also compare their effectiveness against the procoagulant 
activity of RNA. Polyphosphate inhibitors were antithrombotic in mouse models of venous and 
arterial thrombosis, and blocked the inflammatory effect of polyphosphate injected intradermally 
in mice.  This study provides proof of principle for polyphosphate inhibitors as 
antithrombotic/anti-inflammatory agents in vitro and in vivo, with a novel mode of action 
compared to conventional anticoagulants. 
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INTRODUCTION 
Polyphosphate (polyP) is a linear polymer of inorganic phosphate residues that is widely 
present in biology.
1
  Of particular interest to hematology, polyP accumulates in many infectious 
microorganisms
2
 and is secreted by activated human platelets
3
 and mast cells.
4
 Work from our 
lab and others has shown that polyP is a potent procoagulant, prothrombotic, and pro-
inflammatory molecule,
5-7
 acting at four points in the clotting cascade:  It triggers clotting via the 
contact pathway;
5,6,8
 it accelerates factor V activation;
5
 it enhances fibrin clot structure;
9,10
 and it 
accelerates factor XI back-activation by thrombin.
11
 
 The ability of polyP (especially, long-chain polyP of the type found in microorganisms
8
) 
to trigger clotting via the contact pathway is interesting in light of an elegant series of studies 
that have shown that the contact pathway is important for thrombosis but dispensable for 
hemostasis.
12-15
  We therefore hypothesized that polyP inhibitors might act as novel 
antithrombotic/anti-inflammatory agents with reduced bleeding side effects.  Raising antibodies 
against polyP is unlikely to be successful because of the ubiquity of polyP and its simple 
structure.  Phosphatases such as alkaline phosphatase can digest polyP,
6,11
 but they take time to 
act and may degrade other phosphate-containing molecules in addition to polyP.  In this study, 
identify a panel of polyP inhibitors including cationic proteins, polymers and small molecules.  
We report their effectiveness as anticoagulants in vitro and as antithrombotic and anti-
inflammatory agents in vivo using mouse models.  We also compare the effectiveness of these 
polyP inhibitors against the procoagulant activity of RNA
16
 and the anticoagulant activity of 
heparin.  This study therefore provides proof of principle for polyP inhibitors as novel 
antithrombotic/anti-inflammatory agents that are directed against a unique target in the blood 
clotting system. 
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EXPERIMENTAL PROCEDURES 
Materials 
Reagents were from Sigma-Aldrich unless otherwise noted.  Long-chain synthetic polyP 
(marketed by Sigma as “phosphate glass, water insoluble”) was differentially solubilized as 
previously described.
8
  Its polymer lengths ranged from about 50 to 1500 phosphates, with a 
modal length of about 650 phosphates,
8
  and its endotoxin content was 1.6 x 10
-3
 units/μg polyP 
(by Limulus assay; Charles River Laboratories).  Biotinylated long-chain polyP was prepared as 
described.
17
 All polyP concentrations in this paper are given in terms of the concentration of 
phosphate monomers (monomer formula:  NaPO3). 
 Other supplies included human platelet factor 4, antithrombin, plasma kallikrein, factor 
Xa and α-thrombin (Enzyme Research Laboratories); human factor XI (Haematologic 
Technologies); pooled normal plasma (George King Bio-Medical); and Sar-Pro-Arg-p-
nitroanilide (Bachem). Recombinant polyP-binding domain from E. coli exopolyphosphatase 
(PPXbd) was produced as described.
11
 Liposomes made by sonication had 10% 
phosphatidylserine, 40% phosphatidylethanolamine, 50% phosphatidylcholine (Avanti Polar 
Lipids). Recombinant human tissue factor was relipidated as described.
18
 
 
Inhibition of polyP binding to thrombin 
Other than the high-throughput screens, thrombin binding to immobilized biotinylated polyP in 
streptavidin-coated, 96-well microplates was performed essentially as previously described.
17
 
Briefly, 35 nM human α-thrombin was incubated with candidate inhibitor in 20 mM Hepes 
NaOH pH 7.4, 50 mM NaCl, 0.1% BSA, 0.05% Tween-20, 0.05% NaN3 for 1 hour in wells 
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containing biotin-polyP. After washing, thrombin was quantified by cleavage of 400 μM Sar-
Pro-Arg-p-nitroanilide (Bachem).  
 
High-throughput screening assay 
High-throughput screens were conducted at the High-Throughput Screening Facility (HTSF) at 
the University of Illinois.  High-binding 384-well plates (Corning) were coated overnight at 
room temperature with 50 μL/well of 10 μg/mL avidin (Invitrogen) in water, then washed twice 
with 100 μL/well of TBS (50 mM Tris-HCl buffer pH 7.4, 100 mM NaCl, 0.05% NaN3) 
containing 0.05% Tween-20.  Biotinylated polyP was then immobilized on the wells (and, in the 
process, the wells were simultaneously blocked with BSA) by incubating the wells for 3 hours at 
room temperature with 50 μL/well of 20 μM biotin-polyP in TBS plus 1% BSA and 0.05% 
Tween-20.  The wells were washed twice with 100 μL/well of 1 M LiCl, followed by two water 
washes.  Each well then received 60 μL of storage buffer (50 mM Tris-HCl buffer pH 7.4 + 
0.05% NaN3) and the plates were stored at room temperature until needed. Thrombin-binding 
assays were performed by removing the storage buffer and dispensing 50 μL/well of 40 nM 
bovine thrombin (BioPharm Laboratories) in 20 mM Hepes-NaOH buffer pH 7.4, 50 mM NaCl, 
1.4 mM CaCl2, 0.5 mM MgCl2, 0.05% Tween-20, 0.05% NaN3, 0.1% BSA.  The wells then 
received 100 nL aliquots of compounds to be tested. (To decrease the number of plates screened, 
five to seven compounds were pooled—always within libraries—and added per well, at 100 nL 
of each compound per well.  Final concentrations in test wells were 1 μg/mL of each compound 
for the Chembridge compounds, or 2 μM of each compound for the NCI/Marvel/HTSF 
compounds.)  Some wells received no compounds, which served as reference wells for the level 
of thrombin bound in the absence of any inhibitor.  The plates were incubated for a minimum of 
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30 minutes (maximum of 3 hours) at room temperature, after which they were washed thrice.  
Each well then received 50 μL/well of 0.4 mM chromogenic thrombin substrate (Sar-Pro-Arg-
pNA) diluted in 20 mM Hepes-NaOH buffer pH 7.4, 0.05% NaN3. The wells were incubated for 
1.8 hours at room temperature, after which the reaction was quenched with 25 μL/well of 0.1 N 
HCl and the absorbance at 405 nm was quantified. (Control experiments indicated that the rate of 
chromogenic substrate hydrolysis remained linear over the 1.8 hour time course, under the 
conditions tested.) 
 
Compound libraries screened 
Detailed descriptions of all four of the libraries screened in this study are available at HTSF web 
site (http://scs.illinois.edu/htsf/compound_collections.html), including comprehensive structural 
information files for the compounds in each library, readable by the ChemBioFinder program.  
The libraries screened in this study, which together included about 175,000 compounds, were: 
(1) ChemBridge MicroFormat Library (about 150,000 compounds); (2) HTSF House Library 
(about 4,700 compounds); (3) Marvel Library (about 10,000 compounds); and (4) NCI Library, 
comprising (a) Open Set (about 8,000 compounds), (b) Diversity Set (about 2,000 compounds), 
and (c) Natural Products and Challenge Set (about 300 compounds). 
  
Inhibition of heparin-catalyzed inactivation of factor Xa by antithrombin 
Antithrombin (120 nM), unfractionated heparin (1.5 x 10
-2
 units/mL) and candidate inhibitor 
were incubated at room temperature for 2 minutes with 4.6 nM human factor Xa in 30 mM 
Hepes NaOH pH 7.4, 100 mM NaCl, 0.1% BSA.  Factor Xa activity was quantified by 
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hydrolysis of 250 μM Spectrozyme Xa substrate (American Diagnostica) and converted to 
percent heparin activity by reference to a standard curve. 
 
Plasma clotting assays 
Plasma clotting times were quantified at 37°C using a STart4 coagulometer (Diagnostica Stago). 
Contact pathway tests used final concentrations of 33% plasma, 25 µM liposomes, 41.7 mM 
imidazole pH 7.0 and 8.33 mM CaCl2. Contact activator, inhibitor and liposomes were mixed 
with prewarmed plasma for 3 minutes, then clotting was initiated with CaCl2. Activator 
concentrations were selected to give 80-100 second clotting times: 10 μg/mL long-chain polyP; 
10 μg/mL kaolin; 100 μg/mL diatomaceous earth; or 100 μg/mL polyguanylic acid (RNA). 
Tissue factor clotting tests used 30 pM relipidated tissue factor. 
 
Whole blood thromboelastometry 
Human blood studies were approved by the University of Illinois Institutional Review Board. 
Thromboelastometry was performed using ROTEM
®
 (Pentapharm) with supplied software. Non-
anticoagulated whole blood was collected via venipuncture (discarding the initial 3 mL) from 
normal human donors, then immediately transferred to the supplied plastic cups (280 μL per cup) 
and thoroughly mixed with 20 μL candidate inhibitor in TBS plus either 20 μL 1.7 mM long-
chain polyP in TBS or tissue factor reagent (Ex-tem, Pentapharm). Final concentrations were 
82% whole blood, 0 or 100 μM polyP, and inhibitor as indicated.  
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In vivo thrombus formation 
Animal studies were approved by the IACUC of the Medical College of Wisconsin (venous 
thrombosis) or the University of Illinois (arterial thrombosis). For venous thrombosis, 
electrolytic injuries were induced on exposed femoral veins of pentobarbital-anesthetized 
C57BL/6 mice, as described.
19
  Three to five minutes before thrombus induction, rhodamine 6G-
labeled platelets (up to 1 x 10
7
 per mouse) and Alexa 647-labeled anti-fibrin antibodies (10-20 
μg per mouse) were injected into the jugular vein at volumes up to 100 μL, followed by inhibitor, 
unfractionated heparin (APP Pharmaceuticals) or vehicle; fluorescence imaging of the thrombus 
induction site was then recorded for 60 minutes. Data among groups were analyzed by one-way 
ANOVA, with between-group comparisons using p values calculated from post-hoc Tukey test.  
For arterial thrombosis, C57/BL6 male mice (6-8 weeks old) were anesthetized using isoflurane, 
polyP inhibitors were injected retro-orbitally, the left carotid artery was exposed, and blood flow 
monitored with a Doppler vascular flow probe (Transonic, 0.5 PSB) connected to a perivascular 
flow meter (Transonic, TS420).  To induce thrombosis, two pieces of 1 x 2 mm filter paper 
(Whatman GB003) saturated with freshly prepared 5% anhydrous FeCl3 in 0.9% saline were 
applied to the deep and superficial surfaces of the artery.  After 5 minutes, the filter papers were 
removed and the vessel irrigated with saline. Blood flow was monitored from FeCl3 application 
for 30 minutes or until occlusion, defined as no detectable flow for one minute.  Flow data were 
interpreted with LabScribe2 (iWorx Systems). 
 
In vivo vascular leakage 
Vascular leakage assays were employed to quantify polyP-induced extravasation of Evans blue 
dye in animal studies approved by the University of Illinois IACUC. Wild-type ICR mice 
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(Harlan Laboratories) anesthetized with isoflurane were injected retro-orbitally with 4% Evans 
blue in saline (1 μL/g body weight). PolyP inhibitors or saline were administered retro-orbitally 
(contralateral eye). After 40 minutes, three dorsal skin locations were injected intradermally with 
25 μL of saline (negative control), 100 μM bradykinin (positive control), or 20 mM long-chain 
polyP.  After 30 minutes, animals were euthanized, skins removed for punch biopsy (12 mm 
diameter), and Evans blue quantified as described.
6
  Data were compared between groups by 
Mann-Whitney Rank Sum test. 
 
RESULTS 
High-throughput screening for polyP inhibitors 
We previously showed that polyP binds tightly to thrombin,
20
 a central protease in blood clotting. 
We used this interaction to develop a high-throughput screen for polyP inhibitors by first 
immobilizing biotinylated polyP on avidin-coated multiwell plates, then incubating wells with 
mixtures of thrombin and potential inhibitors, washing, and quantifying relative amounts of 
bound thrombin by chromogenic substrate hydrolysis. Candidate inhibitors were identified from 
high-throughput screening of a library of approximately 175,000 small molecules as well as a 
panel of 42 additional cationic compounds, polymers and proteins chosen for their possible 
association with a polyanion like polyP. For the latter panel (listed in Table 4.1), we 
hypothesized that cationic substances would bind to polyP, thereby competitively inhibiting its 
interaction with clotting proteins. 
Nine of the tested wells from the initial high-throughput screen of about 175,000 
compounds exhibited a ≥30% decrease in the rate of chromogenic substrate hydrolysis and were 
therefore flagged as containing potential inhibitors of thrombin-polyP binding. The 46 individual 
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compounds in these nine wells were re-tested singly in secondary screens to identify the actual 
inhibitors responsible for the reduction in thrombin binding.  The secondary screens consisted of: 
(1) a repeat of the thrombin-polyP binding assay; (2) a kallikrein-polyP binding assay in which 
100 nM human plasma kallikrein (Enzyme Research Laboratories) was substituted for thrombin 
and H-D-Pro-Phe-Arg-pNA substrate (Bachem) was used to detect bound kallikrein; (3) a test of 
direct thrombin inhibition, in which the compound was added directly to 1 nM thrombin in 
solution, and the rate of chromogenic substrate hydrolysis was quantified; and (4) a test of direct 
kallikrein inhibition, in which the compound was added directly to kallikrein in solution, and the 
rate of chromogenic substrate hydrolysis was quantified.  The purpose of the parallel assays of 
both thrombin-polyP and kallikrein-polyP binding was to identify compounds that could inhibit 
the association of polyP with two different polyP-binding proteins, the idea being that this would 
identify compounds with a general ability to inhibit polyP-protein interactions (presumably via 
the compound binding to polyP). The purpose of the test of direct inhibition of thrombin and 
kallikrein was to identify compounds that decreased the measured signal, not by blocking polyP-
thrombin or polyP-kallikrein binding, but by inhibiting the enzymatic activity of these proteases 
even in the absence of polyP. 
Eight of the tested compounds showed reduced signal in one or more of these secondary 
assays, the results of which are summarized in Table 4.2.  Four of the compounds (numbered A, 
B, D and G) exhibited less than 20% inhibition in the thrombin-polyP binding assay, and were 
therefore not promising leads to explore further. The other four compounds in Table 4.2 
(numbered C, E, F and H) exhibited >90% inhibition in the thrombin-polyP binding assay.  Of 
these latter four compounds, three (C, E and F) inhibited the enzymatic activity of free thrombin 
by >98%, one of which (C) also inhibited the enzymatic activity of free kallikrein by 97%. Thus, 
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these three compounds are direct protease inhibitors and apparently did not decrease the signal in 
the thrombin-polyP binding assay by actually interfering with thrombin binding to polyP. One of 
the compounds, surfen (compound H) decreased the signal in the thrombin-polyP binding assay 
by 95% and the signal in the kallikrein-polyP binding assay by 55%, while having a modest 
effect on the enzymatic activity of free thrombin. Thus surfen, which is also reported to be a 
small-molecule antagonist of heparin and heparan sulfate,
21
 was chosen for further analysis. 
It was perhaps surprising that this relatively large screen identified just a single 
compound (surfen) that inhibited the binding of both thrombin and kallikrein to immobilized 
polyP under the conditions tested.  A possible explanation is that the screen was performed at 
rather low concentrations of test compounds (typically, 1 μg/mL), so that only very potent 
inhibitors could be identified.  Also, the libraries used in this study might not include simple 
polyamines and in any case they did not include polymers or proteins. Given the simple, 
repeating structure of polyP and its highly anionic nature, cationic polymers and proteins might 
be expected to bind tightly to polyP and thereby abrogate its procoagulant functions. 
Accordingly, we screened the additional panel of 42 cationic proteins, polymers and small 
molecules for ability to inhibit polyP-thrombin interactions. The majority of the cationic 
substances in this panel inhibited thrombin binding to polyP, with the results summarized in 
Table 4.1. 
 
In vitro potency of polyP inhibitors 
Potencies of prospective polyP inhibitors were determined using thrombin-polyP binding assays 
(example inhibition curves in Figure 4.1). IC50 values for the 21 most potent inhibitors are 
plotted in Figure 4.2A on the basis of both mass and molarity. Of these, surfen was identified 
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from the high-throughput screen and the rest came from the panel of 42 cationic compounds, 
polymers and proteins.  On a mass basis, low MW polyethyleneimine was the most potent (IC50, 
10 ng/mL) while the recombinant, isolated polyP-binding domain of E. coli 
exopolyphosphatase
22
 (PPXbd) was the least potent (IC50, 8.5 µg/mL).  On a molar basis, poly-L-
lysine was the most potent (IC50, 0.49 nM) while spermidine was the least potent (IC50, 11.7 
µM).  Four generations of cationic poly(amido amine) (PAMAM) dendrimers, with 
ethylenediamine cores and terminal NH2 groups, all inhibited polyP binding to thrombin. 
 We chose eleven of the inhibitors for further scrutiny for the following reasons (with the 
compound numbers here in parentheses being the same as those in Figure 4.2A): low (inhibitor 
1) and high (inhibitor 3) MW polyethyleneimine are among the most potent inhibitors; polybrene 
(inhibitor 2) is commonly included in Prothrombin Time clotting tests to inactivate heparin; 
spermine (inhibitor 4) is an endogenous polyamine that might modulate polyP function; polyP 
interacts with histone H1 (inhibitor 6) to modulate its procoagulant activities;
23
 surfen (inhibitor 
7) is a small-molecule antagonist of heparin and heparan sulfate;
21
 intravenous protamine 
(inhibitor 8) is used clinically to reverse heparin anticoagulation;
24
 polymyxin B (inhibitor 9) is a 
clinical antibiotic that targets bacterial lipopolysaccharide (but perhaps polyP is an additional 
target of this drug, and furthermore, Salmonella lacking polyP kinase exhibit increased 
polymyxin B sensitivity
25
); platelet factor 4 (inhibitor 10) is secreted from activated platelets and 
neutralizes heparin;
26
 and PPXbd (inhibitor 11) potently blocks polyP-mediated factor XI 
activation by thrombin.
11
 In addition, cationic PAMAM dendrimers have received much recent 
attention for nanoparticle formation and drug delivery; we focused on generation 1.0 dendrimer 
(inhibitor 5; structure given in Figure 4.3) because lower generation cationic dendrimers are 
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reportedly less toxic than higher generation dendrimers or amine-functionalized linear 
polymers.
27
 
Heparin, like polyP, is a highly anionic linear polymer (although unlike polyP, heparin is 
strongly anticoagulant via binding to antithrombin).  Cationic inhibitors of polyP might also bind 
to anionic glycosaminoglycans and thus exhibit complex in vivo activities.  On the other hand, 
heparin and polyP have different anionic groups (sulfates versus phosphates) with different 
spacing and charge densities, so a given inhibitor might bind preferentially to one or the other 
polyanion.  Figure 4.2B compares IC50 values of the eleven selected polyP inhibitors, plotted on 
the y axis for potency for abrogating factor Xa inactivation by a mixture of heparin and 
antithrombin, and on the x axis for abrogating thrombin binding to polyP. Compounds 
interacting more potently with polyP than heparin lie above the dotted line, with the most potent 
and specific polyP inhibitors in the upper left. Spermine was 152 times more potent against 
polyP than against heparin/antithrombin, while polymyxin B, histone H1, polybrene, low MW 
polyethyleneimine and PPXbd were 4 to 7 times more potent against polyP than against 
heparin/antithrombin.  On the other hand, platelet factor 4 was 18 times less potent against polyP 
than against heparin/antithrombin. 
 
Potency and specificity of polyP inhibitors in clotting assays 
We next evaluated the ability of these eleven inhibitors to block polyP-initiated clotting of 
human plasma. We expected at least some of these inhibitors to be considerably less effective in 
plasma clotting assays compared to assays using purified proteins, since plasma has many 
proteins and substances that might compete for binding to these candidate inhibitors. Also, to 
initiate plasma clotting, polyP must interact with multiple proteins in the contact pathway, which 
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differ in their affinities for polyP.
11,17
  To investigate inhibitor potency in human plasma, we 
therefore quantified the concentrations of inhibitors necessary to double the clotting time of 
plasma triggered by long-chain polyP, compared to clotting times triggered by other agents 
known to activate the contact pathway, including RNA,
16
 powdered kaolin, and diatomaceous 
earth. Cationic polyP inhibitors might also interfere with downstream clotting reactions (for 
example, by binding to the anionic lipid, phosphatidylserine); accordingly, we quantified the 
inhibitor concentration necessary to double the plasma clotting time triggered by relipidated 
tissue factor, the protein that initiates clotting in normal hemostasis.
28
  Figure 4.2C shows that, 
while low and high MW polyethyleneimine and protamine (inhibitors 1, 3 and 8) inhibited 
polyP-induced clotting, they also significantly prolonged the tissue factor clotting time 
(confirming the reported anticoagulant effect of protamine
29
). The other eight inhibitors tested 
did not significantly prolong tissue factor clotting times at concentrations up to 100 µg/mL 
(Figure 4.2C); of these, generation 1.0 PAMAM dendrimer (inhibitor 5) was the most potent 
inhibitor of polyP-initiated clotting. Over the concentration range tested, PPXbd (inhibitor 11) 
inhibited clotting triggered by polyP but not by RNA, kaolin, diatomaceous earth or tissue factor. 
Spermine (inhibitor 4) was also a highly specific inhibitor of polyP-triggered plasma clotting, 
although it had some ability to attenuate clotting triggered by diatomaceous earth. 
 
Efficacy of polyP inhibitors in whole-blood thromboelastometry 
Coagulation of whole blood is more complex than plasma clotting, as it includes contributions 
from blood cells, including platelets.  Consequently, we selected two polyP inhibitors 
(generation 1.0 dendrimer and the antibiotic, polymyxin B) to investigate their effects on polyP-
triggered coagulation of whole blood in vitro, by measuring the viscoelastic properties of the 
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developing clot using thromboelastometry. When clotting was initiated by adding long-chain 
polyP to whole blood, both generation1.0 dendrimer (Figure 4.4A) and polymyxin B (Figure 
4.4B) prolonged clot formation in a concentration-dependent manner. On the other hand, neither 
inhibitor, over the same concentration ranges, significantly altered the thromboelastometry 
profiles of whole blood clotting initiated by tissue factor (Figure 4.4C and 4.4D). 
 
PolyP inhibitors abrogate the procoagulant activity of platelet polyP 
We next investigated the ability of polyP inhibitors to diminish the procoagulant effect of platelet 
polyP, since polyP is known to be secreted by activated platelets.
3,6
  In the first approach, we 
added polyP inhibitors to freshly drawn human blood, from which we prepared platelet-rich 
plasma. We then activated the platelets using a thrombin receptor agonist peptide (TRAP) and 
quantified thrombin generation in real time. In parallel experiments we triggered clotting by 
adding tissue factor to the platelet-rich plasma instead of TRAP. Both PPXbd (Figure 4.5A) and 
generation 1.0 dendrimer (Figure 4.5B) significantly delayed the onset of thrombin generation 
(lag time) as well as the time to peak thrombin, with only marginal effects on the peak thrombin 
levels themselves. In contrast, neither polyP inhibitor significantly altered thrombin generation 
when clotting was triggered with tissue factor. 
In the second approach, we examined the ability of releasates from activated human 
platelets to accelerate factor XI activation by thrombin, which we recently showed was entirely 
due to the presence of polyP.
11
 All five of the tested polyP inhibitors abrogated platelet releasate-
dependent factor XI activation by thrombin (Figure 4.6); IC50 values were: low MW 
polyethyleneimine, 107 ± 1.7 ng/mL; generation 1.0 dendrimer, 360 ± 13 ng/mL; spermine, 17.1 
  
90 
 
± 1.4 μg/mL; PPXbd, 91.7 ± 2.5 μg/mL; and polymyxin B, 128 ± 2.8 μg/mL (mean ± standard 
error; n=4). 
 
Efficacy of polyP inhibitors in a mouse models of venous and arterial 
thrombosis 
PolyP contributes to thrombosis in mouse models.
6
  We therefore examined polyP inhibitors in a 
mouse venous thrombosis model driven by electrolytic injury to the femoral vein.
19
  Intravenous 
administration of generation 1.0 dendrimer or polymyxin B inhibited the accumulation of fibrin 
(Figure 4.7A) and platelets (Figure 4.7B) in the developing thrombus (as did heparin, provided 
for comparison). Peak accumulation of these thrombus markers (comparing mean relative 
intensities 26 minutes after injury) was significantly (p<0.05) lower for animals treated with 
dendrimer, polymyxin B or heparin compared to animals receiving saline. We also examined 
polyP inhibitors in a mouse arterial thrombosis model driven by FeCl3 application to the carotid 
artery.  Intravenous administration of generation 1.0 dendrimer, low MW polyethyleneimine or 
polymyxin B prior to FeCl3 application reduced or slowed vessel occlusion (Figure 4.7C). Log-
rank analyses showed that median patency time was significantly prolonged in mice injected 
with generation 1.0 dendrimer (p<0.01; n=8), polymyxin B sulfate (p<0.01; n=10), or low MW 
polyethyleneimine (p<0.01; n=8) versus mice injected with vehicle (n=11).  PolyP inhibitors 
therefore significantly attenuate both venous and arterial thrombosis. 
 
In vivo anti-inflammatory activity of polyP inhibitors 
PolyP injected intradermally in mice induces vascular leakage that is dependent upon localized 
activation of the contact pathway and concomitant bradykinin production.
6
  To evaluate whether 
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cationic molecules could inhibit these proinflammatory effects of polyP in vivo, we employed a 
modified Miles vascular leakage assay. Generation 1.0 dendrimer or polymyxin B was 
administered intravenously to mice along with Evans blue dye.  After 40 minutes, polyP or 
bradykinin was injected intradermally and local vascular leakage detected by extravasation of 
Evans blue. Generation 1.0 dendrimer significantly abrogated vascular leakage induced by polyP 
(Figure 4.7D; p<0.001) but not by bradykinin (Figure 4.7D; p=0.504). Results obtained with 
polymyxin B were highly variable (Figure 4.7D) and not statistically significantly different from 
control animals (p=0.549). 
 
DISCUSSION 
This study demonstrates proof of principle that inhibitors of polyP, including cationic 
small molecules, polymers and proteins, can block the procoagulant and pro-inflammatory 
effects of polyP, both in vitro and in vivo.  Using in vitro clotting assays, the potencies of these 
inhibitors toward polyP varied considerably, as did their specificities toward polyP compared to 
heparin, RNA, minerals, or tissue factor.  Spermine and PPXbd, in particular, were selective for 
inhibiting the procoagulant activity of polyP over that of other clotting activators.  Spermine was 
also much more effective at blocking the procoagulant activity of polyP than the anticoagulant 
activity of heparin/antithrombin.  On the other hand, both generation 1.0 dendrimer and 
polymyxin B—while more potent toward polyP—also significantly reduced the procoagulant 
activity of RNA and non-physiologic, mineral-based activators of the contact pathway. Inhibitors 
such as these may thus have utility as general inhibitors of the contact pathway of blood clotting 
triggered by anionic polymers and surfaces in vivo.  In particular, the generation 1.0 dendrimer 
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was highly effective in vivo at reducing severity of venous thrombosis, arterial thrombosis, and 
polyP-mediated vascular leakage. 
Our finding that spermine, norspermine and spermidine are potent polyP inhibitors is 
noteworthy since the naturally occurring polyamines, spermine, spermidine, and putrescine 
inhibit aggregation of human platelets,
30-36
 and systemic administration of polyamines is reported 
to prevent carotid artery occlusion in a canine thrombosis model.
37
  The latter investigators 
concluded that the antithrombotic activity of polyamines was due to inhibition of platelet 
aggregation, although it is tempting to speculate that inhibition of platelet-secreted polyP 
procoagulant activity may have also contributed to their protective effects.  Direct tissue 
injection of spermine was effective in preventing footpad edema in a rodent model,
38
 and 
spermine administration was neuroprotective in an ischemic brain injury model in rats.
39
 
Interestingly, brain contains long-chain polyP,
40
 and deficiency of contact pathway clotting 
factors is neuroprotective in mouse models of cerebral artery ischemia-reperfusion.
13
  It would 
therefore be interesting to examine the in vivo utility of polyP inhibitors in brain injury models. 
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Table 4.1.  Panel of cationic compounds, polymers and proteins 
Compound No. IC50 (or % inhibition)* 
Low MW polyethyleneimine [1] 10 ng/mL 
Polybrene  [2] 19 ng/mL 
High MW polyethyleneimine [3] 35 ng/mL 
Generation 3.0 dendrimer  40 ng/mL 
Generation 2.0 dendrimer  47 ng/mL 
Norspermine  52 ng/mL 
Spermine [4] 57 ng/mL 
Generation 1.0 dendrimer [5] 58 ng/mL 
Histone H1 [6] 59 ng/mL 
Poly-D-lysine  79 ng/mL 
Poly-L-arginine  81 ng/mL 
Protamine sulfate [8] 0.11 μg/mL 
Poly-L-lysine  0.14 μg/mL 
Generation 0.0 Dendrimer  0.14 μg/mL 
Heparin  0.27 μg/mL 
Polymyxin B [9] 0.38 μg/mL 
Histone H2A/H2B dimer  0.38 μg/mL 
Histone H2B  0.46 μg/mL 
Histone H3.1/H4 tetramer  0.53 μg/mL 
Histone H4  0.84 μg/mL 
Colistin  0.91 μg/mL 
Histones (mixed)  0.93 μg/mL 
Histone H2A  1.3 μg/mL 
Spermidine  1.7 μg/mL 
Histone H3.1  2.5 μg/mL 
Human platelet factor 4 [10] 3.8 μg/mL 
PPXbd [11] 8.5 μg/mL 
Lon protease polyP-binding 
domain 
 
72 μg/mL 
1,3-diaminopropane  0.47 mg/mL 
Ethylenediamine  0.89 mg/mL 
Norspermidine  (62% inhibition at 200 μg/mL) 
1,2-bis(3-
aminopropylamino)ethane 
 
(53% inhibition at 200 μg/mL) 
Kanamycin  (48% inhibition at 200 μg/mL) 
DNase I  (36% inhibition at 200 μg/mL) 
RNase A  (23% inhibition at 100 μg/mL) 
Bacitracin  (12% inhibition at 200 μg/mL) 
Methylenediamine  (73% inhibition at 6 mg/mL) 
Ammonium chloride  (44% inhibition at 2.7 mg/mL) 
Melamine  (0% inhibition at 200 μg/mL) 
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Cystamine  (0% inhibition at 200 μg/mL) 
Histamine  (0% inhibition at 200 μg/mL) 
Histidine  (0% inhibition at 200 μg/mL) 
Each substance was tested at 200 μg/mL (or indicated concentrations) for inhibition of thrombin 
binding to immobilized biotin-polyP. Those exhibiting >70% inhibition were retested at varying 
inhibitor concentrations, from which IC50 values were derived (listed here in order of decreasing 
potency). Numbers in square brackets are the compound numbers used in Figure 4.2. 
 
 
Table 4.2.  Secondary screening of eight compounds identified from the high-throughput screen of 
approximately 175,000 compounds 
    Percent inhibition of: 
#   Chemical Name Library 
Concentration 
tested 
Thrombin 
binding to 
polyP 
Kallikrein 
binding 
to polyP 
Free 
thrombin 
activity 
Free 
kallikrein 
activity 
A. 
N-benzyl-2,2,6,6-
tetramethyl-4-
piperidinamine 
dihydrochloride 
Chembridge 3 µg/mL 0% 0% 36.1% ---* 
B. 
[(6-nitro-1,3-benzodioxol-
5-
yl)methylene]malononitrile 
Chembridge 10 µg/mL 17.5% 0% 11.1% 2.5% 
C. 
2-(allylthio)-1-(1,3-
benzodioxol-5-ylcarbonyl)-
1H-benzimidazole 
Chembridge 10 µg/mL 95.1% 81.4% 99.6% 97.4% 
D. 
N-(2,4-dichlorophenyl)-N'-
{5-[(4-nitrophenoxy) 
methyl]-1,3,4-thiadiazol-2-
yl}urea 
Chembridge 10 µg/mL 0% 0% 5.3% 1.5% 
E. 
1-(3,4-dimethoxybenzoyl)-
3-(2-furyl)-1H-1,2,4-triazol-
5-amine 
Chembridge 10 µg/mL 98.6% 18.8% 98.9% 39.3% 
F. 
5-(benzylthio)-1-butyryl-3-
phenyl-1H-1,2,4-triazole 
Chembridge 10 µg/mL 92.8% 9.6% 99.5% 12.3% 
G. 
2-(3- nitrophenyl)-3,1- 
benzoxazin -4(4H)-one 
NCI Open 
Plate Set 
2 µM 2.0% 0% 3.8% 0.6% 
H. 
Surfen (bis-2-methyl-4-
amino-quinolyl-6-
carbamide) 
NCI 
Diversity 
Set 
2 µM 95.6% 55.3% 32.2% ---* 
*not tested 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1.  Examples of plots of inhibition of thrombin binding to immobilized polyP for 
four selected inhibitors. The percent inhibition of thrombin binding to polyP is plotted for the 
following inhibitors that encompassed a range of IC50 values: low MW polyethyleneimine (), 
generation 1.0 PAMAM dendrimer (), polymyxin B (), and spermidine (). The dotted line 
signifies 50% inhibition. Data are mean ± standard error (n=3). 
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Figure 4.2.  Relative potencies of polyP inhibitors. (A) Inhibitor concentrations resulting in 
50% reduction of thrombin binding to immobilized polyP (IC50) are plotted for the 21 most 
potent substances tested, expressed in terms of mass (left) and molarity (right). Inhibitors that 
were also used in panels b and c are numbered in parentheses. Data are mean ± standard error 
(n=3). (B) Plot of IC50 values of the 11 numbered substances from panel a for inhibition of 
heparin-mediated inactivation of factor Xa by antithrombin (y axis) versus inhibition of thrombin 
binding to immobilized polyP (x axis). Dotted line represents equivalent potency. Data are mean 
± bidirectional standard error (although error bars are within the symbols; n=3). (C) 
Effectiveness of polyP inhibitors in prolonging clotting. Clotting of human plasma was initiated 
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by long-chain polyP (P), polyguanylic acid (RNA), kaolin (K), diatomaceous earth (Dia), or 
tissue factor (TF). Data are mean inhibitor concentrations that doubled the clotting time relative 
to no inhibitor (ECdouble) ± standard error (n=4). Horizontal dotted lines indicate that the clotting 
time with that initiator was either unaffected by the inhibitor or was not prolonged sufficiently to 
reach a doubling point even at 100 µg/mL inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Chemical structure of the generation 1.0 cationic PAMAM dendrimer used in 
this study. 
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Figure 4.4.  Generation 1.0 dendrimer and polymyxin B inhibit clotting of whole human 
blood initiated by polyP but not by tissue factor. Thromboelastometry (ROTEM) profiles are 
given for clotting of freshly-drawn, non-anticoagulated whole human blood initiated by long-
chain polyP (A,B) or tissue factor (C,D), in the presence of generation 1.0 dendrimer (A,C) or 
polymyxin B (B,D). The x axis is time from addition of clotting trigger; y axis is amplitude of 
clot strength. 
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Figure 4.5.  (A) PPXbd and (B) generation 1.0 dendrimer delay thrombin generation in 
human plasma containing activated platelets. Real-time thrombin generation in plasma was 
quantified using Calibrated Automated Thrombogram assays (Thrombinoscope; Diagnostica 
Stago). Either 500 μg/mL PPXbd, 20 μg/mL dendrimer or saline were added to freshly drawn, 
citrated human blood, from which platelet-rich plasma was prepared and the platelet 
concentration adjusted to 150,000/μL. To some platelet-rich plasmas, TRAP was added at 10 μM 
to activate platelets. After 5 minutes, FluCa reagent (fluorogenic substrate + CaCl2) was added 
and thrombin generation was quantified. Parallel assays were performed on the same platelet-
rich plasmas not pre-treated with TRAP, but in which clotting was triggered using FluCa reagent 
that also contained 5 pM tissue factor (TF). Thrombin generation parameters are plotted as mean 
± standard error (for 5 donors assayed in triplicate). Indicated p values are from paired t-tests 
with and without inhibitor. 
 
  
100 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6.  PolyP inhibitors reverse the ability of platelet releasates to accelerate factor XI 
activation by thrombin.  Initial rates of activation of 30 nM human factor XI by 20 nM human 
α-thrombin were determined in the presence of releasate prepared from TRAP-stimulated human 
platelets as described
11
, normalized to the rate of factor XI activation without any added polyP 
inhibitor. Percent inhibition is plotted versus inhibitor concentration for the following: low MW 
polyethyleneimine (); generation 1.0 dendrimer (); spermine (); PPXbd (); or polymyxin 
B (). Data are mean ± standard error (n=4). IC50 values calculated from these curves are given 
in the text. (In the second stage of the assay, factor XIa levels were quantified, as previously 
described,
11
 by monitoring the rate of cleavage of the chromogenic substrate, L-Pyr-Pro-Arg-p-
nitroanilide. At the concentrations used, none of the inhibitors altered the rate of hydrolysis of 
this substrate by factor XIa.) 
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Figure 4.7.  In vivo antithrombotic and anti-inflammatory efficacies of polyP inhibitors. 
(A,B) Murine model of venous thrombosis. Inhibitors were administered intravenously to mice 
prior to initiation of electrolytic injury of the femoral vein (time=0 in the graphs). Data are mean 
relative intensities for accumulation of fluorescently labeled fibrin-specific antibodies (A) or 
labeled platelets (B) in the developing thrombus for mice receiving: red circles, 4 μg/g 
generation 1.0 dendrimer (n=10);  blue squares, 2 μg/g polymyxin B (n=8); orange inverted 
triangles, 100 units/kg unfractionated heparin (n=5); or open triangles, vehicle only (n=14). Bars 
represent one standard error. (C) Murine model of arterial thrombosis, with Kaplan-Meier curves 
showing percentage of mice with patent arteries. Inhibitors were injected retro-orbitally 10 
minutes before ferric chloride injury to the carotid artery.  Blood flow was monitored by 
Doppler, with occlusion defined as no flow for one minute.  Log-rank analyses indicated that 
median patency time was significantly longer for mice injected with 8 µg/g generation 1.0 
dendrimer (p<0.01, n=8), 4 µg/g polymyxin B (p<0.01, n=10), or 5 µg/g low MW 
polyethyleneimine (p<0.01, n=8) versus mice injected with vehicle (n=11).  (d) Murine model of 
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polyP-induced vascular leakage. Mice were given separate retro-orbital injections with Evans 
Blue dye and either a polyP inhibitor (48 µg/g generation 1.0 dendrimer or 20 µg/g polymyxin 
B) or vehicle. After 40 minutes, saline, bradykinin, or polyP were injected intradermally at 3 
sites on the back. After an additional 30 minutes, mice were euthanized and dye was extracted 
from skin biopsies for quantification. Plots show median (central horizontal lines), mean 
(triangles), 25-75
th
 percentile (top and bottom of boxes), and 10-90
th
 percentile (whiskers) 
concentrations of extracted dye. Dendrimer administration resulted in significantly less dye 
leakage at the site of polyP injection compared to control animals (p<0.001). Each group (no 
inhibitor, dendrimer and polymyxin B) contained 15 mice. 
 
REFERENCES 
1. Ault-Riché D, Fraley CD, Tzeng CM, Kornberg A. Novel assay reveals multiple 
pathways regulating stress-induced accumulations of inorganic polyphosphate in Escherichia 
coli. J Bacteriol. 1998;180(7):1841-1847. 
 
2. Kornberg A, Rao NN, Ault-Riché D. Inorganic polyphosphate: a molecule of many 
functions. Annu Rev Biochem. 1999;68:89-125. 
 
3. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain 
polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol 
Chem. 2004;279(43):44250-44257. 
 
4. Moreno-Sanchez D, Hernandez-Ruiz L, Ruiz FA, Docampo R. Polyphosphate is a novel 
pro-inflammatory regulator of mast cells and is located in acidocalcisomes. J Biol Chem. 2012:In 
press. 
 
5. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate 
modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci U S A. 2006;103(4):903-908. 
 
  
103 
 
6. Müller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and 
procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156. 
 
7. Morrissey JH, Choi SH, Smith SA. Polyphosphate: an ancient molecule that links 
platelets, coagulation, and inflammation. Blood. 2012;119(25):5972-5979. 
 
8. Smith SA, Choi SH, Davis-Harrison R, et al. Polyphosphate exerts differential effects on 
blood clotting, depending on polymer size. Blood. 2010;116(20):4353-4359. 
 
9. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood. 
2008;112(7):2810-2816. 
 
10. Mutch NJ, Engel R, Uitte de Willige S, Philippou H, Ariens RA. Polyphosphate modifies 
the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and 
plasminogen to fibrin. Blood. 2010;115(19):3980-3988. 
 
11. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of 
factor XI by thrombin. Blood. 2011;118(26):6963-6970. 
 
12. Müller F, Renné T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol. 
2011;18(5):349-355. 
 
13. Kleinschnitz C, Stoll G, Bendszus M, et al. Targeting coagulation factor XII provides 
protection from pathological thrombosis in cerebral ischemia without interfering with 
hemostasis. J Exp Med. 2006;203(3):513-518. 
 
14. Merkulov S, Zhang WM, Komar AA, et al. Deletion of murine kininogen gene 1 
(mKng1) causes loss of plasma kininogen and delays thrombosis. Blood. 2008;111(3):1274-
1281. 
 
  
104 
 
15. Hagedorn I, Schmidbauer S, Pleines I, et al. Factor XIIa inhibitor recombinant human 
albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. 
Circulation. 2010;121(13):1510-1517. 
 
16. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural 
procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007;104(15):6388-6393. 
 
17. Choi SH, Collins JN, Smith SA, Davis-Harrison RL, Rienstra CM, Morrissey JH. 
Phosphoramidate end labeling of inorganic polyphosphates: facile manipulation of 
polyphosphate for investigating and modulating its biological activities. Biochemistry. 
2010;49(45):9935-9941. 
 
18. Smith SA, Morrissey JH. Rapid and efficient incorporation of tissue factor into 
liposomes. J Thromb Haemost. 2004;2(7):1155-1162. 
 
19. Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. 
Arterioscler Thromb Vasc Biol. 2011;31(6):1351-1356. 
 
20. Mutch NJ, Myles T, Leung LL, Morrissey JH. Polyphosphate binds with high affinity to 
exosite II of thrombin. J Thromb Haemost. 2010;8(3):548-555. 
 
21. Schuksz M, Fuster MM, Brown JR, et al. Surfen, a small molecule antagonist of heparan 
sulfate. Proc Natl Acad Sci U S A. 2008;105(35):13075-13080. 
 
22. Saito K, Ohtomo R, Kuga-Uetake Y, Aono T, Saito M. Direct labeling of polyphosphate 
at the ultrastructural level in Saccharomyces cerevisiae by using the affinity of the 
polyphosphate binding domain of Escherichia coli exopolyphosphatase. Appl Environ Microbiol. 
2005;71(10):5692-5701. 
 
  
105 
 
23. Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin 
generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. 
Blood. 2011;118(7):1952-1961. 
 
24. Rotteveel RC, Roozendaal KJ, Weijers RN, Eijsman L. Influence of heparin, protamine 
and polybrene on the time integral of thrombin generation (endogenous thrombin potential). 
Haemostasis. 1996;26(1):1-10. 
 
25. Kim KS, Rao NN, Fraley CD, Kornberg A. Inorganic polyphosphate is essential for long-
term survival and virulence factors in Shigella and Salmonella spp. Proc Natl Acad Sci U S A. 
2002;99(11):7675-7680. 
 
26. Michalski R, Lane DA, Pepper DS, Kakkar VV. Neutralization of heparin in plasma by 
platelet factor 4 and protamine sulphate. Br J Haematol. 1978;38(4):561-571. 
 
27. Boas U, Heegaard PM. Dendrimers in drug research. Chem Soc Rev. 2004;33(1):43-63. 
28. Morrissey JH. Tissue factor: a key molecule in hemostatic and nonhemostatic systems. 
Int J Hematol. 2004;79(2):103-108. 
 
29. Chu AJ, Wang ZG, Raicu M, Beydoun S, Ramos N. Protamine inhibits tissue factor-
initiated extrinsic coagulation. Br J Haematol. 2001;115(2):392-399. 
 
30. Corona-de-la-Peña N, Uribe-Carvajal S, Barrientos-Rios R, Matias-Aguilar L, Montiel-
Manzano G, Majluf-Cruz A. Polyamines inhibit both platelet aggregation and glycoprotein 
IIb/IIIa activation. J Cardiovasc Pharmacol. 2005;46(2):216-221. 
 
31. Dalla Via L, Francesconi M, Mazzucato M, et al. On the mechanism of the spermine-
exerted inhibition on alpha-thrombin-induced platelet activation. Thromb Res. 2000;98(1):59-71. 
32. Pakala R. Effect of polyamines on in vitro platelet aggregation and in vivo thrombus 
formation. Cardiovasc Radiat Med. 2002;3(3-4):213-220. 
 
  
106 
 
33. Joseph S, Krishnamurthi S, Kakkar VV. Effect of the polyamine-spermine on agonist-
induced human platelet activation--specific inhibition of "aggregation-independent" events 
induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium 
ionophore. Thromb Haemost. 1987;57(2):191-195. 
 
34. Mendez JD, Zarzoza E. Inhibition of platelet aggregation by L-arginine and polyamines 
in alloxan treated rats. Biochem Mol Biol Int. 1997;43(2):311-318. 
 
35. Agam G, Gartner TK, Livne A. Inhibition of platelet aggregation and endogenous lectin 
activity by oligoamines. Thromb Res. 1984;33(3):245-257. 
 
36. de la Peña NC, Sosa-Melgarejo JA, Ramos RR, Méndez JD. Inhibition of platelet 
aggregation by putrescine, spermidine, and spermine in hypercholesterolemic rabbits. Arch Med 
Res. 2000;31(6):546-550. 
 
37. Pakala R. Inhibition of arterial thrombosis by polyamines in a canine coronary artery 
injury model. Thromb Res. 2003;110(1):47-51. 
 
38. Zhang M, Wang H, Tracey KJ. Regulation of macrophage activation and inflammation 
by spermine: a new chapter in an old story. Crit Care Med. 2000;28(4 Suppl):N60-66. 
 
39. Clarkson AN, Liu H, Pearson L, et al. Neuroprotective effects of spermine following 
hypoxic-ischemic-induced brain damage: a mechanistic study. FASEB J. 2004;18(10):1114-
1116. 
 
40. Kumble KD, Kornberg A. Inorganic polyphosphate in mammalian cells and tissues. J 
Biol Chem. 1995;270(11):5818-5822. 
 
 
 
 
 
  
107 
 
 
5
This chapter in its entirety has been published as Choi SH, Smith SA, Morrissey JH. Polyphosphate is a 
cofactor for the activation of factor XI by thrombin. Blood. 2011;118(26):6963-6970. 
 
CHAPTER 5:  POLYPHOSPHATE AS A COFACTOR FOR FACTOR XI ACTIVATION 
BY THROMBIN AND FACTOR XIa
5 
 
ABSTRACT 
Factor XI deficiency is associated with a bleeding diathesis but factor XII deficiency is 
not, indicating that, in normal hemostasis, factor XI must be activated in vivo by a protease other 
than factor XIIa.  Several groups have identified thrombin as the most likely activator of factor 
XI, although this reaction is slow in solution. While certain non-physiologic anionic polymers 
and surfaces have been shown to enhance factor XI activation by thrombin, the physiologic 
cofactor for this reaction is uncertain.  Activated platelets secrete the highly anionic polymer, 
polyphosphate, and our previous studies have shown that polyphosphate has potent procoagulant 
activity.  We now report that polyphosphate potently accelerates factor XI activation by α-
thrombin, β-thrombin and factor XIa, and that these reactions are supported by polyphosphate 
polymers of the size secreted by activated human platelets.  We therefore propose that 
polyphosphate is a natural cofactor for factor XI activation in plasma, which may help explain 
the role of factor XI in hemostasis and thrombosis. 
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INTRODUCTION 
In the original cascade/waterfall model of coagulation,
1
 factor XI (FXI) is activated by 
factor XIIa (FXIIa), a member of the contact pathway of blood clotting.  Patients with severe 
FXI deficiency may exhibit bleeding tendencies,
2,3
 especially postoperative or posttraumatic 
bleeding in tissues with robust fibrinolytic activity.
4-6
  On the other hand, individuals with severe 
deficiencies in FXII, high-molecular-weight kininogen (HK) or prekallikrein do not exhibit 
bleeding diatheses at all, indicating that the proteins responsible for triggering the classical 
contact pathway of blood clotting are completely dispensable for hemostasis.
7
  Thus, in normal 
hemostasis, FXI must be activated in vivo by a protease other than FXIIa.  A solution to this 
conundrum was proposed in 1991 by Naito and Fujikawa
8
 and by Gailani and Broze
9
  who 
reported that thrombin up-regulates its own generation by feeding back to activate FXI, leading 
to a “revised model of coagulation.”9-11 More recently, Matafonov et al.12 identified that β-
thrombin and γ-thrombin, proteolyzed derivatives of α-thrombin, can also activate FXI in 
plasma. 
The proposal that FXI activation by thrombin plays a significant role in blood clotting in 
vivo is somewhat controversial.
13-15
 In solution, the rates both of FXI activation by thrombin and 
of FXI autoactivation are slow but are markedly enhanced in the presence of polyanions,
8,9,16,17
 
although most studies have employed nonphysiologic cofactors such as dextran sulfate or high 
concentrations of sulfatides.  The relevant physiologic cofactors for FXI activation by thrombin 
in plasma, if any, have yet to be definitely determined. 
Polyphosphate (polyP) – a linear polymer of inorganic phosphate residues – accumulates in 
a variety of microorganisms
18
 and is secreted by activated human platelets.
19
 In the present study, 
we demonstrate that polyP potently accelerates FXI activation by α-thrombin, β-thrombin and 
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FXIa.  Using carefully defined polymer lengths, we report that polyP polymers of the size 
secreted by activated human platelets are very active in stimulating FXI activation by thrombin 
in both a purified system and in plasma.  We further report that activated platelets and platelet 
releasates promote FXI activation by thrombin.  Together, these findings indicate that polyP is a 
potent natural cofactor for FXI activation by thrombin, which may help explain the role of FXI 
in normal hemostasis. 
 
EXPERIMENTAL PROCEDURES 
Materials 
PolyP preparations of narrow size distributions were prepared as previously described,
20
 and are 
indicated in this study by their polymer length followed by “mer” (e.g., 167mer).  A 
heterogeneous polyP preparation comprising 20 to 300mers was biotinylated on terminal 
phosphates using amine-PEG2-biotin from Pierce (Rockford, IL) as described.
21
  Note that all 
polyP concentrations are reported in this study in terms of phosphate monomer concentration 
(monomer formula:  NaPO3), except for Figure 3D which reports polyP polymer concentrations. 
Purified FXI, FXIa, FVa, β-thrombin, corn trypsin inhibitor (CTI), mouse anti-human 
FXI monoclonal antibody, and FXI- or FXII-deficient plasmas were from Hematologic 
Technologies (Burlington, VT).  α-thrombin was from Enzyme Research Laboratories (South 
Bend, IN).  Dextran sulfate with an average Mr of 500 kDa and protease-free bovine serum 
albumin (BSA) were from Calbiochem (San Diego, CA).  L-2145 (L-Pyr-Pro-Arg-p-nitroanilide) 
was from Bachem (Torrance, CA).  PCPSPE liposomes (20% phosphatidylserine, 40% 
phosphatidylcholine, 40% phosphatidylethanolamine; Avanti Polar Lipids, Alabaster, AL) were 
made by sonication.  Polybrene, benzamidine, 4-(2-aminoethyl) benzenesulfonyl fluoride 
  
110 
 
hydrochloride (AEBSF), phenylmethanesulfonyl fluoride (PMSF), streptavidin, theophylline, 
PGE1, thrombin receptor agonist peptide (SFLLRN-NH2, TRAP), and hirudin were from Sigma-
Aldrich (St. Louis, MO). Biacore CM5 sensorchips were from GE Healthcare (Piscataway, NJ).  
EcPPXc, the recombinant polyP-binding domain of Escherichia coli exopolyphosphatase fused 
to maltose-binding protein and a His6 tag, was produced as described.
22
  Recombinant 
Saccharomyces cerevisiae exopolyphosphatase fused to a His6 tag (rPPX1) was produced as 
described.
23
 
 
Preparation of stimulated platelet suspensions and platelet releasates 
Activated platelets and platelet releasates were prepared as follows. Fresh whole blood from 
normal, non-smoking donors not on medication was collected into 3.2% sodium citrate, 2 M 
PGE1, and 1 mM theophylline via atraumatic venipuncture.  (All volunteer blood donors gave 
written informed consent under a blood-drawing protocol approved by the local Institutional 
Review Board.) Platelet-rich plasma was collected following centrifugation of blood at 37
o
C at 
200 x g, after which the plasma was re-centrifuged at 1500 x g to collect the platelets.  Pelleted 
platelets were washed by centrifugation once with Tyrode’s buffer (1 g/L D-glucose, 0.2 g/L 
CaCl2, 0.1 g/L MgCl2, 0.2 g/L KCl, 8 g/L NaCl, 0.05 g/L NaH2PO4, 1 g/L NaHCO3) containing 
3.2% citrate, 2 M PGE1, and 1 mM theophylline, once with Tyrode’s buffer containing 2 M 
PGE1 and 1 mM theophylline, and once in Tyrode’s buffer without additives.  The resulting 
platelet pellets were resuspended at 5.3 x 10
6
/L (approximately 17-fold their concentration in 
whole blood) or 1.6 x 10
7
/L (approximately 50-fold whole blood concentration) in Tyrode’s 
buffer and stimulated with 4 M TRAP for 10 minutes at 37oC with agitation. In some 
experiments, FXI activation was analyzed in the suspension of activated platelets, while in other 
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experiments FXI activation was analyzed using platelet releasates. To obtain cell-free releasate, 
activated platelets were pelleted by centrifugation at 2000 x g for 10 minutes, after which the 
supernatant was collected and re-centrifuged at 13,000 x g for 10 minutes to deplete residual 
platelets and particles.  The resulting platelet releasates were stored frozen until use.  Some 
platelet releasate samples were boiled for 30 minutes to denature proteins prior to being 
employed in FXI activation assays. 
 
Activation of FXI 
30 nM FXI and 5 nM α-thrombin were incubated with either polyP, stimulated platelet 
suspension, platelet releasate, or dextran sulfate at 37°C in 30 mM Hepes (pH 7.4), 50 mM NaCl, 
and 0.1% BSA. In some reactions, activated platelets or platelet releasates were treated with 70 
g/mL rPPX1 for 1 hour at 37°C or pre-incubated with 250 g/mL EcPPXc immediately prior to 
FXI activation assays. Timed samples (0 to 20 minutes) were removed and quenched by addition 
of polybrene (6 g/mL final) to neutralize polyP and hirudin (0.14 to 0.5 U/mL final) to 
inactivate thrombin, after which the generated FXIa was quantified by measuring rates of L-2145 
hydrolysis using a Spectramax microplate reader (Molecular Devices, Sunnyvale, CA). At the 
concentrations used, neither polyP nor polybrene affected L-2145 hydrolysis by FXIa. 
FXI autoactivation reactions incubated with polyP or dextran sulfate and either 30 or 60 
nM FXI were conducted similarly except that they lacked α-thrombin, and only polybrene (6 
g/mL final) was used to quench the timed samples.  Rates of L-2145 hydrolysis were converted 
to FXIa concentrations using a standard curve.  Second-order rate constants (k2) for FXI 
autoactivation were calculated as described.
24
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For SDS-PAGE analyses of FXI autoactivation, 60 nM FXI was incubated with polyP or 
dextran sulfate in 30 mM Hepes (pH 7.4), 50 mM NaCl, and 0.1% polyethyleneglycol (Mr = 
8000).  At various time points, aliquots were removed into reducing SDS sample buffer, resolved 
by SDS-PAGE (Bio-Rad Laboratories, Hercules, CA), and proteins visualized by silver 
staining.
25
   
 
FXIa autolysis 
6 nM FXIa was incubated with polyP preparations of varying polymer lengths (whose 
concentrations were adjusted to yield 3 nM polymer) at 37°C in 30 mM Hepes (pH 7.4), 50 mM 
NaCl, and 0.1% BSA.  Timed samples (0-2 minutes) were diluted and quenched with polybrene 
(6 g/mL final), and the residual FXIa concentration was determined by quantifying the rate of 
L-2145 hydrolysis compared to a standard curve. 
 
Surface plasmon resonance (SPR) analyses 
SPR binding studies were performed at 25°C using a Biacore 3000 instrument (Biacore, 
Columbia, MD). Streptavidin was bound to CM5 sensorships by standard amine coupling; after 
blocking and washing, biotin-polyP was captured on the surface. Varying concentrations of α-
thrombin, -thrombin, FXI, or FXIa in 50 mM Tris-HCl (pH 7.4), 50 mM NaCl, and 0.005% 
surfactant P20 were flowed over the surface at 50 L/min using a 2 minute association phase and 
5 minute dissociation phase, with background subtraction using a streptavidin-coated reference 
cell without polyP.  The running buffer for α- or -thrombin contained 5 mM benzamidine, while 
FXI and FXIa were pretreated with 4 mM AEBSF for 30 minutes prior to use to block the active 
sites of FXIa.  Sensorchips were regenerated by washing with 1 M NaCl between runs. Binding 
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kinetics were analyzed according to the 1:1 Langmuir binding model.  Kd values were calculated 
from the quotient of the derived dissociation (kdiss) and association (kass) rate constants. 
 
Plasma clotting assay 
Clotting times of citrated human plasma were quantified at 37°C using a STart4 coagulometer 
(Diagnostica Stago, France). Prewarmed polyP in HBA (25 mM Hepes, pH 7.4, 1% BSA) was 
mixed in coagulometer cuvettes with prewarmed FXI- or FXII-deficient plasma to which CTI 
(100 g/mL) and PCPSPE (60 M) had previously been added.  -thrombin in HBA was then 
immediately added and the mixture was incubated for 1 min 37°C, after which clotting was 
initiated with addition of CaCl2.  Final concentrations were 33% plasma, 20 µM PCPSPE, 33 
g/mL CTI, 0-5 µM polyP, 8.33 mM Hepes (pH 7.4), 0.3% BSA, 12 nM -thrombin and 8.33 
mM CaCl2. 
 
Thrombin generation assay 
Thrombin generation in human plasma was quantified at 37°C using a Calibrated Automated 
Thrombogram (CAT) system employing Thrombinoscope software (Diagnostica Stago, France). 
Prewarmed polyP in HBA in microplate wells was mixed with prewarmed FXI- or FXII-
deficient plasma to which CTI (100 g/mL), FVa (20 nM), and PCPSPE (30 M) had previously 
been added. The FluCa reagent (containing CaCl2 and the thrombin fluorogenic substrate) was 
then added and thrombin generation profiles were collected.  Final concentrations included 67% 
plasma, 20 µM PCPSPE, 13 nM FVa, 67 g/mL CTI, 0-50 µM polyP, 8.33 mM Hepes (pH 7.4), 
0.17% BSA, and 20 nM -thrombin. For some control experiments, anti-FXI antibody (1 g/mL) 
was preincubated with FXII-deficient plasma at 37°C for 30 minutes prior to use. For others, 5 
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g/mL FXI was added to FXI-deficient plasma immediately after the FXI had been preincubated 
(at 500 g/mL FXI in 25 mM Hepes pH 7.5) for 30 minutes with 0.5 mM PMSF to abolish any 
contaminating FXIa activity. As an additional control, 50 pM FXIa was added to FXI-deficient 
plasma and the rate of thrombin generation was measured.  In some samples, polyP was digested 
with 40 g/mL rPPX1 for 1 hour at 37°C, or pre-incubated with 250 g/mL EcPPXc, prior to 
thrombin generation assays. 
 
RESULTS 
 
PolyP enhances FXI activation by thrombin 
Previous studies have shown that FXI activation by thrombin is greatly accelerated in the 
presence of nonphysiologic polyanions such as dextran sulfate.
8,9
 We hypothesized that the 
highly anionic polymer, polyP, may serve as a physiologic cofactor for this reaction.  
Accordingly, we examined the rate of activation of 30 nM FXI by 5 nM α-thrombin over 20 
minute time courses in the presence of varying concentrations of polyP of varying polymer 
lengths (Figure 5.1).  In the absence of polyP, we observed very low rates of FXI activation, 
consistent with previous reports in the absence of polyanions (Figure 5.1A). Short-chain polyP 
(22mer) did not measurably stimulate FXI activation by α-thrombin at any tested polyP 
concentration, but longer polyP polymers (65mer, 167mer and 350mer) strongly enhanced FXI 
activation in a concentration-dependent manner (Figure 5.1A).  The bell-shaped dose-response 
curve for polyP suggests a template mechanism, in which both thrombin and FXI, or FXI and 
FXIa, assemble on the same polyP molecule. 
Optimal enhancement of FXI activation occurred at 4 M polyP for the 167mer and 
350mer preparations, so this polyP concentration was used to examine the relationship between 
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polyP polymer length and enhancement of FXI activation by α-thrombin. The results (Figure 
5.1B) show that polyP preparations with polymer lengths >50 phosphate units significantly 
enhanced FXI activation by thrombin, with optimal rates observed with polymers that were 
100mers or longer. We then compared the cofactor activity of polyP versus dextran sulfate and 
found that FXI activation by α-thrombin in the presence of 4 M polyP (255mer) was 
significantly greater than that obtained in the presence of 1 g/mL dextran sulfate (Figure 5.1C). 
The isolated polyP-binding domain of E. coli exopolyphosphatase (EcPPXc) has previously been 
utilized as a specific probe for localizing polyP in yeast cell walls,
22,26
 so we examined its ability 
to specifically inhibit the cofactor function of polyP.  The inclusion of 30 g/mL EcPPX 
profoundly inhibited FXI activation by α-thrombin in the presence of polyP, but had no effect on 
FXI activation by α-thrombin in the presence of dextran sulfate (Figure 5.1C). 
 
Activated platelets and platelet releasates enhance FXI activation 
Activated human platelets secrete polyP with polymer lengths about 60 to 100 phosphates 
long,
19,27
 which is in the size range that we found in Figure 5.1B would enhance FXI activation 
by α-thrombin.  We therefore hypothesized that polyP secreted from activated platelets should 
serve as a cofactor for FXI activation by thrombin.  Releasates from activated platelets markedly 
accelerated the rate of FXI activation in the presence of 5, 10, or 20 nM α-thrombin (Figure 
5.2A).  In addition to polyP, activated platelets release a host of granule contents including many 
proteins, so we sought to determine the contribution of polyP to the ability of the platelet 
releasate to accelerate thrombin-mediated FXI activation.  Boiling will denature almost all 
proteins, while purified polyP’s cofactor activity is unaffected by boiling (not shown), so we 
examined if this cofactor effect in platelet releasates survived boiling.  Figure 5.2A shows that 
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boiled platelet releasates augmented thrombin-mediated FXI activation slightly better than non-
boiled releasates.  This increase in cofactor function may be because boiling denatures proteins 
in platelet releasates that might compete with thrombin and FXI for binding to polyP.  On the 
other hand, treatment of platelet releasates with EcPPXc, or digestion of releasates with 
recombinant exopolyphosphatase (rPPX1), abolished their ability to enhance FXI activation 
(Figure 5.2A), consistent with the idea that polyP secreted from activated platelets is the 
augmenting cofactor for FXI activation by α-thrombin. 
We also investigated the effect of whole stimulated platelets (i.e., activated platelets plus 
their releasate) in supporting FXI activation by 20 nM α-thrombin.  We found that whole 
activated platelets in suspension also strongly enhanced FXI activation by α-thrombin, although 
not quite as strongly as platelet releasate alone (Figure 5.2B).  This reduction in FXI activation 
rate might be explained by thrombin, FXI and/or FXIa binding to the surface of activated 
platelets and therefore being less available for interaction with polyP.
28
 Nevertheless, our results 
demonstrate that suspensions of stimulated whole platelets efficiently promote FXI activation by 
thrombin.  In a control experiment, incubating EcPPXc with activated platelets or releasate 
decreased the rate of thrombin-mediated FXI activation to approximately the same baseline rate 
of FX activation seen with thrombin but without platelets or releasate (Figure 5.2B).  
Furthermore, without added thrombin, very low rates of FXI were observed in the presence of 
platelets or releasates (Figure 5.2B). 
 
PolyP accelerates FXI autoactivation and FXIa autolysis 
In the experiments in Figure 5.1, we observed essentially linear initial rates of FXI activation in 
the presence of polyP when we included 5 nM α-thrombin as the FXI activator; however, in the 
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absence of thrombin but in the presence of polyP, we observed sigmoidal progress curves for 
FXIa generation, with a substantial lag phase before FXIa was detectable (Figure 5.3A).  This 
behavior is typical of FXI autoactivation (i.e., FXIa-mediated FXI activation), which has been 
observed when purified FXI is incubated at appropriate concentrations with a variety of 
(typically non-physiologic) anionic polymers.
8,9,17
 The experiment in Figure 5.3A shows that 
polyP (77mer or 255mer) supported more robust autoactivation of 60 nM FXI than did an 
optimal concentration of dextran sulfate. 
It is possible that FXI activation by thrombin in the presence of polyP actually consists of 
direct FXI activation by thrombin, plus FXI autoactivation once significant amounts of FXIa are 
generated.  Therefore, we systematically examined the ability of polyP to enhance the rate of 
FXI autoactivation (i.e., FXI activation without thrombin), and determined the second-order rate 
constants for this reaction as a function of polyP polymer length. The results (Figure 5.3B) show 
that polyP polymers longer than 100mers maximally enhanced FXI autoactivation, while 
polymers in the range of 60-100 phosphate units long supported FXI autoactivation but at a 
slower rate.  FXI autoactivation was not detectable with polyP polymers shorter than 60mers or 
in the absence of polyP. 
Parallel samples from the FXI autoactivation reaction in Figure 5.3A were visualized on 
silver-stained SDS-PAGE (Figure 5.3C), showing that the 80 kDa FXI zymogen was converted 
to the 50 and 30 kDa heavy and light chains of FXIa, as expected.
8,9,16
  This experiment 
underscores that polyP (77mer or 255mer) supported much more rapid FXI autoactivation than 
did dextran sulfate (Figure 5.3C).  (When 60 nM FXI was incubated in the absence of polyanions 
for 50 min, no FXIa was detectable by SDS-PAGE; not shown.) 
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FXIa autolysis exhibited a similar dependence on polyP polymer length (Figure 5.3D), 
consistent with studies showing that FXI autoactivation in the presence of dextran sulfate 
eventually leads to degradation of the heavy and light chains of FXIa, with concomitant loss in 
enzymatic activity.
9
  
 
Thrombin, FXI and FXIa bind with high affinity to immobilized polyP 
We previously reported that polyP binds -thrombin with high affinity (Kd approximately 5 nM) 
when measured using SPR experiments in which thrombin was bound to the sensorchip and 
polyP was flowed over the surface.
29
  Using polyP bound to microplates, we have also reported 
high affinity polyP binding for -thrombin (Kd about 66 nM) and FXIa (Kd about 6 nM).
21
  In 
this study, we further evaluated the binding interaction between polyP and thrombin, FXI and 
FXIa utilizing SPR in which biotinylated polyP was immobilized on sensorchips and the proteins 
were flowed over the surface.  FXI, FXIa, -thrombin and -thrombin all bound tightly to 
immobilized polyP (Figure 5.4), yielding the following association (kass) and dissociation (kdiss) 
rate constants and Kd values:  α-thrombin, kass = 5.12 x 10
6
 M
-1
 s
-1
, kdiss = 7.71 x 10
-2 
s
-1
, Kd = 
15.1 nM;  -thrombin, kass = 3.85 x 10
6
 M
-1
 s
-1
, kdiss = 3.12 x 10
-2 
s
-1
, Kd = 8.1 nM; FXI, kass = 
1.64 x 10
6
 M
-1
 s
-1
, kdiss = 1.05 x 10
-2 
s
-1
, Kd = 6.4 nM;  and FXIa, kass = 1.92 x 10
6
 M
-1
 s
-1
, kdiss = 
2.91 x 10
-3 
s
-1
, Kd = 1.5 nM. 
 
PolyP can accelerate clotting of plasma, and enhance thrombin generation in plasma, in a 
thrombin- and FXI-dependent manner 
Although multiple studies have reported the activation of FXI by thrombin using purified 
proteins,
8-12
 some have questioned whether this reaction can proceed to any significant extent in 
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plasma.
13-15
 We therefore examined whether polyP could accelerate the clotting of plasma in a 
thrombin- and factor XI-dependent manner.  To eliminate interference from the activation of FXI 
by FXIIa, we used FXII-deficient plasma and also added CTI to inhibit any remaining traces of 
FXIIa that might be generated. Also, since our previous studies had shown that polyP accelerates 
the conversion of FV to FVa, which itself can alter the kinetics of thrombin generation,
30
 we 
supplemented the FXII-deficient plasma with 20 nM FVa, in order to eliminate any contribution 
of polyP-mediated FV activation to thrombin generation. (FVa was not added to clotting assays 
performed with a mechanical coagulometer, as pilot studies indicated no impact of added FVa on 
clot times; data not shown.) And finally, because α-thrombin will promptly clot fibrinogen on its 
own (obfuscating any effects on FXI activation), we added -thrombin to the FXII-deficient 
plasma, since -thrombin has greatly diminished ability to clot fibrinogen but retains the ability 
to activate FXI.
12
 
We performed clotting assays (in a coagulometer) using citrated FXII-deficient plasma 
containing CTI, to which we added -thrombin and polyP, and then measured the time to clot 
formation following addition of CaCl2.  Figure 5.5A shows that adding 22mer polyP preparations 
to such clotting assays does not alter the clotting time, while adding longer polyP polymers 
(65mer, 101mer, 211mer or 445mer) shortened the clotting times in a concentration-dependent 
manner.  (In control experiments without -thrombin, the clotting times were all >500 seconds; 
not shown.)  FXI-deficient plasma (also containing CTI) exhibited prolonged clotting times in 
this assay, and the clotting times were essentially unaffected by the presence of polyP 445mer 
(Figure 5.5A).  These results show that polyP shortens the -thrombin clotting time of plasma in 
a manner that is dependent on FXI but independent of FXII.  This is consistent with the notion 
that thrombin activates FXI in plasma in a polyP-mediated manner. 
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We also used the CAT system to examine the ability of polyP to enhance thrombin-
mediated thrombin generation in plasma.  Figure 5.5B shows mean thrombin generation profiles 
in FXII-deficient plasma to which 20 nM -thrombin was added together with polyP (101mer).  
Increasing concentrations of polyP (up to 50 M) yielded increased thrombin bursts, while 
essentially no thrombin generation was observed in the presence of polyP but in the absence of 
-thrombin (not shown).  In Figure 5.5C, we examined the ability of 50 M polyP of varying 
polymer lengths to enhance thrombin generation, and found that polyP caused increased 
thrombin generation in a polymer size-dependent manner.  Figure 5.5D summarizes the mean 
peak thrombin levels generated in experiments described in Figure 5.5B and C, showing that 
peak thrombin levels increased with polyP concentration (for the 101mer), and also showing the 
peak thrombin levels at 50 M polyP for the 65mer and 445mer polymers.  Furthermore, 
treatment of polyP 445mer with either EcPPXc or rPPX1 abrogated thrombin generation (Figure 
5.5D).  Figure 5.5E shows that adding a blocking antibody to FXI abolished polyP-mediated 
thrombin generation in FXII-deficient plasma.  Also, there was no observable polyP-mediated 
thrombin generation in FXI-deficient plasma (Figure 5.5F), although this was restored when 
purified FXI was added back to the FXI-deficient plasma (Figure 5.5G). Lastly, polyP did not 
enhance thrombin generation in FXI-deficient plasma to which FXIa was added (Figure 5.5H). 
 
DISCUSSION 
Deficiencies of FXII, prekallikrein or high MW kininogen are not associated with 
bleeding tendencies, while individuals with severe FXI deficiency can exhibit mild to moderate 
bleeding diatheses, most particularly injury-induced bleeding in tissues with high fibrinolytic 
activity.  This has led to the proposal that the primary role of FXI is not to participate in the 
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initiation of blood coagulation, but to further thrombin generation, possibly for activation of 
thrombin-activatable fibrinolysis inhibitor (TAFI) to protect and consolidate the clot.
31-33
  A 
body of work supports a model in which FXI is activated by thrombin, a process that is 
accelerated by anionic molecules and surfaces. Furthermore, previous studies have shown that 
FXI activation by thrombin is enhanced in the presence of activated platelets.
34-36
  We recently 
showed that polyP of the size secreted by human platelets accelerates blood clotting reactions
20,30
 
and binds with high affinity to -thrombin and FXIa.21,29  Taken together, these findings led us 
to formulate and test the hypothesis that polyP, a natural polyanion secreted by activated 
platelets,
19,27
 mediates FXI activation by -thrombin. 
Using purified proteins, we found that polyP polymers of the sizes secreted by platelets 
(60-100mers)—and larger—potently accelerated FXI activation by α-thrombin, possibly by a 
template mechanism, with polyP being more active than the nonphysiologic polyanion, dextran 
sulfate.  We also showed that polyP-mediated FXI activation by α-thrombin was specifically 
abrogated by EcPPXc, the isolated polyP-binding domain of E. coli exopolyphosphatase, 
indicating that this recombinant protein may be used to interrupt the procoagulant activity of 
polyP. Consistent with reports of anionic polymers accelerating FXI autoactivation
8,17
 and 
autolysis,
9
 we found that polyP polymers >50 phosphate units long strongly enhanced FXI 
autoactivation. These results suggest that the combination of thrombin and polyP in plasma could 
result in the generation of additional thrombin through a combination of polyP-mediated FXI 
activation by thrombin and polyP-mediated FXI autoactivation. 
Oliver et al.
36
 demonstrated that FXII-independent activation of FXI by thrombin was 
augmented in the presence of activated platelets while Wielders et al.
35
 showed that thrombin 
initiates and augments FXI-dependent thrombin generation in platelet-rich plasma.  To date, 
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however, the platelet-derived cofactor for FXI activation by thrombin, and the underlying 
mechanism, has not been well defined.  In this study, we showed that platelet releasates 
enhanced FXI activation by α-thrombin, an activity that was not diminished by boiling (to 
denature potentially confounding proteins, including platelet-derived FXI
34
), but that was 
abrogated by EcPPXc treatment or rPPX1 digestion.  Furthermore, suspensions of activated 
platelets also strongly enhanced thrombin-mediated FXI activation, albeit at rate approximately 
2-fold lower than that of platelet releasates.  It is possible that binding of some of the thrombin, 
FXI, and/or FXIa to the surface activated platelets
28
 could therefore reduce their interaction with 
polyP, and that this might explain the somewhat reduced rate of FXI activation in the presence of 
platelets compared to the same concentration of platelet releasate.  Taken together, our findings 
indicate that platelet polyP may be a natural, physiological cofactor for the activation of FXI by 
thrombin. 
The physiological relevance of FXI activation by thrombin in a plasma environment has 
been questioned.
13,14,37
  Some criticisms include excessively diluting the plasma in FXI-
dependent clotting assays and inadvertent FXI activation by the contact system during blood 
drawing and isolation of plasma.  We addressed these issues using FXII-deficient plasma 
supplemented with CTI to greatly reduce the possibility of FXI activation by FXIIa.  Thrombin 
generation using CAT assays in minimally diluted FXII-deficient plasma demonstrated 
substantial thrombin-mediated thrombin generation in the presence of polyP.  This thrombin 
generation required FXI but not FXII. 
A recent report suggests that FVa can promote FXI activation by α-thrombin.10  We did 
not address this question directly in the present study, but we did find that adding 20 nM FVa to 
FXII-deficient plasma in clotting assays initiated with β-thrombin in the presence of polyP 
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resulted in no further shortening of clotting time compared to FXII-deficient plasma not spiked 
with FVa (not shown).  In further studies, it will be interesting to examine if polyP can synergize 
with FV or FVa to accelerate thrombin-mediated FXI activation. 
Our previous studies established that polyP acts at three points in the blood clotting 
cascade, while the present study adds a fourth point of action (summarized in Figure 5.6).  Using 
carefully size-fractionated polyP preparations,
20
 we previously established that polyP of the size 
range that accumulates in many infectious microorganisms (i.e., hundreds to thousands of 
phosphate units long) potently triggers the contact pathway, accelerates FV activation, and 
enhances fibrin polymerization (Figure 5.6A).  On the other hand, shorter polyP polymers, of the 
size secreted by activated human platelets (i.e., 60 to 100mers) were far less potent than long-
chain polyP in triggering contact activation or in enhancing fibrin polymerization, while 
retaining full ability to promote FV activation (Figure 5.6B).
20
  The present study now shows 
that polyP preparations of the size secreted by human platelets—as well as longer polymers—
potently stimulate the activation of FXI by thrombin as well as FXI autoactivation (Figure 5.6B).  
Taken together, these findings support the notion that platelet polyP primarily functions to 
accelerate and enhance thrombin generation, but not to trigger it.  On the other hand, microbial 
polyP can potently trigger the blood clotting cascade via the contact pathway, together with 
enhancing thrombin generation and fibrin polymerization, possibly as part of the host response to 
pathogens. 
In addition to activated platelets, various injured tissues may also release polyP, as 
mammalian tissues have been reported to contain polyP in sizes ranging from 50mers to 
800mers, with brain containing primarily very long-chain polyP (~800mers).
38
  Interestingly, a 
recent study described a significant reduction in the incidence of ischemic stroke in patients with 
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severe FXI deficiency,
39
 while another found that homozygous FXI knockout mice are protected 
against ischemic brain injury in an experimental stroke model.
40
  Our demonstration that polyP is 
a potent cofactor for FXI activation by thrombin offers a potentially important piece of the 
puzzle regarding the role of FXI in hemostasis and thrombosis. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  PolyP enhances FXI activation by -thrombin.  In all panels, initial rates of FXI 
activation were quantified at 37°C in reactions containing 30 nM FXI, 5 nM -thrombin, and 
polyP or dextran sulfate. (Data are mean  standard error; n=4.) (A) Concentration-dependence 
of polyP-mediated enhancement of FXI activation by -thrombin, tested with four different 
polyP polymer lengths: 22mer (), 65mer (), 167mer (), and 350mer ().  (B) PolyP 
polymer length-dependence of the enhancement of FXI activation by -thrombin, using size-
fractionated polyP preparations at 4 M phosphate. (“0” indicates no polyP.)  (C) EcPPXc 
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abrogates the ability of polyP, but not dextran sulfate, to enhance FXI activation by -thrombin. 
Rates of FXI activation were quantified in the absence (open bars) or presence (solid bars) of 
EcPPXc.  Reaction conditions included: no polyanion (control), with 1 g/mL dextran sulfate 
(DS), or with 4 M polyP (80mer or 255mer, as indicated). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2.  Activated platelets and platelet releasates enhance the rate of FXI activation by 
-thrombin. In all panels, initial rates of FXI activation were quantified at 37°C in reactions 
containing 30 nM FXI, 5 to 20 nM -thrombin, and activated platelets or platelet releasate.  (A) 
Dose-response for platelet releasates from donor A in supporting FXI activation by 5 nM (), 
10 nM (), or 20 nM () -thrombin.  Controls included: boiled releasate () incubated with 
FXI and 20 nM -thrombin; and releasate pre-incubated with 250 g/mL EcPPXc () or pre-
digested with 70 g/mL rPPX1 (ø), then allowed to react with FXI and 20 nM -thrombin. (B) 
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Activated platelets and releasates enhance FXI activation by thrombin.  Initial rates of FXI 
activation by 20 nM -thrombin were quantified in the presence of 10-fold diluted platelet 
releasate (solid bars) or the same dilution of activated platelets + releasate (open bars) from 
donor B, with or without pre-incubation with 250 g/mL EcPPXc.  Controls include FXI 
incubated with activated platelets (or releasate) from donor B but without -thrombin, and FXI 
incubated with -thrombin but without platelets or releasate.   Data are mean  standard error 
(n=3-4) from two separate donors.  Platelets from donor A were activated at a concentration of 
1.6 x 10
7
/L, while platelets from donor B were activated at a concentration of 5.3 x 106/L. 
 
 
 
Figure 5.3.  PolyP accelerates FXI autoactivation and FXIa autolysis.  (A) Progress curves of 
FXI autoactivation in which 60 nM FXI was incubated with 4 M polyP 77mer (), 4 M polyP 
255mer (), or 2 g/mL dextran sulfate ().  (B) PolyP polymer length-dependence of the 
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enhancement of FXI autoactivation.  Second-order rate constants for FXI autoactivation (k2) 
were determined in reactions containing 30 nM FXI and 4 M polyP of the indicated polymer 
lengths. (“0” indicates the absence of polyP.)  (C) SDS-PAGE analyses of FXI autoactivation in 
the presence of polyP (77mer or 225mer) or dextran sulfate (DS). Parallel timed samples from 
the experiment in panel B were resolved on reducing SDS-PAGE and silver stained.  The 
position of FXI (Z) and the FXIa heavy chain (HC) and light chain (LC) are indicated.  The lane 
labeled FXIa contained purified FXIa.  (D) PolyP polymer length-dependence of the 
enhancement of FXIa autolysis. Initial rates of loss of FXIa enzymatic activity were quantified in 
reactions containing 6 nM FXIa and polyP preparations of varying polymer lengths, whose 
concentrations were adjusted to yield 3 nM polymer. (“0” indicates the absence of polyP.)  Data 
in panels A, B, and D are mean  standard error (n=3). 
 
 
Figure 5.4.  -Thrombin, -thrombin, FXI, and FXIa bind with high affinity to 
immobilized polyP.   Binding of -thrombin, -thrombin, FXI, or active-site-inhibited FXIa to 
polyP was quantified using surface plasmon resonance, with biotinylated polyP bound to 
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streptavidin sensorchips, over which varying protein concentrations were flowed. Panels are 
representative sensorgrams for: (A) 2.5 to 20 nM -thrombin; (B) 5 to 80 nM -thrombin (C) 
1.25 to 40 nM FXI; and (D) 2.5 to 20 nM active-site-inhibited FXIa. Kd values were derived as 
described in Methods. 
 
 
 
Figure 5.5.  PolyP plus -thrombin accelerates plasma clotting and enhances thrombin 
generation. (A) PolyP shortens plasma clotting times triggered by -thrombin (measured using a 
mechanical coagulometer).  Citrated FXII- or FXI-deficient plasmas containing 100 g/mL corn 
trypsin inhibitor and 20 M PCPSPE were incubated for 1 minute at 37°C with 12 nM -
thrombin and varying polyP concentrations, after which CaCl2 was added and the time to clot 
formation was measured.  PolyP tested with FXII-deficient plasma included: 22mer (), 65mer 
(), 101mer (), 211mer (), or 445mer (). FXI-deficient plasma was tested with 445mer 
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polyP ().  Data are mean  standard error (n=5).  Panels B and C are mean thrombin 
generation (CAT) curves for FXII-deficient plasmas containing 100 g/mL corn trypsin 
inhibitor, 20 M PCPSPE and 20 nM FVa (4 experiments of triplicate wells). (B) Concentration-
dependence of polyP’s ability to enhance thrombin generation in the presence of 20 nM -
thrombin and varying polyP (101mer at 0-50 M phosphate).  (C) Effect of polyP polymer 
length on thrombin generation in the presence of 20 nM -thrombin and with or without 50 M 
polyP (65mer, 101mer or 445mer).  Panels D-H report mean peak thrombin levels from 
experiments represented in panels B and C ( standard error; n=4) obtained with 20 nM -
thrombin and varying polyP.  (D) Peak thrombin levels in FXII-deficient plasma at the indicated 
concentrations of polyP 65mer (), 101mer (), or 445mer (). In control experiments, polyP 
445mer was pre-incubated with 250 g/mL EcPPXc (), or predigested with 40 μg/mL rPPX1 
().  (E) Peak thrombin levels in FXII-deficient plasma preincubated with anti-FXI antibody  
50 M polyP 101mer.  (F) Peak thrombin levels in FXI-deficient plasma  50 M polyP 101mer.  
(G) Peak thrombin levels in FXI-deficient plasma to which 4 g/mL FXI had been added  50 
M polyP 101mer. (H) Peak thrombin levels in FXI-deficient plasma to which 50 pM FXIa had 
been added  50 M polyP 101mer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. Summary of the roles of polyP in blood clotting.  (A) Long-chain polyP (hundreds 
to thousands of phosphate units long) acts at four points in the clotting cascade, indicated in red: 
a, initiates the contact pathway of blood clotting;
20,30
 b, accelerates FV activation;
20,30
 c, 
enhances fibrin polymerization;
20,41
 and d, accelerates FXI activation by thrombin (this study). 
(B) Platelet-size polyP (60 to 100mers) acts most potently at two points in the clotting cascade, 
indicated in red: b, accelerates FV activation;
20
 and d, accelerates FXI activation by thrombin 
(this study). 
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CHAPTER 6:  POLYPHOSPHATE ACCELERATES FACTOR V  
ACTIVATION BY FACTOR XIa  
 
 
ABSTRACT 
The factor Xa-factor Va prothrombinase complex increases the rate at which prothrombin 
is activated by approximately 5 orders of magnitude compared to the rate of the reaction by 
factor Xa alone.  Generation of initiating levels of factor Va from factor V, the inactive precursor 
of factor Va, is a critical event early in hemostasis, as factor V exhibits little or no procoagulant 
cofactor activity.  Alpha-thrombin is the most potent physiological activator of factor V; 
however, the prothrombinase complexes formed before thrombin generation require a source of 
factor Va that precedes the initial thrombin formed by the factor Xa-factor Va complex.  The 
alternative route by which initial levels of factor Va are formed has yet to be definitely 
determined.  Although phospholipid-bound factor Xa is an effective activator of factor V, the 
low concentration of factor Xa during the early phase of coagulation may be insufficient to 
provide the initiating source of factor Va.   
A recent study identified factor XIa as a possible source of the initial thrombin-
independent factor V activation prior to recalcification in the widely used activated partial 
thromboplastin time (aPTT) assay.  Activated platelets secrete the highly anionic polymer, 
polyphosphate (polyP), and our previous studies have shown that polyP has potent procoagulant 
activity.  More recently, we observed that polyP (of the size secreted by human platelets) binds 
with high affinity to factor XIa and potently accelerates factor XI autoactivation and activation 
by thrombin.  We now present evidence that polyP potently accelerates factor V activation by 
factor XIa, and that this reaction is supported by polyP polymers of the size secreted by activated 
human platelets.    
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INTRODUCTION 
Factor V (FV) was discovered by Paul Owren, a Norwegian physician, in 1943 while 
encountering a patient with a congenital bleeding disorder and a prolonged prothrombin time.
1
  
The patient’s symptoms could not be ameliorated by the then known four coagulation factors 
necessary for hemostasis.  This deduction allowed Dr. Owren to identify a fifth component 
required for coagulation that he identified as “factor V.”  Subsequent work identified FV as one 
of the essential components of the complex required for the rapid conversion of prothrombin to 
thrombin.
2-5
  FV is the inactive precursor of FVa that contributes to the blood clotting reaction by 
binding with factor Xa (FXa) on a membrane surface to form the prothrombinase complex.  
Removal of FVa from the prothrombinase complex reduces the rate of thrombin generation by 
four orders of magnitude. 
3,4
  
Human plasma FV circulates at a concentration of 20 nM, as a single-chain procofactor 
with a molecular weight of 330 kDa.
6,7
  Approximately 20% of the total human FV found in 
whole blood is contained in the platelet alpha granules.
8
  The clinical significance of platelet FV 
is underscored by patients with a deficiency in platelet FV (FV-Quebec
9
 or FV-New York
10
) who 
exhibit a bleeding diathesis or by asymptomatic individuals with potent circulating inhibitory FV 
antibodies that cannot access platelet FV.
11
   
Congenital FV deficiency (<2% FV clotting activity) in humans is a rare disorder with a 
reported prevalence of 1 in 1 million.  Furthermore, the severity of bleeding in FV-deficient 
individuals is poorly correlated by FV antigen and activity levels.
12
  However, several reports 
describe FV-deficient patients with mild to severe bleeding disorders consistent of ecchymosis, 
epistaxis, menorrhagia, and bleeding in the mucosal tracts.
9,13-16
  Excessive bleeding has also 
been reported following trauma, surgery, or dental extraction in FV-deficient patients.
10,17-19
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Single-chain procofactor FV comprises three A domains, a long B domain and two C 
domains, organized in an A1-A2-B-A3-C1-C2 structure.
20
  FV is cleaved by FXa or thrombin at 
Arg709, Arg1018, and Arg1545.
21,22
  Proteolysis at these sites removes the B domain and 
releases FVa, which consists of an N-terminal heavy chain (A1-A2, 105 kDa) associated via Ca
2+
 
ions to the C-terminal light chain (A3-C1-C2, 74 kDa).
6,7,20,23
  Generation of initiating levels of 
FVa from FV, the inactive precursor of FVa, is a critical event early in hemostasis, as FV is 
unable to function as a cofactor for FXa catalysis of the conversion of prothrombin to thrombin.
4
  
A few proteases with potential physiological significance have been reported to cleave FV 
including calpain,
24
 neutrophil elastase,
25,26
 tissue factor-factor VIIa complex,
27
 and platelet-
localized proteases.
28
  However, not all of the FV cleavage products derived from these proteases 
are functional in FVa cofactor assays.  The alternative route by which initial levels of FVa are 
formed has yet to be definitely determined.   
Recently, Whelihan et al. identified that FXIa can generate a FVa species that exerts 
cofactor activity in human plasma.
29
  Our laboratory has shown that polyphosphate (polyP) 
accelerates the activation of FV by -thrombin and FXa.30  More recently, we have demonstrated 
that polyP released from activated platelets accelerates FXI activation by FXIa and -thrombin.31  
In the current study, we demonstrate that polyP potently accelerates FV activation by FXIa.  
Furthermore, we report that polyP polymers of the size secreted by activated human platelets, as 
well as releasates from activated platelets, are very active in stimulating FV activation by FXIa.  
We also observed that FVa species derived from FXIa and polyP exhibit cofactor activity in a 
purified system.   Results from these studies not only provide insight into FV structure and 
function but also provide an alternative route by which initial levels of FVa are formed during 
the early phase of coagulation.   
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EXPERIMENTAL PROCEDURES 
Materials 
Size-fractionated polyP preparations of very narrow size distributions were prepared as 
previously described,
32
 and referred to by their polymer length followed by “mer” (for example, 
167mer).  Note that all polyP concentrations reported in this study are given in terms of 
phosphate monomer concentration (monomer formula:  NaPO3).  Platelet releasates were 
prepared as described previously.
31
   
Purified FXIa, FV, FVa, and corn trypsin inhibitor (CTI), dansylarginine N-(3-ethyl-1,5-
pentanediyl)amide (DAPA) and anti-human FV heavy chain AHV-5146 monoclonal antibody 
were from Hematologic Technologies (Burlington, VT).  α-thrombin and FXa were from 
Enzyme Research Laboratories (South Bend, IN).  Rivaroxaban was from Selleckchem 
(Houston, TX).  Peroxidase-conjugated goat anti-mouse immunoglobulin (IgG) and enhanced 
chemiluminescence (ECL)-plus blotting substrate were from Pierce (Rockford, IL).  
Phospholipid vesicles consisting of 20% phosphatidylserine and 80% phosphatidylcholine 
(Avanti Polar Lipids, Alabaster, AL) were made by sonication.  Spermine and hirudin were from 
Sigma-Aldrich (St. Louis, MO).  Aprotinin was from Calbiochem (San Diego, CA).  
Recombinant polyP-binding C-terminus of the Escherichia coli exopolyphosphatase (EcPPXc) 
fused to maltose-binding protein and His6 tag was expressed in E. coli BL21 cells and purified as 
described.
33
  Human prothrombin was a kind gift from Dr. Craig Jackson (San Diego, CA).   
 
 
 
  
141 
 
Western blot analysis of FV activation in the presence of polyP or platelet releasates 
Hirudin-treated human plasma containing 100 g/mL CTI and 50 g/mL rivaroxaban and 
varying concentrations of FXIa (0 – 3 nM) were incubated with polyP at 37°C in 30 mM Hepes 
(pH 7.4), 50 mM NaCl and 0.25% bovine serum albumin.  In a purified system, we incubated 20 
nM FV and varying concentrations of FXIa (0 – 900 pM) with polyP or platelet releasates at 
37°C in 30 mM Hepes (pH 7.4), 50 mM NaCl, 1.2 mM CaCl2 and 2% BSA.  Some platelet 
releasate samples were boiled for 20 minutes to denature proteins before being used in FV 
activation assays.  Control reactions samples included 500 g/mL EcPPXc.  At various time 
points, aliquots were removed into SDS sample buffer and resolved by SDS-PAGE (Bio-Rad 
Laboratories).  Proteins were subsequently transferred to polyvinylidene difluoride (PVDF) 
membranes and probed with anti-FVa heavy chain antibodies followed by peroxidase-conjugated 
anti-mouse IgG.  Antibody binding was visualized using enhanced chemiluminescence (ECL).   
 
Activation of FV and FVa prothrombinase assay  
We incubated 6 nM FV with varying FXIa concentrations (0 – 10 nM) with polyP in 30 mM 
Hepes (pH 7.4), 100 mM NaCl, 2 mM CaCl2 and 0.5% BSA at 37°C.  After 15 minutes, the 
reactions were quenched by addition of spermine (200 g/mL final concentration) to neutralize 
polyP and aprotinin (10 M final concentration) to inhibit FXIa.  The cofactor activity of the 
FXIa-derived FV(a) species was measured via its ability to stimulate FXa-catalyzed thrombin 
generation.  FXIa-treated FV was added to mixtures containing PCPS vesicles (400 nM), 
prothrombin (900 nM), and DAPA (9 M) in 30 mM Hepes (pH 7.4), 100 mM NaCl, 3 mM 
CaCl2, and 0.2% BSA.  The reaction was initiated with human FXa (200 pM final) and thrombin 
generation was measured by the fluorescence intensity caused by the binding of DAPA to 
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thrombin (excitation at 280nm, emission at 545 nm, and cutoff at 515 nm) using a SpectraMax 
microplate fluorometer (Molecular Devices).  DAPA inhibits thrombin activity, thereby allowing 
quantitation of FVa-dependent thrombin generation without feedback activation of any 
unactivated FV.  The rates of increase in fluorescence were converted to FVa concentrations 
using a standard curve.  Control experiments indicated that at the concentrations used, neither 
spermine nor aprotinin affected the prothrombinase assays.   
 
RESULTS 
PolyP supports FV cleavage by FXIa 
Previous studies have shown that FXIa activates FV although the kinetics are slow.
29
  We 
hypothesized that polyP may serve as a physiologic cofactor for this reaction.  Accordingly, we 
measured FV cleavage at physiologically relevant concentrations of FV (20 nM) and FXIa (<1 
nM) in the presence or absence of polyP.  The fragment profile of the purified-protein reactions 
was visualized by using Western blotting with an antibody directed against the FVa heavy chain.  
Figure 6.1 shows that the cleavage of intact FV and appearance of the newly-generated FVa 
heavy chain (105 kDa) was dependent on the presence of both FXIa and polyP (85mer or 
211mer).  Using SDS-PAGE analysis, the cleaved fragments of FXIa/polyP-treated FV 
comigrated in an identical fashion with the heavy and light chains of thrombin-derived FVa (data 
not shown).   Additional control experiments in which FXIa was omitted from the reaction 
showed no cleavage of FV, indicating that the observed activity was not due to protease 
contamination of the FV preparation.   
 We next wanted to investigate the physiologic relevance of polyP-accelerated FV 
activation by FXIa by performing this reaction with endogenous FV in human plasma.  To 
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eliminate interference from feedback activation of FV by α-thrombin or FXa, plasma samples 
were pretreated with rivaroxaban and hirudin.  Plasma samples also contained CTI to prevent 
polyP-mediated contact activation.  Consistent with the results in the purified protein assay, the 
presence of both FXIa and polyP (211mer) in plasma strongly enhanced FV cleavage based on 
the appearance of the FVa heavy chain (Figure 6.2).  These results show that polyP accelerates 
the activation of FV by FXIa in plasma in a manner that is dependent of FXIa but independent of 
thrombin, FXa, and FXII.  This is consistent with the notion that FXIa activates FV in plasma in 
a polyP-mediated manner.     
 
Activated platelet releasates enhance FV activation  
Activated human platelets release polyP with polymer lengths ~ 60 to 100 phosphates,
34,35
 
similar to the size range that we found in Figure 6.1 would enhance FV activation by FXIa.  We 
therefore hypothesized that polyP secreted from activated platelets should serve as a cofactor for 
FV activation by FXIa.  Releasates from activated platelets markedly accelerated FV activation 
in the presence of 4.8 nm FXIa (Figure 6.3).  In addition to polyP, activated platelets release a 
host of granule contents including heat-labile platelet-derived proteases,
24
 so we examined 
whether this cofactor effect in platelet releasates survived boiling.  Figure 6.3 shows boiled 
platelet releasates augmented FXIa-mediated FV activation as well as nonboiled releasates.  On 
the other hand, treatment of platelet releasates with EcPPXc abolished their ability to enhance 
FV activation (Figure 6.3) consistent with the idea that polyP secreted from activated platelets is 
the augmenting cofactor for FV activation by FXIa.   
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FXIa/polyP-derived FVa exerts cofactor activity in a purified system 
To compare the amount of FVa generated by FXIa in the absence or presence of polyP (96mer or 
130mer), we employed a purified prothrombinase assay with limiting amounts of FXa (200 pM).  
The presence of polyP markedly enhanced FVa generation by FXIa, with optimal FV activation 
observed with at least 1 nM FXIa in the presence of 10 M of 130mer and at least 3 nM FXIa in 
the presence of 10 M 96mer (of the size secreted by activated platelets).   In the absence of 
polyP, FXIa-generated FVa was not detectable with FXIa concentrations lower than 4 nM.   
 
DISCUSSION 
 Results from this study confirm and extend previous observations of FXIa-mediated 
activation of FV.  The use of DAPA-based prothrombinase assay provides evidence that polyP 
markedly accelerates FXIa-mediated generation of functional FVa cofactor species that 
effectively converts prothrombin to thrombin in the presence of FXa and phospholipid.  
Furthermore, we tested the capacity of polyP to augment FXIa-mediated activation of FV in both 
a purified system and in plasma using Western blot analysis.  The cleavage pattern of FXIa-
derived FVa was similar to that generated by -thrombin, evident by the appearance of the FVa 
light and heavy chain.   
 The generation of an active FVa cofactor species which effectively functions in the 
prothrombinase complex is a critical component of the coagulation cascade.
36
  The physiologic 
significance of FVa for clot formation is clearly demonstrated in mice with complete deficiency 
of FV results in massive hemorrhage and death during mid-embryogenesis.
37
  Furthermore, FV-
deficient patients suffer moderate to severe bleeding, though residual FV activity is detectable in 
nearly all cases.
38
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 The B-domain of procofactor FV is thought to prevent premature procoagulant activity 
prior to proteolytic processing by sterically blocking binding sites on intact FV.
39,40
  Evidence for 
this notion came from studies using a B-domain-truncated FV derivative that exhibit constitutive 
cofactor activity without intentional proteolysis.
39,41
  Subsequent work by Zhu et al. revealed a 
highly basic region within the B-domain that is conserved among most vertebrates whose 
deletion yielded derivatives with cofactor-like properties in the absence of proteolysis.
42
  These 
findings imply that the basic region of the B-domain serves as an inhibitory function, which, 
under normal physiological conditions, is efficiently removed upon proteolytic processing.
43,44
   
 We previously demonstrated that polyP accelerates FV activation by thrombin and FXa.
30
  
Taken together with our current findings that polyP and activated platelets augment FV 
activation by FXIa, we speculate that platelet polyP may interact tightly with FV.  It is tempting 
to propose that polyP is involved in this release-from-inhibition mechanism by interacting with 
or facilitating the removal of the highly-basic inhibitory sequences within the B-domain.  
Additionally, platelet polyP may explain an explanation for reports that platelet FV is stored in a 
partially activated form which already expresses FVa cofactor activity prior to exposure to FXa 
or thrombin, stored in alpha granules.
8,45
  Future work addressing these hypotheses would 
provide new insights into the mechanism by which polyP accelerates FV procofactor activation 
at the onset of contact pathway-initiated blood coagulation. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. FV cleavage by FXIa in the presence of polyP.  20 nM FV was incubated with 10-
900 pM FXIa for 10 minutes at 37°C in the absence or presence of polyP of 2 different polymer 
lengths:  85mer and 211mer (indicated at the top of the panel). Reaction samples were subject to 
SDS-PAGE and Western blot analysis.  FVa was detected with a monoclonal anti-FV heavy 
chain antibody.  The position of the factor Va heavy chain (HC) is indicated.          
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Figure 6.2. FV cleavage by FXIa in the presence of polyP.  Hirudin-treated plasma containing 
100 g/ml corn trypsin inhibitor and 50 g/ml rivaroxaban was incubated with 0.25-3 nM FXIa 
for 10 minutes at 37°C in the absence or presence of polyP (211mer). Reaction samples were 
subject to SDS-PAGE and Western blot analysis.  FVa was detected with a monoclonal anti-FV 
heavy chain antibody.  The position of the factor Va heavy chain (HC) is indicated.          
 
 
 
 
 
 
 
 
Figure 6.3. FV cleavage by FXIa in the presence of platelet releasates. 20 nM FV was 
incubated with 4.8 nM FXIa for 10 minutes at 37°C in the absence or presence of varying ratios 
of platelet releasate (PR) in FV activation reaction.  Controls include boiled releasate and 
treatment of platelet releasates with EcPPXc (the isolated polyP-binding domain of E. coli 
exopolyphosphatase). 
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Figure 6.4. Prothrombinase activity of FVa generated by FXIa and polyP.  6 nM FV was 
incubated with varying concentrations of FXIa in the absence (red circles) or presence of polyP 
(96mer or 130mer) for 15 minutes at 37°C.  Reactions were stopped by addition of spermine to 
neutralize polyP and aprotinin to inhibit FXIa.   Generated FVa was measured via its ability to 
stimulate FXa-catalyzed thrombin generation in the presence of DAPA .   
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CHAPTER 7:  CONCLUSIONS AND PERSPECTIVES
6
 
 
Similar to other activators of the contact pathway,
1,2
 polyphosphate (polyP) is a highly 
anionic polymer, a property which likely facilitates its binding to the anion-binding sites of high 
molecular weight kininogen (HK) and factor XII (FXII).
3,4
  PolyP accumulates in a variety of 
pathogenic microorganisms
5
 and is secreted by activated human platelets.
6
  The findings reported 
in this thesis add to our knowledge of how polyP modulates blood clotting.  To date, we have 
identified that polyP is a potent modulator of the human blood clotting system, acting at 5 points:  
It initiates the contact pathway of blood clotting in a FXII-dependent manner (requiring very 
long polyP polymers for optimal activity);
7-9
 it accelerates the activation of factor V (FV) by 
thrombin and factor Xa (FXa);
7
 it enhances the thickness of fibrin fibrils;
10
 it accelerates factor 
XI (FXI) activation by thrombin and FXIa
11
; and it accelerates factor V (FV) activation by FXIa 
(reported in chapter 6 of this thesis).  Figure 7.1 summarizes the roles of polyP depending on 
polyP length.  These findings therefore have the potential to explain previously unexplained 
abilities of activated platelets to enhance blood clotting reactions.
12
  It is likely that polyP has 
other, as-yet undiscovered, roles in blood clotting. 
PolyP’s ability to trigger the contact pathway exhibits a profound dependence on polymer 
length, with optimal specific activities requiring very long polyP polymers (Chapter 2).
8
  
Consistent with this finding, polyP purified from Salmonella is extremely potent in triggering the 
contact pathway.
8
  We also found that while platelet-derived polyP—and synthetic polyP of the 
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same size (i.e., 60-100mers)—could trigger clotting via the contact pathway,7,9 it is thousands of 
times less potent than very long-chain polyP (1000-2000mers).
8
  These findings provide an 
explanation for reports, dating back to the 1960s, that activated human platelets express a weak 
but measurable ability to trigger the contact pathway in a FXII-dependent manner (reviewed by 
Caen and Wu
12
).  However, the low specific activity of platelet polyP toward the contact 
pathway is consistent with the idea that platelets are much more effective at accelerating clotting 
reactions than they are at initiating clotting. 
Chapter 5 reports our finding that polyP potently accelerates FXI activation by both 
thrombin and FXIa (i.e., FXI autoactivation).
11
  PolyP of the size secreted by platelets (~60 to 
~100 phosphate units long) strongly supports these reactions. We also found that platelet 
releasates strongly promote FXI activation by thrombin, and we showed that this activity is due 
to polyP.
11
  PolyP binds to both thrombin and FXI, and FXI activation by thrombin exhibits a 
bell-shaped concentration dependence on polyP, consistent with a template-based 
mechanism.
7,11,13
  Chapter 6 demonstrates that platelet-size polyP also supports FV procofactor 
activation by FXIa.  These studies therefore show that platelet polyP modulates normal 
hemostasis independent of FXII. 
In addition to promoting and enhancing clot formation, we recently demonstrated that 
polyP induces bradykinin-mediated capillary leakage,
9
 which is a hallmark of inflammatory 
reactions.  The clear contributions of polyP to thrombus formation and inflammation suggest that 
targeting polyP may be an attractive approach for identifying novel antithrombotic/anti-
inflammatory agents.  In fact, digesting polyP with phosphatases, which enzymatically degrade 
polyP, abrogated activation of the contact system and bradykinin generation, abolished 
procoagulant platelet activity, and blocked platelet-induced thrombosis in mice.
9
  Employing 
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phosphatase as an antithrombotic or anti-inflammatory agent is limited by the relatively slow 
reaction rates and high doses of phosphatase necessary to efficiently digest polyP.  Therefore, it 
would be highly advantageous to have a small-molecule inhibitor that rapidly and tightly binds to 
polyP, thereby blocking its procoagulant and proinflammatory functions.   
In chapter 4, we characterized small-molecule and protein-based polyP inhibitors with 
respect to their ability to specifically inhibit polyP binding to clotting factors and abrogate polyP-
mediated clotting reactions in vitro and ex vivo.  We identified that the isolated polyP binding 
domains of E. coli exopolyphosphatase (EcPPXc) specifically abrogates the procoagulant 
function of polyP.  We further demonstrated that gen. 1 dendrimer and polymyxin B are both 
effective at reducing thrombus growth in mice and that gen. 1 dendrimer attenuates the 
proinflammatory effects of polyP in vivo.  These observations illustrate the ability of a small 
molecule or protein to directly interfere with polyP-mediated inflammatory and thrombotic 
reactions by targeting specific polyP-protein interactions.     
It would be advantageous to extend the studies from chapter 4 and engineer polyP-
binding proteins with increased affinity for polyP.  This can be explored by creating dimers or 
multimers of the isolated polyP-binding domains of E. coli EcPPXc, as a way of increasing their 
effective binding affinity for polyP.  These dimeric proteins can be produced recombinantly by 
linking their coding sequences with an oligopeptide spacer or by chemical crosslinking.  The 
binding affinities of oligomeric forms of polyP-binding proteins will be evaluated by Biacore 
analyses, and also by their potencies in reversing the procoagulant activities of polyP in clotting 
assays and in abrogating thrombin binding to polyP.  If this approach alone does not result in 
sufficiently enhanced polyP binding affinities, phage display technique (using immobilized 
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polyP during the screening phase) can be employed to select mutants of these binding proteins 
with enhanced affinity for polyP.   
For a variety of experiments, it would be desirable to be able to covalently attach biotin, 
epitope tags, dyes, fluorophores, etc., to polyP, and also to covalently immobilize polyP onto 
solid supports such as magnetic beads and multiwell plates.  PolyP can be immobilized onto 
zirconia beads via Lewis acid/base interactions
14
 – a  method the Morrissey lab has used to 
quantify exosite II-mediated thrombin binding to immobilized polyP.
15
  Unfortunately, this 
coupling chemistry is not suitable for attaching other sorts of probes to polyP.  Chapter 3 
identifies reaction conditions under which the terminal phosphates of polyP can be made to enter 
into stable phosphoramidate linkages with almost any primary amine-containing compound, 
using the zero-length coupling reagent, EDAC (1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide).
16
  We have successfully used this coupling chemistry to covalently attach probes 
such as biotin, fluorophores, and polyamines to the terminal phosphates of polyP, and we have 
successfully coupled polyP to a variety of solid supports.
16
  This opens up a number of 
possibilities, including: identifying polyP-binding proteins in biological samples; developing 
high-throughput screens for polyP inhibitors; using biotin- or fluorophore-tagged polyP to 
visualize polyP in vitro and in vivo (including flow cytometry); and developing therapeutics 
based on coupling polyP to solid supports (such as wound dressings) or to targeting molecules or 
nanoparticles.   
Our laboratory recently reported that polyP of approximately the size released by 
activated platelets can reverse the anticoagulant activity of a variety of anticoagulants, including 
unfractionated and low MW heparins, as well as direct inhibitors of thrombin and FXa.
17
  PolyP 
can also shorten the clotting times of plasma from patients with hemophilia A or B, or patients 
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taking vitamin K antagonists.
17
  It is thus tempting to speculate that polyP of the size secreted by 
human platelets – or suitable polyP derivatives – might be useful as injectable hemostatic agents.  
Long-chain polyP may have utility as a topical hemostatic agent, and in fact, adding polyP to 
chitosan-based wound dressings made them substantially more procoagulant.
18
 
Oscar Ratnoff, the late discoverer of FXII, proposed the concept that blood coagulation, 
fibrinolysis and inflammation are intimately related via surface contact, which he called “a 
seamless web of host defense reactions.”19  Together, the studies reviewed above provide 
evidence that polyP is a key player in the web of host-pathogen interactions.  Indeed, long-chain 
microbial polyP is a potent activator of the blood clotting system via the contact pathway and can 
trigger both thrombosis and inflammation (the latter via bradykinin generation and possibly 
complement activation).  The clear contributions of polyP to thrombus formation and 
inflammation suggest that antagonizing polyP function in vivo may be an attractive approach for 
identifying novel antithrombotic/anti-inflammatory agents, perhaps with reduced bleeding side 
effects compared with conventional anticoagulant/antithrombotic drugs. Finally, the detailed 
molecular mechanisms by which polyP acts as such a potent modulator of blood clotting and 
inflammation are still largely unknown, so this will be a fruitful and interesting topic for much 
future research.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1.  The roles of polyP in blood clotting vary depending on polymer length.  (A) 
Microbial long-chain polyP (ranging from less than a hundred phosphates to several thousand 
phosphate units long), acts at five points in the clotting cascade, indicated in red: 1, initiates the 
contact pathway of blood clotting;
7-9
 2, accelerates FV activation and abrogates TFPI function 
(the latter not shown explicitly);
7,8
 3, enhances fibrin polymerization;
8,10,20
 4, accelerates FXI 
back-activation by thrombin;
11
 and 5, supports FV activation by FXIa (Chapter 6).  (B) Platelet-
size polyP (~60 to ~100 phosphate units long) acts most potently at three points in the clotting 
cascade, indicated in red: 2, abrogates TFPI function (and overlaps the minimal size necessary to 
accelerate FV activation);
7,8
 3, overlaps the minimal size necessary to enhance fibrin 
polymerization;
8,10,20
 4, accelerates FXI back-activation by thrombin
11
; and 5, supports FV 
activation by FXIa.   
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